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Introduction 
During the past 25 years, the implantable cardioverter-defibrillator (ICD) has evolved 
from treatment for survivors of cardiac arrest to the standard therapy for patients at 
high risk for ventricular tachyarrhythmias. High-risk patients include not only survivors 
of cardiac arrest but also patients with cardiac diseases who are at risk to develop 
ventricular tachyarrhythmias but still are without symptoms. The current generation of 
devices not only provides treatment for ventricular tachyarrhythmias, but is also 
capable to treat atrial arrhythmias, and by means of biventricular pacing congestive 
heart failure.  
 
The history of ventricular defibrillation 
Prevost and Batelli first introduced the concept of defibrillation in 1899.(1) They noted 
that the application of large voltages across an animal’s heart could stop ventricular 
fibrillation. In 1933, the existing knowledge about defibrillation was refined when 
alternating current was applied for internal defibrillation in dogs.(2) Fourteen years 
later, the first human internal defibrillation by application of alternating current was 
reported.(3) By the 1950s, Kouwenhoven was able to defibrillate dogs externally.(4) 
In 1956, Zoll and coworkers performed the first successful external defibrillation in 
man.(5) Alternating current was changed to direct current (DC) as this current 
appeared more effective and produced fewer side effects.(6,7) The DC pulse 
waveform was further improved in the 1960s.(8,9) The application of external 
defibrillation increased the survival of out-of-hospital cardiac arrest.(10) By the late 
1960s, external cardiac defibrillation was acknowledged as an effective tool of 
terminating ventricular fibrillation and restoring sinus rhythm. 
 
The evolution of the implantable cardioverter-defibrillator 
The idea of developing an automatic implantable defibrillater originated from Dr. 
Michel Mirowski. The concept he pioneered was “blind and immediate defibrillation 
treatment of cardiac arrest”. The device had to quickly recognize and treat ventricular 
fibrillation, and had to be small enough to implant in patients. The first prototype was 
tested in dogs.(11) The first human implantation took place on February 4, 1980, at 
the John Hopkins Hospital.(12) From that moment on, the ICD has evolved from a 
simple shock-only box into a full arrhythmia management device. Steady and 
  
 
10 
remarkable advances in device technology driven by the clinical needs resulted in 
greater patient safety and comfort. 
The first-generation devices were designed to recognize only ventricular fibrillation 
(VF). It soon became apparent that survivors of cardiac arrest also suffered from 
unstable ventricular tachycardia (VT) that degenerated into VF. Therefore, second-
generation devices had next to VF detection also VT detection incorporated. This 
early generation of ICDs could not discriminate between atrial and ventricular 
tachyarrhythmias, resulting in a high incidence of inappropriately delivered shocks, 
especially for atrial fibrillation.(13) However, interpretation and investigation of the 
appropriateness of therapy was limited due to the lack of storage of diagnostic 
information.(14)  
The concept of tiered therapy was introduced in third-generation devices. These 
devices provide bradycardia pacing, antitachycardia pacing (ATP) modalities, as well 
as low- and high-energy shock therapies. The diagnostic information has been 
significantly improved by the storage of intracardiac electrograms.(15,16) In order to 
prevent inappropriate therapy, detection enhancements, like sudden onset and 
stability, were developed to improve arrhythmia discrimination.(17,18) Despite the 
advances in arrhythmia discrimination in tiered-therapy ICDs, a significant proportion 
of patients still experienced inappropriate shocks.(19) With the introduction of dual 
chamber devices, it was postulated that the specificity of arrhythmia discrimination 
might improve further with the addition of atrial information.(20,21) The evolution of 
arrhythmia discrimination continues with further refinement of morphology-based 
algorithms. 
 
Clinical ICD trials 
For several years ICD therapy was limited only to patients who survived 2 episodes 
of cardiac arrest due to VF.(22) Data from the first ICD implantations showed a low 
sudden death rate.(23,24) In 1985, the US Food and Drug Administration approved 
the ICD as a commercial device. At that time, ICD therapy was approved and limited 
for patients who survived 1 episode of cardiac arrest or patients with recurrent 
ventricular arrhythmias that were inducible but not suppressible with antiarrhythmic 
drugs. Studies showed consistently a low sudden death rate in ICD patients. 
However, in these uncontrolled studies, shock delivery was assumed to represent a 
life saved. Not all delivered shocks were appropriate, not every arrhythmia would 
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have been fatal if not terminated.(25) Other cardiac causes of death replaced sudden 
cardiac death.(26) To investigate the potential benefit of defibrillator therapy both for 
primary and secondary prevention of sudden cardiac death, randomised, clinical 
trials were designed. Three trials, Antiarrhythmics Versus Implantable Defibrillators 
(AVID), the Canadian Implantable Defibrillator Study (CIDS), and the Cardiac Arrest 
Study Hamburg (CASH), confirmed the use of defibrillator therapy for secondary 
prevention of potentially fatal ventricular tachyarrhythmias.(27-29) The concept of 
prophylactic defibrillator therapy for patients at high risk for cardiac arrest made risk 
stratification necessary. The Multicenter Automatic Defibrillator Implantation Trial 
(MADIT) was based on the risk model of nonsustained VT and low ejection fraction 
(EF) in postinfarction patients.(30) The results of this trial were supported by the 
results of the Multicenter Unsustained Tachycardia Trial (MUSTT).(31) In both 
studies, patients with coronary artery disease, low EF, and nonsustained VT in whom 
a sustained VT or VF could be induced at electrophysiologic study had survival 
benefit from defibrillator therapy.  
In the second MADIT study (MADIT II), stable post-infarction patients with EF ≤ 30% 
without requirement of nonsustained VT or electrophysiologic study were 
randomised.(32) The results of this trial again demonstrated a significant reduction in 
all-cause mortality in patients treated with an ICD. This trial provoked a lot of debate 
about the issue of adequate risk stratification. Additional data on prophylactic ICD 
implantation was provided by the results of the Sudden Cardiac Death in Heart 
Failure Trial (SCD-HeFT).(33) Data from this trial confirmed that amiodarone does 
not improve survival in patients with depressed EF (≤ 35%) and congestive heart 
failure. Simple, shock-only ICD therapy improved survival in both ischemic and 
nonischemic cardiomyopathy patients, beyond the improvement afforded by optimal 
drug therapy. ICD therapy became an established therapeutic modality for primary 
and secondary prevention of sudden cardiac death in post-infarction patients. 
Although ICD therapy is beneficial among patients with left ventricular dysfunction, it 
may also result in morbidity, such as inappropriate shocks. Not all patients with 
depressed left ventricular function should immediately receive an ICD. Adequate risk 
stratification and device selection for each patient will certainly continue over the next 
years. 
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Abstract 
Background: The implantable cardioverter defibrillator (ICD) has become a widely 
accepted therapy for patients with severe life-threatening ventricular 
tachyarrhythmias. The aim of this study was to illustrate the possible advantages of 
ICDs with respect to survival and clinical events. 
Methods and results: Between 1998 and 2000, 92 patients (age, 58±15 years; 
ejection fraction, 36±15%; coronary artery disease, 71%) were treated with an ICD in 
combination with an endocardial lead system. Benefit of the ICD was estimated as 
the difference between total cardiac death and the projected death rate of fast 
ventricular tachyarrhythmias (>200 bpm), assuming that most fast ventricular 
tachyarrhythmias would have been fatal without termination by the ICD. Adverse 
events were classified according to European standards.  
The cardiac mortality rate was 5.5% and 9.8%, at 1 and 2 years respectively. The 
recurrence rate of fast VT (>200 bpm) was 22.4% and 30.2%, at 1 and 2 years 
respectively. The observed difference between cardiac death and projected death 
was very significant (P=0.002) and suggests a clear benefit from ICD implantation. 
Low ejection fraction (<35%) and NYHA class ≥ II correlated with a higher projected 
death. The most common adverse event was inappropriate therapy (18%). 
Conclusion: The data in our small series supports the existing data that especially 
patients with poor ejection fraction (<35%) benefit from ICD implantation. The 
adverse event rate was low. However, inappropriate therapy remains a matter of 
concern. Given the high workload of correct screening and follow-up, we expect that 
the actual number of centers in the Netherlands, permitted to implant ICDs, will not 
be able to cope with the widening spectrum of ICD indications.  
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Introduction 
The implantable cardioverter defibrillator (ICD) has become a widely accepted 
therapy for the treatment of patients with severe life threatening ventricular 
tachyarrhythmias.1,2 Driven by clinical needs, the evolution of ICD systems into full 
cardiac arrhythmia management devices continues.3 Technologic development in 
device therapy includes increased and improved diagnostics, and comprehensive 
and specific therapy. Indeed, several shortcomings of conventional ICDs still exist. 
One of the most important is inappropriate therapy due to supraventricular 
tachycardia.4 Several approaches to avoid “spurious” interventions caused by this 
arrhythmia are possible. One way to avoid unnecessary shocks is to use the atrial 
signals for decision making, by implanting an additional atrial lead. Reliable sensing 
of atrial activity also allows the recognition of atrial fibrillation, which then can be 
treated with more advanced systems as well.5,6 
The potential of the ICD to prolong life has been challenged by the argument that 
although the ICD reduces the rate of sudden death, it does not reduce cardiac death 
or total mortality.7 The benefit from ICD implantation might last the longest for 
patients without heart failure or with mild heart failure.8 On the other hand, post-hoc 
analysis of the AVID trial suggested that only patients with left ventricular ejection 
fraction (LVEF) < 35% have benefit.1 
The aim of this overview of our first 92 patients in whom we implanted an ICD is to 
illustrate the possible advantages of arrhythmia management devices with respect to 
survival and clinical events. 
 
 
Material and Methods 
Patients 
Between October 1998 and October 2000, 92 consecutive patients were treated with 
an ICD in combination with an endocardial lead system because of a history of 
sustained malignant ventricular tachyarrhythmia, aborted sudden death, or syncope 
attributable to a ventricular tachyarrhythmia. 
 
Implantation method 
The ICD pulse generator and endocardial leads were inserted through a single left 
pectoral incision. We used a left cephalic vein cutdown and/or a left subclavian 
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puncture for lead insertion. The ventricular lead was placed at the right ventricular 
apex, while the atrial lead was positioned in the right atrial appendage or lateral free 
wall by active fixation. In case of a biventricular device, the lead for left ventricular 
pacing was positioned via the left subclavian vein in one of the tributaries of the 
coronary sinus. The capture and sensing thresholds of both atrial and ventricular 
leads were tested. The presence of far-field R wave sensing in the atrial electrogram 
was to be excluded. If present, the atrial lead was relocated at another location until 
appropriate sensing could be achieved. 
All patients underwent defibrillation threshold testing and a pre-hospital discharge test 
with reinduction of ventricular fibrillation. 
 
Follow-up 
Follow-up started at the time of ICD implantation. Regular follow-up was scheduled at 
3-month intervals. In case of therapy delivery by the device, patients were advised to 
visit the out-patient clinic. Subsequently, the memory of the device was interrogated 
and the therapy was adapted to the clinical findings if necessary.  
All therapeutic device interventions were classified as appropriate or as inappropriate 
(that is, intervention of the device for events not be a ventricular tachyarrhythmia) 
according to stored electrograms. 
 
Definitions and classification of events  
Cardiac death: cardiac deaths were classified into sudden and nonsudden. Sudden 
death was defined as death occurring without preceding symptoms or within 1 hour 
after the onset of or sudden change in symptoms. An unexpected, insufficiently 
documented, and unwitnessed death was conservatively also classified as sudden.9 
Electric storm: electric storm was defined as three or more episodes of VT or VF 
requiring ICD therapy in a 24-h period.10 
Benefit of the ICD: benefit of the ICD was estimated by the difference between the 
total cardiac death and the projected death rate of fast ventricular tachyarrhythmias, 
assuming that most fast ventricular tachyarrhythmias would have been fatal without 
termination by the ICD. Recorded nonfatal events included fast ventricular 
tachyarrhythmias were defined as ventricular tachyarrhythmias with cutoff rates of  > 
200 beats/min and according to Böcker et al. > 240 beats/min.8 
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Adverse event: according to European standards, an “adverse event” was “any 
undesirable clinical occurrence in a subject whether it was considered to be device 
related or not.”11,12 A procedure-related event was defined as being directly or 
indirectly caused by the implantation procedure. A device-related event was defined 
as an event related to the implanted ICD system including leads. A non-device-
related adverse event was defined as hospital admission. 
 
Statistical analysis 
The Kaplan-Meier method was used to generate survival curves. The following end 
points were used: 1. VT, 2. fast VT (> 200 bpm) or VF, 3. fast VT (> 240 bpm) or VF, 
4. total death, and 5. total death plus occurrence of fast ventricular tachyarrhythmias 
representing projected death. Benefit of the ICD implantation was estimated by the 
difference between curves for total cardiac death and calculated projected deaths. 
Fisher´s exact test was used to analyze the difference between Kaplan-Meier curves. 
Univariate analysis with 95% confidence intervals was used to analyze the influence 
of various covariates on the occurrence of fast VT and projected death. 
 
 
Results 
Patients 
A total of 92 patients were considered for implantation of an ICD in combination with 
an endocardial lead system. The patient characteristics are summarized in Table 1. 
There were 75 men (82%) and 17 women (18%) with a mean age of 58 ± 15 years 
(range 17–82 years). Mean LVEF as determined by nuclear isotopes was 36 ± 15% 
range (12-74 %). The underlying diseases were coronary artery disease in 71% of 
the patients, dilated cardiomyopathy in 13%, hypertrophic cardiomyopathy in 2%, and 
other cardiac diseases in 14%. 
 
Patient deaths 
There were 5 patient deaths (5 men, mean age 59 ± 20 years). All deaths except 1 
were witnessed in the hospital. One death was classified as “unknown and occurring 
suddenly” because it was unwitnessed, insufficient information was available, and it 
occurred outside the hospital. The ICD was not available for interrogation. 
  
 
22 
Two patients died of progressive heart failure after implantation, and the other 2 
patients died of an electric storm, one of them during an exacerbation of heart failure. 
 
Table 1. Patient Characteristics 
Patient Characteristics 
Gender, M/F 75/17 
Age, years 58±15 
LV ejection fraction, % 36±15 
Antiarrhythmic drug therapy, n  
Amiodarone 32 
Sotalol 10 
ß-blockade 15 
Underlying cardiac disease, n  
CAD 65 
CMP 12 
History of atrial tachyarrhythmias, n 33 
Indication for ICD implantation, n  
SCD, cardiac arrest 38 
VT, cardiac arrest 19 
VT 30 
Other 5 
Type of ICD, n  
Single chamber 15 
Dual chamber 61 
Biventricular 16 
LV = left ventricular; CAD = coronary artery disease; 
CMP = cardiomyopathy; ICD = implantable 
cardioverter defibrillator; SCD = sudden cardiac death; 
VT = ventricular tachycardia 
 
 
Incidence of all VT/VF 
During a mean follow-up of 364 ± 189 days (range 40 – 737 days), 31 (34%) patients 
had at least 1 episode of ventricular tachyarrhythmia presenting at a median interval 
of 39 days (range 1 – 550 days) after implantation. The recurrence rate of ventricular 
tachyarrhythmia was 36% and 43% at 1 and 2 years respectively (Figure 1). All 
episodes of ventricular tachyarrhythmia were appropriately detected and terminated 
by the device. 
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Figure 1. Actuarial survival rate for freedom of sustained ventricular tachyarrhythmias of any 
rate requiring intervention of the ICD. VF: ventricular fibrillation; VT: ventricular tachycardia. 
 
 
Incidence of fast VT or VF 
Twenty patients (22%) had at least 1 episode of fast VT (> 200 bpm) or VF 
presenting at a median interval of 57,5 days (range 6 – 550 days) after implantation. 
Fast VT (> 240 bpm) or VF was present in 9 patients (10%) at a median interval of 67 
days (range 6 – 550 days) after implantation. The majority of patients in both fast VT 
groups had NYHA class II. The mean LVEF was 29 ± 12% for patients with fast VT (> 
200 bpm) or VF versus 35 ± 15% for patients with fast VT (> 240 bpm) or VF. The 
actuarial event-free rate for fast VT (> 200 bpm) was 77.6% and 69.8% at 1 and 2 
years respectively, whereas the actuarial event-free rate for fast VT (> 240 bpm) was 
88% at 1 year and remained than constant. 
In a univariate model a lower ejection fraction only correlated with a higher 
recurrence of fast ventricular tachyarrhythmias with rates > 200 bpm (P=0,04). The 
NYHA class failed to reach significance in both groups of fast VT. 
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Figure 2. Actuarial survival rates for freedom from death of cardiac origin and of projected 
(project.) death due to ventricular tachycardia (VT) with cycle lengths < 300 ms (> 200 bpm) 
and / or ventricular fibrillation (VF). 
 
 
Survival 
The total mortality rate was 5.5% and 9.8%, at 1 and 2 years respectively. The 
projected death rates (total mortality plus occurrence of fast VT or VF) were 24,0% 
and 33,8% for fast VT (> 200 bpm) and 12.3% and 14.6% for fast VT (> 240 bpm), at 
1 and 2 years respectively (Figure 2). For the total group, the estimated benefit from 
ICD implantation, calculated as the difference between the curves total mortality and 
the projected death rate, increased from 18,5%  (1 year) to 24,0% (2 years) for fast 
VT (> 200 bpm). The estimated benefit of ICD implantation was 6.8% (1 year) and 
4.8% (2 years) in case of the projected death with cutoff rate > 240 bpm. 
The estimated benefit of ICD implantation only reached significance in patients with 
fast VT (> 200 bpm) (P=0.002). The difference in benefit of ICD implantation between 
the groups with fast VT (> 200 bpm versus > 240 bpm) showed a significantly greater 
benefit for the group with fast VT > 200 bpm (P=0.04). 
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The covariates LVEF (P=0,03) and NYHA class (P=0,05) correlated with a higher 
projected death rate for fast VT (> 200 bpm) in a univariate model. Both covariates 
failed to reach significance for fast VT (> 240 bpm). 
 
Procedure-Related Adverse Events 
Adverse events related to the implantation procedure were observed in 12 (13%) 
patients (Table 2). No perioperative deaths were reported. 
The most common adverse events were lead dislodgment (4 pts) and pneumothorax 
(4 pts). Related with implantation of biventricular devices, the LV lead dislodged most 
often (n=2, 13% of biventricular devices). The second most frequent adverse event 
was pneumothorax due to puncture of the left subclavian vein (5% of 77 subclavian 
punctures). 
One patient received inappropriate therapy due to a connector problem, which was 
resolved the next day by re-operation. 
 
Table 2. Procedure-Related Adverse Events 
 Number of patients (%) 
Pneumothorax 4 (4%) 
Coronary sinus dissection 1 (1%) 
Fever/sepsis/infection 1 (1%) 
Wound/pocket problems 1 (1%) 
Lead dislodgment  
Atrial lead 1 (1%) 
Right ventricular lead 1 (1%) 
Left ventricular lead 2 (2%) 
Lead connection 1 (1%) 
 
 
Device-Related Adverse Events 
The event with the highest incidence was inappropriate therapy, which was observed 
in 17 (18%) patients (Table 3). In 11 patients, this was due to supraventricular 
tachyarrhythmias which required hospitalization for cardioversion in 6 of them. 
Subsequently, 2 patients underwent AV node ablation. 
T wave oversensing was observed in 6 patients (1 Medtronic, 5 Biotronik). This was 
resolved by reprogramming the sensitivity. 
A decreased sensing efficacy was present in 2 patients. This was corrected by 
repositioning of the right ventricular lead in 1 patient. The other patient received a 
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special designed coronary sinus lead with left atrial sensing and pacing capabilities, 
as in the right atrium no sufficient sensing signals were available. 
 
Table 3. Device-Related Adverse Events 
 Number of patients 
Inappropriate therapy 17 
SVT 11* 
T wave 6* 
Va 1 
Sensing problems 2 
SVT = supraventricular tachycardia; Va = ventricular 
arrhythmia 
* including patients with more than one different event 
 
 
Non-Device-Related Adverse Events 
In 9 (10%) patients, all presenting with an electric storm, hospitalization was required 
for adjustment of drug therapy and general measures (Table 4). Five of these 
patients developed slow ventricular tachycardias (≤ 150 beats/min) and 
reprogrammation of the device was required. Subsequently, in 2 of them VT ablation 
was performed to resolve the problem. 
Hospitalization for signs of congestive heart failure was required in 6 patients. In 4 of 
these patients, an electric storm occurred in the presence of heart failure. 
 
Table 4. Non-Device-Related Adverse Events 
 Number of patients 
Hospitalization for CHF 6* 
Hospitalization for atrial arrhythmias 7 
Hospitalization for ventricular arrhythmias 9* 
Electric storm 12* 
CHF = congestive heart failure 
* including patients with more than one different event 
 
 
Discussion 
The results in this study are in concordance with earlier findings that patients with a 
history of cardiac arrest or ventricular tachyarrhythmias refractory to drug therapy 
benefit from ICD implantation. The potential benefit was estimated as the difference 
between overall mortality and the projected death rate had the device not been 
implanted. The latter was based on the recurrence of fast and presumably fatal 
  
 
27 
ventricular tachyarrhythmias without termination by the device. The estimated benefit 
from ICD implantation is comparable with the benefit as reported by Böcker et al. for 
the overall group (15.9% and 23.5% at 1 and 3 years respectively.8 It is hard to 
imagine such gain in life expectancy might have been obtained with drugs. The AVID 
trial reported a reduction in mortality of 27% at 2 years in the ICD group compared to 
the group with antiarrhythmic drug therapy.1 The recently published CASH trial 
confirms the superiority of ICD therapy over antiarrhythmic drug therapy as they 
demonstrated a 37% survival benefit from ICD therapy.13 However, the mean LVEF 
of patients in the CASH trial (46%) was higher than in the AVID trial (32%), propably 
due to a larger population without organic heart disease in CASH. Data from the 
AVID trial suggested that patients who appear to benefit most from ICD implantation 
are those with a LVEF < 35%.1 These data are further supported by the MADIT and 
MUSTT trial which both focused on patients with low EF.2,14 In our study, the mean 
LVEF for the whole group was 36%, and 29% for patients with fast ventricular 
tachyarrhythmias. 
 
In the present study, there were no perioperative deaths, which is in line with a 
mortality rate of < 1% associated with implantation of endocardial defibrillation lead 
systems. If we would have used the American definition for surgical mortality, all 
mortality within one month would have been identified as such. This would have 
resulted in 1 death, a mortality rate of 1%. However, it is very difficult to accept this 
early death as “surgical”, and in this case it should rather be considered as failure of 
the therapy. The incidence of procedure-related adverse events was low in our 
series. The observed incidence of lead dislodgments was lower than observed in 
other studies.15 The higher incidence of LV lead dislodgment in patients with 
biventricular devices can be reduced by further improvement of the implantation 
technique and design of the LV lead. 
The second most frequent procedure-related adverse event was pneumothorax 
which is related to puncture of the left subclavian vein.16 The observed incidence in 
our group was low and is line with other reported values.16,17 
As observed with second-generation ICD therapy with limited programmability, 
inappropriate therapy was the most frequent event.4 This inappropriate therapy was 
most often triggered by atrial fibrillation with rapid ventricular response. Despite 
enhancements in technology (improved algorithms and/or the addition of atrial 
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signals), 11 patients (12%) received inappropriate therapy for supraventricular 
tachyarrhythmias. Also, T wave oversensing may lead to inappropriate 
tachyarrhythmia detection. During early follow-up, the evaluation of oversensing 
during sinus rhythm and pacing is necessary to avoid this sensing problem with 
reprogrammation.18 
The overall incidence of inappropriate therapy (18%) is in line with other reports 
emphasizing that inappropriate therapy is the most common adverse event among 
ICD patients.15,17 
 
 
Limitations of the study 
In our study, patients were their own control. As endpoint we used projected death. 
This was based on the assumption that fast ventricular tachyarrhythmias might have 
been fatal in the absence of an ICD. Obviously, both underestimation and 
overestimation of the benefit imposed by ICD therapy cannot be excluded. First, a 
minority of patients might have died from their ventricular tachyarrhythmia slower 
than 200 bpm. Especially, for patients with advanced heart failure who might not 
even tolerate a slower tachycardia or incessant tachycardia. Second, a minority of 
patients might have survived a fast ventricular tachycardia long enough to obtain 
medical attention. Further investigation of these patient groups is warranted. 
 
 
Conclusions 
Finally, we were very pleased that we could reproduce the existing data in literature 
with this small series. This reflects a rigid patient selection with conservative criteria. 
The complication rate and surgical mortality had a very acceptable prevalence, and 
this was probably due to the low profile we kept for the procedure (implantation by 
experienced cardiologists, no general anesthesia). Our follow-up included pre-
hospital discharge testing, out-patient technical and medical follow-up, and 
psychosocial support of patients and family. However, we feel that the attention for 
individual patient problems is still insufficient at present.  
As the Netherlands, with a reported number of  16 new ICD implantations per million 
per year in 1997 are not even reaching the implantation figures of other European 
countries such as Belgium (28/mil.), Denmark (33/mil.), and Germany (49/mil.), the 
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recent increase of implantation centers in the Netherlands was certainly justified19. In 
fact, the National Health Service of the United Kingdom anticipates that 50 per million 
inhabitants, will be the actual, desirable target.20 From these figures, it seems very 
unlikely that the actual number of centers in the Netherlands will be able to cope with 
the widening spectrum of indications. In particular, patients with the most evident 
benefit (“MADIT” and “MUSTT”) are not treated today under the regulations of the 
Ministry of Health. A solution could be that ´peripheral centers`, rather ‘satellite 
centers’, will start again with more rigid screening for those patients considered at 
high risk. As a consequence, facilities for clinical electrophysiology should be offered 
to these centers, which however, is impossible for budgetary reasons at present. 
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Abstract 
Aims: Defibrillation threshold testing is no longer routinely performed as devices 
became more effective. We assessed the lowest effective defibrillation (LED) level at 
implantation and before hospital discharge and related this with outcome.   
Methods and results: 146 consecutive patients with biphasic shock, active can 
devices were studied. Both intraoperative and predischarge tests were completed in 
127 patients, of whom 67 had ≥ 3 VF inductions at implant. Improvement was defined 
when LED decreased with ≥ 3 J. The LED was significantly higher at implantation 
compared to predischarge (P < 0.001). Improvement was seen in 73/127 patients 
(58%). In the group with ≥ 3 VF inductions, an implantation LED > 9 J was related 
with a lower LVEF (P < 0.01); 34 patients (51%) had improvement in LED. During 
follow-up, 18 patients died, 4 received heart transplantation. No different outcome 
was observed in patients with and without improvement. However for those with ≥ 3 
VF inductions, an independent predictor of mortality was implantation LED > 9 J 
without improvement at the second test. 
Conclusion: Repeated defibrillation efficacy testing before hospital discharge may 
confirm that a relatively high defibrillation energy is required. This is related to a 
higher mortality in long-term follow-up. 
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Introduction 
The implantable cardioverter-defibrillator (ICD) became widely accepted for the 
treatment of patients with severe life threatening ventricular tachyarrhythmias(1-3). 
The functions of the ICD and the shock lead integrity are usually tested after 
implantation or prior to hospital discharge(4). Device related problems leading to ICD 
malfunction have become less common due to advances in ICD technology. 
Improvements in lead technology have reduced the risk of lead malfunction(5,6). The 
introduction of biphasic shock waveforms and active can devices improved the 
defibrillation efficacy(7-10). These enhancements have led to a general feeling that 
defibrillation threshold or efficacy testing is no longer important. In order to determine 
the necessity of predischarge testing, the results of ICD testing at implant and 
predischarge were studied and related to patient outcome. 
 
 
Methods 
Patients 
The study population consisted of 127 patients who received an ICD in combination 
with an endocardial lead system. Baseline clinical characteristics, including age, 
gender, left ventricular ejection fraction (LVEF), the presence of coronary artery 
disease (CAD), cardiomyopathy, cardiothoracic (CT) ratio, presenting arrhythmia, 
and pharmacologic treatment were documented. The patient characteristics are 
shown in Table 1.  
 
ICD implantation 
The implantation procedure was performed in the electrophysiology laboratory under 
local anesthesia. The biphasic shock, active can ICD pulse generator and the 
transvenous lead system were inserted through a single left pectoral incision. A left 
cephalic vein cutdown and/or a left subclavian puncture were used for lead insertion. 
The atrial lead was located at the right atrial appendage or lateral free wall by active 
fixation. The right ventricular lead was placed in the right ventricular apex by active 
fixation. The right ventricular lead had either one defibrillation coil or two defibrillation 
coils. For biventricular devices, the left ventricular lead was placed in a tributary of 
the coronary sinus. The ICD pulse generators and defibrillation leads are 
summarised in Table 2. 
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Table 1. Baseline clinical and demographic data 
Characteristic  
Number of cases 127 (100%) 
Gender (Male) 105 (83%) 
Age (years) 59 ± 14 
LVEF  0.35 ± 0.15 
Underlying disease  
Coronary artery disease 92 (72%) 
Dilated cardiomyopathy 21 (17%) 
Hyperthrophic cardiomyopathy 4 (3%) 
NYHA functional class  
I – II 94 (72%) 
III – IV 36 (28%) 
Cardiothoracic ratio 0.54 ± 0.06 
Index arrhythmia  
VF 46 (36%) 
SMVT 70 (55%) 
NSVT 11 (9%) 
Medications   
Amiodarone 46 (36%) 
Beta-blocker 49 (39%) 
Digoxin 26 (20%) 
ACE inhibitor 88 (70%) 
Diuretics 70 (56%) 
ACE = angiotensin-converting enzyme; LVEF = left 
ventricular ejection fraction; NSVT = nonsustained 
ventricular tachycardia; NYHA = New York Heart 
Association; SMVT = sustained monomorphic ventricular 
tachycardia; VF = ventricular fibrillation 
 
Defibrillation efficacy testing 
During the implantation procedure, defibrillation efficacy was tested with the use of a 
step-down defibrillation protocol. The initial delivered shock energy for testing was 15 
J.  If successful, the energy was decreased with steps of 3 J on successive trials until 
defibrillation failed. In case of failure of the initial 15-J shock, the energy was 
increased in 3-J steps on subsequent trials until defibrillation was successful. Testing 
was performed under short-lasting deep sedation by the administration of diazepam 
combined with etomidate. The lowest energy, successful to convert ventricular 
fibrillation to sinus rhythm, was defined as the lowest effective defibrillation (LED). 
For acceptance of the configuration, the LED had to be equal or less than the 
maximum defibrillation energy of the device minus a safety margin of 10 J. 
Ventricular fibrillation was induced via the test program of the ICD by a 50-Hz burst or 
a T wave shock(11). Ventricular fibrillation was defined as a fast polymorphic 
ventricular rhythm with a cycle length < 250 ms that resulted in no phasic blood 
pressure. In case of non-successful defibrillation, an internal rescue shock with the 
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maximum energy of the device or an external maximal shock from a precharged 
defibrillator with the use of epicutaneous self-adhesive patches was delivered. In 
patients with severe LV dysfunction, the procedure was shortened to demonstrate 
that 2 consecutive shocks with a safety margin of 10 J were successful.  
An improvement in LED was defined as a decrease in defibrillation energy of ≥ 3 J at 
the predischarge test.  
 
Table 2. Implanted ICD systems 
ICD system Number 
Biotronik (44) 
DC – ICD 44 
Single coil defibrillation lead 44 
Guidant/CPI (34) 
SC – ICD 27 
BV – ICD 7 
Single coil defibrillation lead 1 
Dual coil defibrillation lead 33 
ELA Medical (8) 
DC – ICD 8 
Single coil defibrillation lead 8 
Medtronic (60) 
SC – ICD 16 
DC – ICD 28 
BV – ICD 16 
Single coil defibrillation lead 45 
Dual coil defibrillation lead 15 
BV – ICD = biventricular implantable cardioverter defibrillator; 
DC – ICD = dual chamber implantable cardioverter defibrillator;  
SC – ICD = single chamber implantable cardioverter defibrillator. 
 
Numbers between brackets indicate the total number for a specific 
brand 
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Statistical analysis 
Continuous variables were expressed as mean ± standard deviation. Chi-square 
testing was used for analysis of categorical variables, and Student’s t test was used 
for analysis of continuous variables. Kaplan-Meier actuarial method was used to 
calculate the survival rate over time. Survival analysis was initiated at the time of ICD 
implantation. Differences between pairs of survival curves were tested by log-rank 
test. Cox proportional hazards model was used to identify independent predictors of 
mortality. Patients who received cardiac transplantation were censored at the time of 
cardiac transplantation. P < 0.05 was considered statistically significant. 
 
 
Results 
Clinical characteristics 
Of the 146 consecutive patients, 19 were excluded from analysis as they were not 
tested at both occasions. The study population consisted of 127 patients. The clinical 
characteristics of these patients are summarised in Table 1. The mean age of the 
patients was 59 ± 14 years (range: 20-82 years). The mean LVEF was 0.35 ± 0.15 
(range: 10-76%). Cardiomyopathy was present in 25 (20%) patients, 21 (17%) 
patients had dilated cardiomyopathy and 4 (3%) had hyperthrophic cardiomyopathy. 
Indications for ICD therapy were as follows: NSVT with subsequent inducible 
sustained ventricular tachyarrhythmias in 11 (9%) patients, spontaneous sustained 
VT in 70 (55%), and VF in 46 (36%). 
 
Survival 
During a mean follow-up of 38 ± 14 months, 18 patients died (17 men, mean age 60 
± 16 years). The mortality rates were 4.7%, 9.6%, and 25.1%, at 1, 2, and 5 years 
respectively. Deaths were considered to be sudden cardiac in 4 (22%) and non-
sudden cardiac in 10 (55%). In 1 case, death was attributed to non-cardiac cause. 
Three cases (17%) were un-witnessed deaths. There were no deaths related to ICD 
implantation. Four (3%) patients underwent cardiac transplantation. The mean 
interval of cardiac transplantation after ICD implantation was 21 months. 
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Defibrillation data at implantation 
 A total number of 93 patients (73%) had an LED ≤ 15 J at this test. The proportion of 
patients with LED ≤ 12 J, ≤ 9 J, and ≤ 6 J was 53%, 38%, and 14%, respectively. 
 
Defibrillation data prior to hospital discharge 
A total number of 108 patients (85%) had an LED ≤ 15 J at this test. This test was 
performed after a median of 1 day after implantation. The proportion of patients with 
LED ≤ 12 J, ≤ 9 J, and ≤ 6 J was 75%, 62%, and 34%, respectively. Overall, the LED 
at implantation was significantly higher compared to the LED at predischarge testing 
(12.9 ± 4.9 J versus 10.4 ± 5.0 J; P < 0.001). A total number of 73 patients (57%) had 
an improvement of ≥ 3 J. 
 
Variables in relation to LED 
There was no significant difference in LED between patients with a single coil 
defibrillation lead (n=88) and patients with a dual coil defibrillation lead (n=39) at 
implantation (12.7 ± 4.8 J vs 13.3 ± 4.9 J) and at predischarge testing (10.2 ± 5.0 J vs 
10.7 ± 5.0 J). The shock impedance for all patients significantly decreased from 56 ± 
12 Ω at implantation to 51 ± 10 Ω at predischarge (P < 0.001). At predischarge, the 
shock impedance significantly decreased in patients with a single coil defibrillation 
lead as well as in patients with a dual coil defibrillation lead.  
 
Subanalysis of patients with at least 3 VF inductions at implantation 
For this group (n=67), the average LED was 11.8 ± 5.7 J. In Table 3, the clinical 
characteristics are summarised for 2 subgroups, dichotomized at an LED value 9 J. 
There were no significant differences between the two patient groups with regard to 
clinical data as age, amiodarone use, coronary artery disease, and CT ratio. Only the 
LVEF was significantly different (P < 0.01). An improvement of ≥ 3 J was observed in 
34 patients (50.7%). In the 30 patients with implantation LED > 9 J, the LED 
improved from 16.9 ± 4.4 J to 13.9 ± 5.1 J at predischarge (P < 0.001). In the 37 
patients with implantation LED ≤ 9 J, it remained unchanged. 
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Factors related to mortality 
This is presented in table 4. In the group tested at 2 occasions, mortality was similar 
in patients with and without improvement in LED. In the group with 3 VF inductions at 
baseline, the difference for those without improvement was borderline significant. 
Subgroup analysis for those with an implantation LED > 9 J, revealed a significantly 
higher mortality when no improvement was observed at the second test (P = 0.02) 
(Figure 1). Cox proportional hazard analysis in the total group of 67 patients revealed 
a baseline LED > 9 J and no improvement at the second test as independent 
predictors of mortality (P < 0.03). The presence of coronary artery disease, 
cardiomyopathy, and LVEF were not identified as predictors of mortality.  
 
Table 3. Patients with 3 VF inductions at implantation  
Patient characteristics LED ≤ 9 J LED > 9 J p value 
Gender (M/F) 34/3 24/6 NS 
Age (years) 60,5 ± 13,6 60,0 ± 14,4 NS 
LVEF (%) 37,4 ± 14,0 26,8 ± 12,7 < 0,01 
Underlying cardiac disease (n)    
CAD 26 22 NS 
CMP 8 8 NS 
CT ratio 0,54 ± 0,06 0,55 ± 0,05 NS 
Antiarrhythmic drug therapy (n)    
Amiodarone 13 12 NS 
β-blockers 7 8 NS 
Sotalol 6 3 NS 
None 11 7 NS 
Shock impedance (Ω) 59 ± 12 52 ± 12 < 0,05 
Mortality (n) 4/37 5/30 NS 
CAD = coronary artery disease; CMP = cardiomyopathy; CT = cardiothoracic; F = female; LED = 
lowest effective defibrillation; LVEF = left ventricular ejection fraction; M = male; NS = not significant 
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Table 4. Mortality 
Subgroup of patients 
  
Improvement No improvement 
 
 Total mortality Mortality Mortality p value 
Total group 18/127 8/73 10/54 NS 
     
3 VF inductions  9/67 2/34 7/33 P = 0.07 
LED ≤ 9J 4/37 1/15 3/22 NS 
LED > 9J 5/30 1/19 4/11 P = 0.02 
     
LED = lowest effective defibrillation; NA = not applicable; NS = not significant 
 
 
Figure 1. Kaplan-Meier curves for total mortality in patients (n=30) with 3 VF inductions at 
implantation, and a baseline defibrillation threshold > 9 J. Improvement in defibrillation 
efficacy at the second test versus no improvement.  
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Discussion 
This study has both technical and clinical implications. The major findings are that 
patients without improvement of defibrillation efficacy at the second test tended to 
have a higher mortality, especially if implantation LED was > 9 J. From a technical 
point of view repeated testing of defibrillation efficacy is no longer necessary in the 
majority of patients. However, the finding that a relatively high energy level to convert 
VF is required, suggests that such a patient has a worse prognosis if this is 
confirmed during repeated testing. 
 
Technical aspects of defibrillation efficacy testing 
Finding a low effective energy level for conversion of VF to sinus rhythm means that 
the probability that a patient will be safely converted during future events is 
high(12,13). The primary function of defibrillation threshold testing is to confirm that 
the safety margin for defibrillation is adequate. A difference of ≥ 10 J between the 
maximum output of a device and the lowest effective energy level has been accepted 
as an adequate safety margin(14). However, these early studies were conducted in 
devices with an epicardial lead system and monophasic waveforms. The idea that 
such finding is predictive for successful therapy was also confirmed with transvenous 
devices(13). The development of active pectoral pulse generators, transvenous lead 
systems, and biphasic waveforms resulted in lower and more stable defibrillation 
thresholds. On the other hand, an absolute safety margin of 10 J does not provide a 
100% probability of successful defibrillation(15). The results of the Low-Energy-
Endotak-Trail (LEET) demonstrated that a relative safety margin is just as safe and 
effective as an absolute safety margin(16). The rate of successful defibrillation at 
twice the energy level of the DFT was 99.5%. During follow-up, this study 
demonstrated no significant difference in conversion rate between twice the DFT and 
maximum output as first-shock energy. These results were recently confirmed in the 
Low Energy Safety Study(17). A safety margin of 5 J was found to be adequate and 
safe with a dual-coil lead and active can device. However, to determine a much more 
accurate value, a step-up/down protocol with multiple induced VF episodes must be 
used(17). 
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Clinical aspects of defibrillation efficacy 
Clinical long-term follow-up data have reported potential adverse consequences of 
an elevated defibrillation threshold(18,19). A higher sudden cardiac death rate was 
reported in the presence of a low safety margin(18,19). Arrhythmic death, accounting 
for 42% of total mortality in the ICD group, could be attributed to failing conversion in 
patients with a high DFT(20). Several studies were designed to identify 
characteristics that may predict the finding of an elevated defibrillation threshold. 
Amiodarone therapy, body surface area, and left ventricular dilation were the 
predictors of high thresholds for nonthoracotomy defibrillation with monophasic as 
well as biphasic waveforms(21-23). In a recent study, clinical parameters were of 
limited use for predicting DFTs in a dual coil active can system(24). None of the 
recent studies showed a correlation between LVEF and DFTs. In our study, the LVEF 
was significantly lower in patients with a LED > 9 J.  
 
Changes in defibrillation efficacy 
Long-term stability of the defibrillation efficacy is important, especially among patients 
with a high DFT and a low safety margin. Changes in DFT are influenced by several 
factors, such as the lead system and the defibrillation waveform. A long-term 
increase in DFT was observed with the use of monophasic defibrillation waveforms in 
combination with a transvenous lead system(25). This was also detected in a 
biphasic series with lead-only and subcutaneous patch configurations(26). In contrast 
to these data, biphasic active can devices combined with a transvenous lead system 
prevented such rise(27). Recently, a significant decrease of DFTs over time with a 
dual-coil, active pectoral lead system was reported(28). In our study, the LED was 
significantly lower at the second test. The LED at implantation can not have been 
influenced by a long lasting anesthesia, as was usual in the era of thoracotomy. 
However, the implantation values can have been influenced by surgical variables, 
such as stress and the presence of a loose pocket. The finding that the impedance 
changed between both tests is another argument to believe that the predischarge 
test is a more “reliable” measurement. 
With the advances in technology, defibrillation thresholds are lower and remain 
stable. The risk to find an increased defibrillation threshold becomes lower than in 
previous times, and good safety margins are usually obtained in almost all patients. 
Even if the safety margin is low, consecutive shocks usually convert the arrhythmia to 
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a normal rhythm, and patients are saved from instantaneous arrhythmic death. The 
fact that our patients with marginal findings had similar mortality as the others 
confirms the idea, that we are faced with the problem of heart failure rather than with 
an arrhythmic problem. The role of a second defibrillation threshold test after 
implantation can than be questioned. Our study shows that despite the current 
generation of biphasic shock, active can pectoral ICDs, a subset of patients requires 
a second defibrillation test. With this second test, patients with a worse prognosis can 
be identified.  
 
Study limitations 
This study was not designed as a prospective trial. However, the data used were 
based on a continuously updated and a prospective complete database. We did not 
assess the LED at longer intervals after implantation, but limited the study to 
predischarge testing. The data must be interpreted with caution, as the number of 
patients with at least 3 VF inductions is small. 
 
 
Conclusion 
From a technical point of view, defibrillation efficacy testing at predischarge is no 
longer necessary in experienced hands, in conventional situations(29,30). With the 
advances in technology, defibrillation thresholds are low and stable. A predischarge 
test is probably more correct for patients who required relatively high defibrillation 
energy to convert the arrhythmia to normal sinus rhythm. The confirmation that 
relatively high defibrillation energy is required during repeated testing suggests that 
mortality is higher during follow-up for these patients. 
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Abstract 
The expanding indications for ICD therapy and the complexity of current devices will 
have impact on follow-up policy. The application of ICD therapy requires an elaborate 
attention to on technical aspects, arrhythmias, and the clinical course of the 
underlying disease. Currently, the quality of medical supervision is dependent on 
scheduled regular follow-up visits. A disadvantage of long intervals can be a delay in 
the physician’s or patient’s awareness of changes in the clinical status. Some 
patients will need more intensive follow-up while others will have the device as an 
innocent bystander and only need technical follow-up. A possibility to address this 
situation, is the transmission of data, already stored in the implanted device. This will 
guarantee a continuous patient surveillance and could possibly help to avoid 
unnecessary control visits. 
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Introduction 
The implantable cardioverter defibrillator (ICD) is an effective therapy as shown in 
prospective, randomized trials for primary and secondary prevention of cardiac 
death(1-4). The workload involved in ICD implantation and follow-up is increasing, 
due to expanding indications and socioeconomic factors. Furthermore, improvement 
in ICD technology is rapidly advancing. Recent developments are the management 
of supraventricular tachyarrhythmias and devices incorporating cardiac 
resynchronization therapy(5, 6). Despite this technical progress, modern ICD 
application continues to require careful and more elaborate attention with respect to 
the many variables of the arrhythmias and the clinical course of the underlying 
disease. 
 
Normal follow-up after ICD implantation 
Regular technical follow-up visits, usually scheduled at 3-monthly intervals were 
initially intended for capacitor reformation. The feature of automatic capacitor 
reformation allowed to concentrate on other items which included battery status, 
shock impedance, therapy history, bradycardia pacing parameters, and stored 
electrograms(7, 8). With these technical improvements it becomes theoretically 
possible to increase the follow-up interval. 
A disadvantage of long intervals can be a delay in the physician’s or patient’s 
awareness of changes in the clinical status. As a result, prevention of disease 
progression and the inherent optimization of therapy can face a setback, e.g. in 
patients who are at high-risk for developing congestive heart failure. Some guidelines 
on ICD therapy recognized this potential problem while others did not address the 
necessity for frequent follow-up(9, 10). 
In spite of this rigid follow-up scheme, unscheduled visits will occur, e.g. after ICD 
discharges. Some patients will indeed need very intensive follow-up with 
reprogramming, adaptation of drug therapy (for heart failure, ischemic events or 
arrhythmias), psychological and social support while others will have the device as 
an innocent bystander and need only minimal technical and clinical check-up. 
Another major concern is that a large subset of interventions may be inappropriate, 
especially in the primary prevention setting(4). Therefore, the workload for an 
electrophysiology department will increase over the next decade.  
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A possibility to address this situation, is the transmission of data which is already 
stored in the implanted device. This will allow an almost continuous patient 
surveillance.  
 
History of Remote or Home Monitoring 
In the early 1970’s, the concept of TransTelephonic Monitoring (TTM) was introduced 
to monitor the longevity of pacemakers(11). In the late 1970’s and 1980’s, the 
usefulness of TTM as a diagnostic tool has expanded to other problems including 
sensing, capture, lead defects, and arrhythmias(12, 13). The clinical utility of TTM 
was confirmed in the 1990’s(14). Transtelephonic interrogation of pacemakers is 
common in the USA but has never gained acceptance in Europe. Transtelephonic 
monitoring is dependent on the active coorperation of the patient, as the patient has 
to place a special device over his/her pacemaker. This arrangement cannot be 
expected to work properly for the majority of patients. A new concept of monitoring 
which relies to a minor extent on the patients cooperation has now been 
implemented in pacemaker therapy. The results are beneficial with respect to 
supraventricular arrhythmia detection and monitoring of AV conduction(15). The 
reported transmission success of messages was high, approximately 92%. The 
patient satisfaction with the convenience, handling, and reliability of the home 
monitoring system ranged from 93 to 97% in SF-36 surveys(16). The cost 
effectiveness of home monitoring was calculated and home monitoring in pacemaker 
patients could result in a significant reduction of 20% in Medicare costs(17).  
 
Home Monitoring System 
A device which is suitable for remote monitoring has the ability to transmit a periodic 
message and in some devices also patient-activated messages. Such transmission 
can be done in several ways, transtelephonic or other networks (e.g. via satellite). In 
a recent commercially avialable model, the data are received by a patient device, 
which transmits an encrypted message to a “Home Monitoring Service Center”. 
There, the message is decrypted and forwarded via fax to the attending physician. 
This message is called “Cardio Report” which contains diagnostic information. 
The first available system for ICD’s is a single-chamber rate adaptive ICD, Belos VR-
T (Biotronik, Berlin, Germany), in combination with a patient device RUC 1000-A 
(Biotronik, Berlin, Germany). The patient device is a dedicated GSM-telephone, 
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which transfers the message to the service-center, when GSM-network service is 
available in the living area of the patient.  
 
Table 1. Possibilities of diagnostic and therapeutic information with home monitoring with 
actual arrhythmia devices 
 
Clinical Information General 
 − Electrogram in actual rhythm 
 − Heart rate 
 − Heart rate variability 
 Pacing related 
 − Percentage atrial pacing 
 − Percentage AV synchrony 
 − Percentage ventricular pacing 
 − Number of mode switches 
 Tachyarrhythmia related 
 − Number of AT episodes 
 − Number of AF episodes 
 − Number of VT episodes 
 − Number of VF episodes 
 − Number of nonsustained episodes 
 − Number of delivered ICD therapies 
 − Number of aborted ICD therapies 
 − Electrogram of arrhythmia 
 Sensor related 
 − Motion 
 − Respiration 
 − Pressure 
  
Technical Information  
 Battery status and voltage 
 Shock impedance 
 P- and R-wave amplitudes 
 Autocapture thresholds 
 Impedance of pace / sense leads 
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Applications of home monitoring in ICD therapy 
Follow-up or guidance of therapy at a distance from the patient has been realised for 
several diagnostic and therapeutic procedures. When applied to ICD therapy, 
supervion of both clinical and technical aspects becomes possible. Table 1 gives an 
indication of what might be possible on short term. Some of these features are 
already possible with currently available ICD’s, some as remote reprogramming are 
still to be implemented (Table 2). 
Table 2. 
Possibility of Bidirectional Transmission 
- device interrogation 
- device (re)programmation 
 
 
Clinical aspects 
Tachyarrhythmias    
Diagnostic data such as the numbers of aborted and delivered ICD therapies are an 
indicator of the total incidence of tachyarrhythmias (Figure 1). Frequently recurring 
episodes of ventricular tachyarrhythmias in patients may indicate increasing 
instability and progression of cardiac disease(18, 19). Treatment of the underlying 
cardiac disease can be optimized by device reprogrammation and/or additional 
antiarrhythmic drug therapy. 
 
Congestive heart failure 
An indication of progression of congestive heart failure can be reflected by 
physiologic parameters as heart rate (e.g. averaged over several days) or in the 
incidence of arrhythmias. Mild heart failure can deteriorate into severe heart failure 
by means of ischemia, or by atrial or ventricular arrhythmias. The arrhythmias may 
lead to ischemia and remodeling(20). Arrhythmias may also drive the progression of 
heart failure, particularly atrial fibrillation(21). Atrial fibrillation has been associated 
with a higher incidence of recurrent ventricular arrhythmias(22).  
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Figure 1. Data from the Cardio Report showing the tables and graphs for detection of VT 
and delivered VT therapies. Cardio Report (Biotronik, Berlin, Germany). 
ATP = antitachycardia pacing; VF = ventricular fibrillation; VT = ventricular tachycardia 
 
 
Inappropriate therapy 
Aborted or delivered ICD therapies can either be appropriate or inappropriate. 
Inappropriate therapy due to supraventricular tachyarrhythmias is a well-known 
problem in ICD therapy(23-26). Frequent ICD therapies, appropriate and 
inappropriate, result, in addition to patient’s inconvenience, in earlier battery 
depletion and decrease device longevity. Further, ICD therapy has a proarrhythmic 
potential(27). 
 
Technical aspects: lead and generator 
Failure of the ICD can be catastrophic because the device must be lifesaving. 
Technical failures which are lead- or generator-related are not rare(28). Technical 
monitoring of an elementary (shock only) device at intervals of 3 months in the office 
was usually sufficient for routine follow-up. However, the increasing complexity of 
devices with additional technical features (e.g. capture of a left ventricular pacing 
lead in the coronary sinus) warrants other ways of monitoring. If this can be done 
continuously out off the office, failures of the implanted system will be immediately 
detected.  
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Impact and cost-effectiveness of home monitoring 
A multicenter trial in Europe and the USA is designed to investigate the diagnostic 
potential of transmitted data with regard to the necessity for patient follow-up. The 
primary goal is to individualize patient follow-up with home monitoring. The 
secondary goals are therapy optimization, acceptance of the home monitoring 
service, and a change of the cost-effectiveness ratio.  
 
Future perspectives 
A next step has to be taken when it will become evident that such transmission is 
reliable and safe. The potential to correct or improve programming is there. More 
complicated devices with additional sensors (e.g. thorax impedance, ventricular wall 
pressure) will allow more sophisticated physiological information to be measured, 
stored, and transmitted, to improve patient care. 
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Abstract 
Lead fracture due to Twiddler’s syndrome, was detected in a 68-year-old patient 1 
month after implantation of an ICD by means of the incorporated home monitoring 
system. The patient was admitted and the lead replaced. This case illustrates the 
clinical benefit of the home monitoring system. 
 
 
Introduction  
Twiddler’s syndrome as a pacemaker complication was first described by Bayliss et 
al in 1968.1 In these cases the pacemaker is turned over and over, such that the lead 
is wound around itself. This syndrome has also been described in implantable 
defibrillator cardioverter (ICD) patients.2 This report describes a patient in whom the 
diagnosis of twiddler’s syndrome was made after a report from the home monitoring 
system of the ICD implanted in this patient. 
 
 
Case report 
A 68-year-old man had an ICD implanted in August 2003.  In 2001 the patient 
experienced an inferior wall myocardial infarction. In July 2003 he developed 
progressive angina and a coronary angiogram was performed. His ejection fraction 
was 45% and triple vessel disease was found. He underwent coronary artery bypass 
grafting (CABG) (LIMA graft-LAD, saphenous vein graft-MO-RDP) without 
complications. One day after the CABG he was resuscitated due to very rapid 
monomorphic VT with a frequency of 240 beats/min. In the days thereafter, multiple 
episodes of nonsustained VT were recorded. Programmed stimulation was 
performed 18 days after the CABG and a sustained monomorphic VT could be 
repeatedly induced. It was decided to implant an ICD. The patient gave informed 
consent for participation in the international Home Monitoring Technology for ICD 
therapy study.  The medical ethical committee of the hospital approved the protocol 
of this study. In this study the Belos VR-T ICD (Biotronik GmbH, Berlin, Germany) is 
used. Due to its integrated long-distance telemetry, this ICD is capable of periodically 
transmitting therapy and status data to the patient device RUC 1000-a (Biotronik), 
usually placed on the bedside cabinet of the patient, and then to a dedicated service 
center. The service center decodes the data and faxes it to the physician at specified 
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time intervals. The purpose of the study is to find the diagnostic power of 
telemetrically transmitted data. 
After local anesthesia, the cephalic vein was located and an electrode (Medtronic 
Sprint 6945, Medtronic Inc, Minneapolis, MN, USA) was introduced and positioned in 
the right ventricular apex. This lead was connected to a Belos VR-T ICD (Biotronik) 
which was placed in a left subcutaneous pocket. After successful testing of the 
implanted system, the patient was discharged the following day. Forty-three days 
after the implantation, a home monitoring report was received (Fig. 1). This report 
showed a steep increase in impedance after an initial period of low impedance. A 
lead rupture was suspected.  The patient was called for an urgent check-up.  A chest 
X-ray was done (Fig. 2) and the diagnosis of twiddler’s syndrome was made. A 
second procedure was scheduled.  After opening of the wound, the tightly wound 
lead was clearly visible (Fig. 3). Further dissection disclosed a complete fracture of 
the lead. The lead had to be cut more distally to advance a stylet. With gentle traction 
the lead could be extracted. A new lead (Medtronic Sprint 6945, Medtronic Inc.) was 
introduced through the left subclavian vein and connected to the ICD, which was 
secured in the pocket with a suture.  
 
 
Discussion 
 Twiddler’s syndrome early after implantation has been described before.3 This case 
clearly demonstrates the potential of the home monitoring system. However since the 
report was only seen a few days after the acute increase in impedance one feels the 
need for an automatic warning feature. Technical features of the home monitoring 
system have been previously described4 and are promising, at least in areas with 
sufficient net coverage. 
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Figure 1. Home monitoring report showing a decline in impedance (09/25/03) followed a few 
days later by a steep rise in impedance 
 
 
 
Figure 2. Chest X-Ray of the patient shows a tightly wound lead. 
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Figure 3. After opening the pocket the twisted lead is clearly seen. 
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A 38-year-old male patient with a recent large anterior wall myocardial infarction had 
sustained monomorphic ventricular tachycardia with a rate of 142 beats/minute 
causing palpitations and signs of congestive heart failure. A Biotronik Phylax AV 
pulse generator (Biotronik, Berlin, Germany), a Kainox RV 75 electrode (Biotronik, 
Berlin, Germany), and a Medtronic model 4568 electrode (Medtronic Inc., 
Minneapolis, MN, USA) were implanted. 
Two months after implantation he received his first shock. Endocardial electrograms 
suggested that the episode of ventricular tachycardia was initiated by a paced 
ventricular complex (the long downward spike in channel 1) following a sudden delay 
in the AV conduction. The tachycardia was detected by the ICD and antitachycardia 
pacing was given. The figure shows a stored endocardial electrogram – upper 
tracing: marker channel (atrial/ventricular); second tracing: atrial intracardiac 
electrogram; lower tracing: ventricular intracardiac electrogram. Sinus rhythm, cycle 
length 710 ms, with a sudden delay in the AV node (250 ms), a ventricular paced 
beat followed by ventricular tachycardia, cycle length 420 ms; A, artefact. 
In the tracing an artefact in the lower ventricular electrogram (channel 3) falling 
before the P wave in the atrial electrogram (channel 2) is observed. As our patient 
had premature ventricular beats, we hypothesise that this artefact presumably 
represents a premature ventricular beat with an amplitude that is different from the 
preceding sinus beats and the beats during ventricular tachycardia. Its timing in the 
atrial and ventricular electrogram coincides perfectly with the ventricular tachycardia, 
and what we initially considered as a ventricular paced beat is probably a fusion of 
the ventricular pacing synchronous with the ventricular tachycardia, without an 
apparent reset of this tachycardia. Furthermore, it is not uncommon that sustained 
monomorphic ventricular tachycardia is initiated by beats with another morphology. 
Whether the electrogram really reflects the signals as recorded by the amplifiers can 
be discussed, they certainly misled us in our initial interpretation. 
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Abstract  
Aim: Inappropriate therapy, due to poor discrimination of supraventricular 
tachycardia (SVT) and ventricular tachycardia (VT) remains a major problem in 
patients with an implantable cardioverter defibrillator (ICD). Theoretically, the addition 
of atrial sensing in discrimination algorithms should improve this differentiation. The 
aim of the study is to evaluate the performance of a new tachycardia discrimination 
algorithm, SMART DetectionTM. 
Methods and results: Twenty-six patients received a nonthoracotomy ICD system 
(Phylax AV, Biotronik, Germany). All documented spontaneous arrhythmia episodes 
were analyzed. 
During a mean follow-up of 8 months, a total number of 139 events with stored 
electrograms were recorded in 12 patients. The final diagnosis was ventricular 
fibrillation (VF) or polymorphic VT (n=20), monomorphic VT (n=69), SVT (n=26), 
other ventricular arrhythmia (n=3) and T wave oversensing (n=21). In 6 episodes a 
dual tachycardia was present. Considering SVT episodes, inappropriate therapy 
occurred in 2 cases of atrial flutter due to stable ventricular rate (<30 ms), 1 case of 
atrial tachycardia and 2 cases of sinus tachycardia due to a sudden onset (>10 %). 
Conclusion: With the SMART DetectionTM algorithm, discrimination of VT from SVT 
achieved a sensitivity of 100%, with an accuracy of 95,6% for all ventricular 
arrhythmias. In case of SVT, the algorithm appropriately detected and inhibited 
therapy in 88% of atrial fibrillation. 
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Introduction 
The implantable cardioverter defibrillator (ICD) has become a widely accepted 
therapy for the treatment of patients with severe life-threatening ventricular 
tachycardia (VT) and ventricular fibrillation (VF)[1,2]. However, inappropriate therapy 
delivered by ICDs for supraventricular tachyarrhythmias remains a clinical problem 
and has been reported to affect 16-22% of the patients[3,4]. Enhanced detection 
criteria, such as onset, stability, and morphology template matching might improve 
the specificity of ICD therapy[5,6,7]. Arrhythmia discrimination is improved further by 
comparing the timing of atrial and ventricular signals in dual chamber ICDs[8,9]. 
Accordingly, a new tachycardia discrimination algorithm, SMART DetectionTM 
(Biotronik, Berlin, Germany) which is used in the Phylax AV defibrillators (Biotronik, 
Berlin, Germany), was developed to discriminate between supraventricular and 
ventricular arrhythmias by performing a stepwise analysis of the atrial and ventricular 
events with regard to their rate, regularity and patterns of AV relationship. 
This report describes the initial experience with the SMART DetectionTM algorithm 
incorporated in the Phylax AV dual chamber ICD. 
 
 
Methods 
Patient population 
During the period between October 1998 and April 2000, 26 patients underwent 
implantation of a Phylax AV dual chamber ICD. The devices were implanted with 
endocardial leads. Indications for ICD therapy included (1) 13 patients with out-of-
hospital cardiac arrest due to VF, (2) 11 patients with poorly tolerated sustained 
monomorphic VT and 2 patients with sustained polymorphic VT (pVT). 
 
Implantation technique 
The ICD pulse generator and endocardial leads were inserted through a single left 
pectoral incision. We used a left cephalic vein cutdown or a left subclavian puncture 
for lead insertion. The ventricular leads were placed at the right ventricular apex, 
while the atrial leads were located at the right atrial appendage or lateral free wall by 
active fixation. The capture and sensing thresholds of both atrial and ventricular 
leads were tested. Far-field R wave sensing in the atrial electrogram was to be 
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excluded. If present, the atrial lead was relocated at another location until appropriate 
sensing could be achieved. 
 
Device overview 
The Phylax AV is a tiered-therapy dual chamber ICD that provides dual chamber 
sensing and pacing in standard and post-shock situations, antitachycardia pacing 
(ATP) modalities, as well as low- and high-energy shock therapies. The device is an 
‘active can’ model and applies onset, stability and the SMART DetectionTM algorithms 
for tachyarrhythmia classification. The criteria onset and stability are applied in 
conjunction with the SMART DetectionTM algorithm. 
The defibrillation leads used were Kainox RV 75 and Kainox RV-S 75 (Biotronik, 
Berlin, Germany) endocardial ventricular leads with an integrated pace/sense and 
defibrillation function. The Kainox RV 75 is a tripolar, tined lead with pace/sense and 
defibrillation function with one distal defibrillating coil. The Kainox RV-S 75 has the 
same features, but comes with an active fixation tip. The endocardial lead used for 
the right atrium was a bipolar active-fixation lead, with an interelectrode spacing of 
8.9 mm or 17.8 mm (Model CapsureFix 6940 and 4568, Medtronic Inc., USA). 
 
SMART DetectionTM algorithm and sensing function 
The SMART DetectionTM algorithm is only applied to the VT detection zone to 
discriminate between supraventricular and ventricular tachyarrhythmias. The 
algorithm detects and analyzes atrial and ventricular events to determine their 
averaged rate, stability, and their relationship patterns (Fig. 1). The AV relationship is 
analyzed by applying the following evaluation criteria, multiplicity and P-R 
monotonicity. Multiplicity is the numerical relationship of atrial signals to ventricular 
signals. P-R monotonicity is the degree of change in the timing relationship of atrial 
events to ventricular events. The RR stability was programmed to 50 msec and onset 
to 10-15% for all patients. The VF and VT detection zones were individualized at the 
physicians’ discretion. 
The initial sensing setting was programmed to 0.375 mV and 0.5 mV for the atrium 
and ventricle respectively. In all patients, the post ventricular atrial refractory period 
(PVARP) was programmed to the nominal value of 240 msec.  
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Figure 1. The SMART DetectionTM algorithm based on averaged atrial and ventricular rate, 
stability, and atrioventricular (AV) relationship. Initial arrhythmia detection is based on the 
continuous analysis of the average atrial and ventricular rate. If the ventricular rate exceeds 
the atrial rate, i.e. RR < PP, the device delivers therapy for VT if the VT sample count is 
fulfilled. In case of RR > PP, the device recognizes the rhythm as a possible SVT. The device 
analyses the RR stability and the numerical relationship of atrial to ventricular signals. In 
case of 1:1 conduction, RR = PP, at the first level the RR stability is verified. Depending on 
RR stability, the system analyzes either the PP intervals or the PR intervals for stability. 
 
 
Follow-up 
For all patients regular follow-up was arranged at our out-patients’ facility every 3 
months or after spontaneous ICD discharges. The event counters and the stored 
intracardiac electrograms were retrieved. Only events with stored electrograms were 
included in this analysis in order to detect errors of the SMART DetectionTM algorithm 
resulting in the delivery of inappropriate therapy. 
 
Data analysis 
All data are presented as mean values ± standard deviation, unless otherwise 
specified. Student’s t-test was used to compare discrete variables where appropriate. 
A two-tailed P value < 0.05 was considered to be significant. 
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Results 
Patient population 
The patients included in this study are summarized in Table 1. Most of the patients 
were male (77%) and had coronary artery disease (77%). Seven patients (27%) had 
amiodarone as antiarrhythmic drug therapy. All patients were in sinus rhythm at the 
time of implant. Paroxysmal atrial fibrillation was documented in 5 patients (19%). 
One patient had sinus node dysfunction. 
Sixteen patients (62%) received the Kainox RV-S 75 tripolar lead with active fixation. 
In 10 patients (38%) the Medtronic 6940 atrial lead and in 16 patients the Medtronic 
4568 atrial lead was implanted. In one patient, both leads were tunnelled from the left 
to the right side as severe thrombosis was present in the left subclavian vein. During 
follow-up there was no significant difference in the amplitude of the atrial 
electrogram. The amplitude of the atrial electrogram at implant was 2.6 ± 1.3 mV and 
at follow-up (9 months) 3.4 ± 2.0 mV. In one patient, the SMART DetectionTM 
algorithm was programmed off due to loss of atrial sensing. This patient had no 
spontaneous arrhythmia with the deactivated SMART DetectionTM algorithm. One 
patient died from progressive heart failure. 
 
Table 1  Patient characteristics 
No. of patients 26 
Gender M/F 20/6 
Age (years) 59 ± 15 
Structural heart disease 
CAD 
DCM 
HCM 
 
20 
2 
2 
Idiopathic ventricular fibrillation 2 
LVEF (%) 38 ± 16 
Clinical arrhythmia 
VF 
MVT 
PVT 
 
13 
11 
2 
Documented AF 5 
Amiodarone 7 
AF = atrial fibrillation; CAD = coronary artery 
disease; DCM = dilated cardiomyopathy; HCM = 
hypertrophic cardiomyopathy; LVEF = left 
ventricular ejection fraction; VF = ventricular 
fibrillation; VT = ventricular tachycardia. 
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Arrhythmia recurrence during follow-up 
During a mean follow-up of 8 ± 5 months (range 1 to 17 months), 12 patients (46%) 
experienced a total of 139 episodes. In all cases, the electrograms with the 
underlying arrhythmias or events could be analyzed and diagnosed (Table 2). Eighty-
nine episodes of ventricular tachyarrhythmias were documented in 8 patients; 26 
episodes of supraventricular tachyarrhythmias in 5 patients; 3 episodes of ventricular 
arrhythmia in 1 patient, and 21 episodes of T wave oversensing in 4 patients. 
 
Table 2  Number of documented episodes of arrhythmias 
Device 
diagnosis 
Investigator 
diagnosis 
# Episodes 
SVT SVT 21 
 VT 0 
 VF 0 
   
VT SVT 5 
 VT 69 
 VF 0 
 V. bigeminy 3 
   
VF SVT 0 
 VT/VF 20 
   
Total  118 
SVT = supraventricular tachycardia; VF = ventricular fibrillation; 
VT = ventricular tachycardia 
If the device withholds therapy, the rhythm is classified by the 
device as no ventricular tachyarrhythmia. T wave oversensing was 
diagnosed in 21 episodes. 
 
 
Ventricular tachyarrhythmias 
During a mean follow-up of 8 ± 5 months (range 1 to 17 months), 20 episodes of 
pVT/VF with stored electrograms occurred in 4 patients (1 to 7 episodes per patient). 
In all episodes the ventricular rate was faster than the atrial rate (RR < PP). The 
device terminated all but 10 episodes with shock therapy. The remaining 10 episodes 
(50%) were recorded in 4 patients (1 to 7 episodes per patient). The device correctly 
detected the episodes and, according to the VF confirmation algorithm, therapy was 
aborted in these cases of nonsustained pVT/VF. 
Eight patients experienced a total of 69 episodes of VT with corresponding stored 
electrograms (1 to 36 episodes per patient). In 6 episodes (9%) atrial fibrillation was 
present (RR > PP). RR stability during these episodes was 5.8 ± 4.6  msec (range 3-
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35 msec). All episodes were correctly identified and terminated with ATP by the 
device. In 5 cases (7%), 1:1 retrograde conduction was present (RR = PP). These 
episodes were correctly identified by the SMART DetectionTM algorithm. All episodes 
were terminated with ATP by the device. In 58 episodes (84%), the ventricular rate 
was faster than the atrial rate (RR < PP). All but 13 episodes were treated by the 
device by ATP (n=41, 71%) or shock therapy (n=4, 7%).  ATP therapy was withheld 
in the remaining 13 episodes of nonsustained VT. In 2 cases, the ATP therapy 
accelerated the VT into VF and shock therapy by the device terminated the 
arrhythmia. 
 
Supraventricular tachyarrhythmias 
Five patients (19%) experienced a total number of 26 episodes of SVT with a stored 
electrogram. Two (8%) of these episodes were sinus tachycardia (occurring in 2 
patients). One episode of atrial tachycardia occurred in 1 patient. In 23 (88%) cases, 
the arrhythmia was atrial fibrillation or atrial flutter (occurring in 2 patients). The RR 
stability during the episodes of atrial fibrillation or atrial flutter ranged from 2 to 266 
msec (mean 60 ± 56 msec). No episode of atrial fibrillation or atrial flutter was 
recorded in the VF zone. In the VT zone, 2 (9%) episodes of atrial flutter were treated 
by shock therapy due to stable RR intervals (mean 12 ±.9 msec). In the remaining 21 
episodes, the device withheld therapy. The 3 episodes of sinus tachycardia and atrial 
tachycardia were treated by antitachycardia pacing. 
With the SMART DetectionTM algorithm discrimination of VT from SVT achieved a 
sensitivity of 100% with a specificity of 80.7% and accuracy of 95.6% for all 
ventricular tachyarrhythmias.  
 
Incidence of inappropriate ICD therapies 
A total number of 29 episodes (21%) were misclassified as ventricular arrhythmia 
after the initial detection period (8 patients, range 1 to 6 episodes per patient). 
Twenty-one of these episodes were T wave oversensing (4 patients, range 2 to 7 
episodes per patient). In 14 episodes, an inappropriate shock by the device was 
delivered. In the remaining 7 episodes, shock therapy was aborted. In 1 patient, 3 
episodes of ventricular bigeminy were present. The patient received inappropriate 
ATP therapy in all episodes. The remaining episodes were 5 cases of SVT (see 
supraventricular arrhythmias). With respect to the performance of the SMART 
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DetectionTM algorithm, T wave oversensing and ventricular bigeminy are problems 
which are not related to the detection algorithm. 
In addition, during the redetection period no coincidently induced atrial fibrillation was 
present. However, in 2 episodes (1 patient) sinus tachycardia was present after 
appropriate therapy for VF. The sinus tachycardia had cycle lengths shorter than the 
maximum programmed cycle length of the VT detection zone. Due to zone merging 
during the VF redetection period, the patient experienced inappropriate shocks for 
sinus tachycardia. In 1 episode VF was induced by an ICD shock delivered during 
sinus tachycardia in the VF redetection period. This VF was terminated by a further 
ICD shock. The SMART DetectionTM algorithm during the redetection is only applied 
to detect coincidently induced atrial fibrillation. 
 
 
Discussion 
This article presents an early experience with a new arrhythmia detection algorithm 
incorporated in a dual chamber ICD. This study primarily evaluates the performance 
of the algorithm in discriminating between supraventricular and ventricular 
tachyarrhythmias. 
A concern with ‘enhanced’ discrimination of supraventricular from ventricular 
tachyarrhythmias in dual chamber defibrillators is the underdetection of VT. Detection 
failure and/or delay has been described with the use of enhancement criteria in 
single chamber ICDs[10,11,12]. The single chamber enhanced detection criteria used to 
detect a tachyarrhythmia are the same in the Phylax AV. The SMART DetectionTM 
algorithm is used to enhance the specificity of arrhythmia detection with addition of 
information derived from the atrial lead. The activated SMART DetectionTM algorithm 
correctly classified all ventricular tachyarrhythmias. The use of the SMART 
DetectionTM algorithm did not result in a loss of sensitivity in the detection of 
ventricular tachyarrhythmias. 
Recently, additional atrial sensing resulted in improved specificity of arrhythmia 
detection with a potential significant reduction of inappropriate therapies due to 
SVT[8,9,13]. In our study, the SMART DetectionTM algorithm withheld therapy in 21 
cases out of 26. In these cases, atrial fibrillation or atrial flutter was present. Based 
on RR stability, therapy was also inhibited in these episodes with single chamber 
criteria. In several studies, it has been shown that the stability criterion in single 
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chamber ICDs can be used with a high specificity to differentiate atrial fibrillation from 
VT[5,6,14]. However, limitations of the stability criterion during supraventricular 
tachyarrhythmias with rapid and stable ventricular response have been reported[12]. 
In comparison to single chamber detection criteria, the use of dual chamber 
enhancement criteria might further improve the detection during rapid and stable 
ventricular rates in supraventricular tachyarrhythmias. The multiplicity criterion in the 
SMART DetectionTM algorithm is used to detect stable supraventricular 
tachyarrhythmias with n:1 conduction. The criterion is based on the calculation of the 
mean atrial rate as a multiple of the mean ventricular rate. However, a variation in the 
calculated mean atrial rates can lead to inappropriate therapy in 2:1 conducted atrial 
flutter.  
Despite the activation of the SMART DetectionTM algorithm, supraventricular 
tachycardias with 1:1 conduction and a progressive prolonging AV interval can be 
misclassified as VT with retrograde 1:1 conduction. This problem is similar to the 
most common failure described for the PR LogicTM algorithm (Medtronic Inc., 
Minneapolis, USA)[15]. Inappropriate therapy for sinus tachycardia in our study was 
related to incorrect device programming. Normally, a programmed onset of 9% is 
able to prevent inappropriate detection of sinus tachycardia[16]. After reprogramming 
the onset, no episodes of sinus tachycardia were misclassified as VT. 
 
 
Comparison of dual chamber algorithms 
A comparison of the performance of this algorithm with other dual chamber 
algorithms is difficult, because the number of episodes, the number of patients and 
the programmed detection criteria differ between the published studies. Studies with 
dual chamber ICDs have reported positive predictive values for the diagnosis of atrial 
fibrillation and atrial flutter of 92% and 86% respectively, with an incidence of 
inappropriate therapy of 3.8%[7,17]. Other data indicate that while the sensitivity for 
ventricular arrhythmias is high (99 to 100%), the specificity for atrial arrhythmias 
remains rather poor (even as low as 70% in some cases)[18,19]. In a survey by a group 
comparing dual chamber with single chamber detection criteria, no major benefit was 
demonstrated with respect to dual chamber detection criteria[20]. The incidence for 
inappropriate therapy due to supraventricular arrhythmias is still in the range of 
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16%[4]. Recently, we demonstrated a trend towards less inappropriate interventions in 
a retrograde analysis of 123 patients[21]. 
 
 
Limitations of the study 
The efficacy of the SMART DetectionTM algorithm in comparison to single chamber 
enhanced detection criteria is unknown. A randomized study between enhanced 
single chamber detection criteria and the SMART DetectionTM algorithm might 
answer the question. The overall incidence of documented supraventricular 
tachyarrhythmias is low. Information is stored in the memory log in chronological 
order. When the log is full, new episodes of tachyarrhythmias overwrite the older 
episodes in the memory. This means that the incidence of appropriate as well as 
inappropriate detections of tachyarrhythmias may have been underestimated. 
 
 
Conclusions 
In conclusion, the SMART DetectionTM algorithm for tachyarrhythmias is safe for the 
detection of ventricular tachyarrhythmias. The high accurracy for AF is encouraging, 
as other dual chamber algorithms have a low performance in this field[11]. The 
incidence of inappropriate therapy due to atrial fibrillation is reduced. 
  
 
84 
References 
 
1. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators: A 
comparison of antiarrhythmic drug therapy with implantable defibrillators in patients 
resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-
1583. 
2. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator 
in patients coronary artery disease at high risk for ventricular arrhythmia. Multicenter 
Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-
1940. 
3. Grimm W, Flores BF, Marchlinski FE. Electrocardiographically documented 
unnecessary, spontaneous shocks in 241 patients with implantable cardioverter 
defibrillators. PACE 1992;15:1667-1673. 
4. Osswald S, Cron TA, Sterns L, Alt E, Stotts L, Coenen M. New ICD-technologies: First 
clinical experience with dual-chamber sensing for differentiation of supraventricular 
tachyarrhythmias. PACE  1998;21:292-295. 
5. Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular 
tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-
defibrillator. J Am Coll Cardiol 1994; 23:1342-1355. 
6. Brugada J. Is inappropriate therapy a resolved issue with current implantable 
cardioverter defibrillators? Am J Cardiol 1999;83:40D-44D. 
7. Duru F, Bauersfeld U, Rahn-Schönbeck M, Candinas R. Morphology discriminator 
feature for enhanced ventricular tachycardia discrimination in implantable cardioverter 
defibrillators. PACE 2000;23:1364-1374. 
8. Schuger CD, Jackson K, Steinman RT, Lehmann MH. Atrial sensing to augment 
ventricular tachycardia detection by the automatic implantable cardioverter defibrillator: 
A utility study. PACE 1988;11:1456-1464. 
9. Lavergne T, Daubert JC, Chauvin M, et al. Preliminary clinical experience with the first 
dual chamber pacemaker defibrillator. PACE 1997;20:182-188. 
10. Swerdlow CD, Ahern T, Chen PS et al. Underdetection of ventricular tachycardia by 
algorithms to enhance specificity in a tiered-therapy cardioverter-defibrillator. J Am Coll 
Cardiol 1994;24:416-424. 
11. Weber M, Böcker D, Bänsch D et al. Efficacy and safety of the initial use of stability and 
onset criteria in implantable cardioverter defibrillators. J Cardiovasc Electrophysiol 
1999;10:145-153. 
  
 
85 
12. Nanthakumar K, Paquette M, Newman D et al. Inappropriate therapy from atrial 
fibrillation and sinus tachycardia in automated implantable cardioverter defibrillators. 
Am Heart J 2000 ;139 :797-803. 
13. Sticherling C, Schaumann A, Klingenheben T, Hohnloser SH for the Ventak AV II DR 
investigators. First worldwide clinical experience with a new dual chamber implantable 
cardioverter defirbillator. Europace 1999;1:96-102. 
14. Higgins SL, Lee RS, Kramer RL. Stability: An ICD detection criterion for discriminating 
atrial fibrillation from ventricular tachycardia. J Cardiovasc Electrophysiol 1995;6:1081-
1088. 
15. Swerdlow C, Sheth N, Olson WH et al. Clinical performance of a pattern based, dual-
chamber algorithm for discrimination of ventricular from supraventricular arrhythmias 
(abstract). PACE 1998;21:4:800. 
16. Neuzner  J, Pitschner HF, Schlepper, M. Programmable VT detection enhancements in 
implantable cardioverter defibrillator therapy. PACE 1995;18:539-547. 
17. Nair M, Saoudi N, Kroiss D, Letac B. Automatic arrhythmia identification using analysis 
of the atrioventricular association. Application to a new generation of implantable 
defibrillators. Participating centers of the automatic recognition of arrhythmia study 
group. Circulation 1997:95;967-973. 
18. Dijkman B, Wellens HJJ. The VT:SVT discrimination algorithms in dual chamber ICDs-
improved but still not perfect automatic arrhythmia detection (abstract). PACE 
1999;22:853. 
19. Wilkoff BL, Kühlkamp V, Gillberg JM, et al. Performance of a dual chamber detection 
algorithm (PR LogicTM) based on the worldwide Gem DR clinical results (abstract). 
PACE 1999;22:720. 
20. Kühlkamp V, Dörnberger V, Mewis C,  Suchalla R, Bosch RF, Seipel L. Clinical 
experience with the new detection algorithms for atrial fibrillation of a defibrillator with 
dual chamber sensing and pacing. J Cardiovasc Electrophysiol 1999;10:905-915. 
21. Kimman GJ, Theuns D, Klootwijk A,  Tavernier R, Sutter J, Jordaens L. Comparison of 
events and survival in dual versus single chamber ICD’s (abstract). PACE 
1999;22:A73. 
  
  
 
87 
Chapter 7 
 
 
Inappropriate Therapy in Implantable Cardioverter-Defibrillators: 
Review of Timing-based Detection Algorithms 
 
D.A.M.J. Theuns, L.J.L.M. Jordaens 
 
Department of Cardiology 
Erasmus MC, Rotterdam, The Netherlands 
 
Submitted for publication: 2004. 
  
 
88 
Abstract 
To avoid inappropriate therapy for atrial tachyarrhythmias, implantable cardioverter-
defibrillators (ICDs) base distinction of atrial and ventricular tachyarrhythmias on 
timing-based detection criteria. The original single chamber detection criteria have 
been implemented as such in dual chamber devices and resynchronization devices. 
Atrial signals are reliably recognized with atrial leads and better algorithms based on 
atrial signals were developed. Unfortunately, the incidence of inappropriate therapy 
did not decrease over time with the development of detection criteria as was proven 
with comparative studies. Further improvement of arrhythmia detection specificity 
remains necessary. 
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Introduction 
First used as secondary prevention after cardiac arrest, the indication of the 
implantable cardioverter-defibrillator (ICD) has expanded to prophylaxis for patients 
with high risk for sudden cardiac death (primary prevention).(1-3) Despite the fact 
that ICDs are very accurate and effective in the treatment of ventricular arrhythmias, 
a substantial proportion of ICD recipients receives inappropriate therapy. The major 
cause of inappropriate therapy is the prevalence of atrial tachyarrhythmias.(4) This is 
potentially dangerous as it might trigger ventricular tachyarrhythmias.(5) To avoid 
inappropriate therapy, arrhythmia detection enhancements were developed. The 
development of arrhythmia discrimination paralleled the development in diagnostic 
information storage. The current generation of ICDs offers an array of diagnostic 
storage capabilities, which improved not only the understanding of triggers 
precipitating arrhythmias, but also allowed a correct diagnosis of arrhythmias and 
verification of the appropriateness of delivered therapies.  
In this report we will first review the history and the evolution of stored diagnostic 
information and arrhythmia detection enhancements. Next, we will present methods 
to minimize bias in the evaluation of arrhythmia detection algorithms in relation to 
inappropriate therapy. Further, we will provide an overview of the incidence of 
inappropriate therapy in relation to the applied arrhythmia detection enhancements.   
 
 
Historical perspective of diagnostic information and arrhythmia detection 
First- and second-generation devices 
The first ICD implantation in a patient occurred on February 4, 1980 at the John 
Hopkins Hospital.(6) The first-generation devices were designed to recognize 
ventricular fibrillation by rate-only detection. Further, the devices were 
nonprogrammable, committed, and had no telemetry capabilities. Some models used 
a morphology detection algorithm, the probability density function (PDF). This 
algorithm lacked specificity, and soon in the development it was recognized that rate-
only detection systems had advantages over PDF-based systems. In the first-
generation devices, the definition of “appropriate” therapy relied on concomitant ECG 
monitoring. In general, the clinical history of the patient and the presence or absence 
of hemodynamically significant symptoms were taken into account. Only later, it 
became evident that some true ventricular arrhythmias were asymptomatic, and that 
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some atrial arrhythmias could cause severe symptoms.(7, 8) The second-generation 
ICDs had recording of RR intervals. This storage allowed analysis of the rate of the 
arrhythmia preceding and following ICD therapy. Differentiation of arrhythmias was 
based on the regularity of RR intervals. Irregular RR intervals suggested atrial 
fibrillation (AF), while regular RR intervals could indicate sinus tachycardia, atrial 
flutter, or atrial tachycardia as well as ventricular tachycardia. Interpretation of the 
appropriateness of therapy was a major limitation in first as well in second-generation 
devices.(9) As a consequence, clinical decision-making in patients treated with the 
first- and second-generation devices was associated with uncertainty. 
 
Third-generation devices 
From the third-generation, the ICD became a tiered-therapy device that provide 
bradycardia sensing and pacing in standard and post-shock situations, 
antitachycardia pacing (ATP) modalities, as well as low- and high-energy shock 
therapies.(10) The most significant advance in diagnostic information was the 
storage of intracardiac electrogram recordings. This diagnostic information included 
recording of RR intervals preceding and following the arrhythmia, and stored 
electrograms with real-time marker channels of arrhythmias triggering ICD therapy 
(Figure 1).  
In order to prevent inappropriate therapy, enhanced detection criteria were 
developed to improve the specificity of arrhythmia detection.(11) The detection 
criteria are based on characteristics of arrhythmias. The criterion “stability” measures 
the degree of regularity of the ventricular response during the arrhythmia. Atrial 
fibrillation is characterized by an irregular response whereas monomorphic VT is 
typically more stable. The criterion “sudden onset” discriminates monomorphic VT 
from sinus tachycardia based on the increase of rate. 
 
Dual chamber devices 
In addition to sudden onset and stability, an improvement in arrhythmia discrimination 
was proposed by the addition of atrial information.(12) The imposition of the simple 
criterion “ventricular rate > atrial rate” would facilitate differentiation of ventricular 
from supraventricular tachyarrhythmias. This method has limitations in separation of 
1:1 ventriculoatrial conducted tachycardias. Arrhythmia discrimination can be further 
improved by the analysis of the timing and relationship between atrial and ventricular 
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electrograms. Dual chamber discrimination algorithms comprise both single and dual 
chamber detection enhancements. 
 
Atrioverters 
Atrial tachyarrhythmias are common in patients with an ICD.(4) A specific device for 
atrial fibrillation, Metrix atrioverter system (Incontrol Inc., Redmond, WA, USA), was 
developed with a two-step detection algorithm.(13, 14) The first algorithm is used to 
discriminate between sinus and a non-sinus rhythm. The second algorithm, a 
baseline crossing test is invoked to detect atrial fibrillation characterized by random 
atrial activity unrelated to the cardiac cycle. The result of both algorithms was a high 
sensitivity (100%) for the detection of non-sinus rhythm with a specificity of 96% for 
atrial fibrillation.(13) However, concerns were raised whether or not a stand alone 
atrial defibrillator is safe enough or should have ventricular backup defibrillation in 
case of shock induced ventricular proarrhythmia. As such, a dual chamber device 
was developed that provides detection and treatment for atrial fibrillation, atrial 
tachycardia, and ventricular tachyarrhythmias.(15-17) In the majority of these 
devices, the detection of atrial arrhythmias is mainly based on rate. For a more 
accurate classification of atrial tachyarrhythmias, a more advanced atrial detection 
algorithm was developed.(18) This algorithm uses the maximum atrial rate, the 
standard deviation, and the dispersion of atrial rate to classify unstable and stable 
atrial arrhythmias. In case of ventricular arrhythmias, the same detection algorithms 
are applied. 
 
Resynchronization devices 
The latest generation of devices provides treatment for congestive heart failure, by 
means of biventricular pacing. This technique uses a lead in a tributary of the 
coronary sinus for left-ventricular pacing. In the earliest generation of 
resynchronization devices, unique cases of inappropriate therapy were observed.(19, 
20) These cases were due to double-counting of ventricular activity, as ventricular 
sensing was obtained from the right ventricle as well as the left ventricle (Figure 2). 
This problem was solved as current generation of resynchronization devices have 
right ventricular-only sensing. For detection of ventricular arrhythmias, atrioverters 
and resynchronization devices use the same detection algorithms as applied in dual 
chamber ICDs of the same manufacturer. 
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Figure 1. The ICD rhythm strip demonstrates the stored bipolar shock electrogram of a 
spontaneous tachyarrhythmia detected in the ventricular tachycardia zone. The electrogram 
during the tachyarrhythmia changed as compared to the electrogram of the baseline rhythm. 
 
 
 
 
Figure 2. Stored electrogram from a Guidant Contak CD demonstrating ventricular double 
counting. During biventricular pacing, a ventricular premature beat (VBP) initiated a 
ventricular tachycardia (VT). The simultaneous recording of rate-sensing bipoles and the 
electrogram of wide bipolar shocking leads demonstrated ventricular double counting. 
Markers: AS = atrial sensing; VF = ventricular fibrillation window (< 300 ms); Chrg: begin of 
charging; -- : no annotation of stored events before detection of tachycardia. 
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Methodological considerations 
Definitions 
For analysis or comparison of detection algorithms, independent measures are used 
to express the success of discrimination between ventricular tachyarrhythmias and 
atrial tachyarrhythmias. The following definitions are applied when analyzing the 
performance of algorithms: the ability of detection criteria to accurately detect 
ventricular arrhythmias (true positive; TP), accurately detect atrial arrhythmias without 
coexistent ventricular arrhythmias (true negative; TN), falsely detect atrial 
arrhythmias as ventricular (false-positive; FP), and falsely detect ventricular 
arrhythmias as atrial (false-negative; FN). The definitions are presented in Figure 3.  
 
Figure 3. Definitions of tachycardia detection 
The sensitivity of detection algorithms is the probability that a ventricular arrhythmia 
is detected when present [TP/(FN + TP)]. The specificity of detection algorithms is 
the probability that a ventricular arrhythmia was not detected given that a ventricular 
arrhythmia was not present [TN/(FP + TN)]. An absolute specificity cannot be 
calculated due to an underdetection of atrial arrhythmias. Some ICD models do not 
store episodes that satisfied rate criteria but were subquently rejected by the 
detection algorithms. To address this limitation, the positive predictive value of the 
detection algorithm is calculated [TP/(TP + FP)]. The positive predictive value 
measures the appropriateness of all delivered therapies, whereas specificity 
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measures the proportion of inappropriately detected atrial tachyarrhythmias. 
However, the positive predictive value is highly dependent on the ratio 
appropriate/inappropriate detected atrial tachyarrhythmias versus the appropriate 
detected ventricular tachyarrhythmias. 
Another aspect is the interpretation of stored electrograms by the physician. The 
accuracy of electrogram interpretation is higher when an atrial electrogram is 
present.(21) 
 
Pitfalls of performance analysis of detection algorithms 
Some investigators used the concepts of “incremental specificity” and “incremental 
positive predictive value” to express the performance of dual chamber detection. The 
term “incremental” is used to indicate that specificity and positive predictive value are 
related to dual chamber algorithms that operate on top of single chamber rate-only 
detection. The pitfalls of this concept of incremental specificity have been 
discussed.(22)  
A valid analysis of dual chamber algorithm performance requires control of multiple 
parameters. The parameters can be divided into ICD parameters and clinical 
parameters, which can influence the outcome of algorithm performance 
measurements. ICD detection algorithms are only applicable in the ventricular 
tachycardia detection zone. The programmed lower and upper limit of the 
tachycardia detection zone defines the range in which the algorithms are applied. 
This detection range may influence the type of atrial tachyarrhythmias presented to 
the algorithm (sinus tachycardia, atrial fibrillation, atrial flutter, or atrial tachycardia). 
Other important clinical aspects are the frequency and distribution of the different 
atrial tachyarrhythmias. For example, a low programmed tachycardia detection rate 
will present more episodes of sinus tachycardia to the algorithm.  
The analysis can be performed on a per-episode or a per-patient basis. The accuracy 
of a per-episode analysis is higher and allows stratifications by types or rates of 
tachyarrhythmias, whereas per-patient analysis allows to assess reproducible errors, 
and the impact on the treated population. Therefore, as the contribution of large 
number of events by a few patients introduces bias in raw algorithm performance 
measures, statistical methods such as the generalized estimating equation (GEE) 
with an exhangeable correlation structure should be used.(23, 24) This reduces the 
bias considerably. 
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Inappropriate therapy and single chamber devices 
The eighties 
The primary goal of the ICD is to detect and treat life-threatening ventricular 
tachyarrhythmias. The detection of tachyarrhythmias is mainly based on the 
measurement of heart rate. With correct sensing, this ensures 100% sensitivity of 
tachyarrhythmias with rates above the programmed detection rate. However, the 
implemented rate-only detection in the first- and second-generation devices has a 
poor specificity in arrhythmia discrimination.(8) The reported incidence of 
inappropriate therapy during the first decade of ICD therapy ranged between 16% 
and 41%.(25-29) Fogoros et al. analysed the actuarial incidence of therapy in 65 
patients.(7) During follow-up, the actuarial incidence of inappropriate therapy was 17 
± 5% and 21 ± 6%, at 1 and 4 years, respectively. With the first- and second-
generation devices, this incidence may have been underestimated due to the lack of 
electrogram storage. Delivery of inappropriate therapy was only noted during 
fortuitous ECG monitoring.(8, 28) The fact that atrial tachyarrhythmias contributed to 
the incidence of inappropriate therapy was established. The reported incidence of 
inappropriate shocks for atrial fibrillation was approximately 50%.(7, 28) 
Inappropriate therapy for sinus tachycardia occurred in up to 9% of patients.(7, 25, 
28) With tiered-therapy devices the inappropriate detection of atrial tachyarrhythmias 
became a greater problem.(30) This was due to the increased probability of rate 
overlap between the target ventricular tachyarrhythmias and atrial tachyarrhythmias, 
as lower detection zones could be programmed.  
 
Detection enhancements  
The detection enhancements “sudden onset” and “stability” have been implemented 
in the ventricular tachycardia zones of devices to reduce inappropriate detections. 
The proportion of patients experiencing inappropriate therapy with activated detection 
enhancements is presented in Table 1. The reported incidence on a per-patient basis 
ranged between 6% and 21%.(31-38) On a per-episode basis, the incidence ranged 
between 5% and 10%.(30, 39) Despite the reduction in inappropriate therapy, the 
applied detection enhancements have certain limitations. 
The stability criterion was designed to discriminate ventricular tachycardia, 
characterised by stable intervals, from atrial fibrillation with irregular ventricular 
response. This criterion has proven to be reliable in the rejection of atrial fibrillation 
 96
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with a mean ventricular < 170 min-1.(38, 40, 41) However, the performance of the 
stability criterion during atrial fibrillation is dependent on the rate of ventricular 
response. The degree of irregularity of the ventricular response decreases at faster 
rates.(42, 43) 
The onset criterion is designed to discriminate ventricular tachycardia from sinus 
tachycardia and is based on a sudden increase in rate.(Figure 4) The onset criterion 
has a high specificity for rejecting sinus tachycardia.(38-40) Despite this high 
specificity, the sudden onset criterion may prevent detection of ventricular 
tachycardias originating during atrial tachyarrhythmias and ventricular tachycardias 
starting with rates below the tachycardia detection rate. The risk for detection failures 
is increased with increasing values of sudden onset criterion.(44) 
 
Figure 4. Panel A, interval plot showing a tachyarrhythmia with a gradual onset. Panel B, 
interval plot showing a tachyarrhythmia with a sudden onset. (Medtronic, model GEM 7271 
DR).   A-A: AA intervals; • V-V: VV intervals: FVT = fast ventricular tachycardia; VF = 
ventricular fibrillation; VT = ventricular tachycardia. 
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Initially, both detection enhancements have been used infrequently because 
physicians were concerned about underdetection of ventricular tachycardias.(30, 40) 
Serious underdetection was observed in only a minor proportion of the episodes.(38-
40) The addition of sustained rate duration in some devices prevents underdetection 
of ventricular tachycardias by onset criteria. However, the feature ensured 100% 
sensitivity for ventricular tachyarrhythmias at the price of decreased specificity for 
rejection of atrial tachyarrhythmias.(39) The major limitation of the onset and stability 
criterion is the inefficiency to reject sudden onset atrial tachyarrhythmias with stable 
atrioventricular (AV) conduction, e.g. atrial tachycardia and atrial flutter. Complex 
detection enhancements with the addition of atrial information might improve the 
specificity of arrhythmia discrimination.  
 
 
Dual chamber devices 
Dual chamber arrhythmia discrimination 
An early argument for the addition of atrial sensing to improve tachycardia detection 
was proposed by Furman as early as in 1982.(45) The comparison between atrial 
and ventricular rates is a simple and effective arrhythmia discriminator.(12) In the 
majority of ventricular tachycardias, the ventricular rate is faster than the atrial rate. 
Limitations of this simple criterion are the underdetection of ventricular tachycardias 
with 1:1 retrograde AV conduction and ventricular tachyarrhythmias during atrial 
fibrillation. To address this limitation, the analysis of AV relationship was postulated 
as a feature of interest to discriminate sinus tachycardia from ventricular 
tachycardia.(46) Measurement of the AV relationship provides a reliable diagnostic 
tool of AV association. Further, timing relationships between atrial and ventricular 
electrograms can be used to identify atrial tachyarrhythmias with stable 
atrioventricular conduction. 
All dual chamber algorithms comprise both single and dual chamber detection 
enhancements (Table 2). Dual chamber discrimination algorithms include comparison 
of atrial and ventricular rates and/or measures of the atrioventricular relationship. The 
algorithms in dual chamber devices can be roughly divided into 2 groups: 1). 
comparison of atrial and ventricular rates (rate branches), and 2). hierarchical 
analysis of the atrioventricular relationship. 
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Dual chamber algorithms based on rate branches 
Comparison of atrial and ventricular rates is applied in 3 algorithms. The dual 
chamber algorithms in Biotronik (Berlin, Germany) and St. Jude Medical (Sylmar, CA, 
USA) initially divide tachyarrhythmias into three rate branches: ventricular rate > atrial 
rate, ventricular rate < atrial rate, and ventricular rate = atrial rate. In the latter 2 
branches, applicable single and dual chamber arrhythmia discriminators are applied 
to classifiy the arrhythmia. In case of the ventricular rate = atrial rate branch, the 
onset criterion and analysis of the atrioventricular relationship are applied. The 
association or dissociation of the rhythms is monitored based on the stability 
criterion. If the ventricular rhythm is stable and the atrial rhythm is unstable, the 
tachyarrhythmia will be classified as ventricular. If both rhythms are stable, the 
stability of the atrioventricular relationship is analyzed to exclude atrioventricular 
dissociation. 
In Guidant dual chamber devices (St. Paul, MN, USA), priority is given to the single 
chamber detection criteria onset and stability. An aggressively programming of single 
chamber detection criteria in these devices will decrease the sensitivity but increase 
the specificity of arrhythmia discrimination.(47, 48) The dual chamber detection 
criterion “ventricular rate > atrial rate” can be applied to prevent underdetection of 
ventricular tachyarrhythmias. The “Afib threshold” criterion can not prevent 
inappropriate classification of the arrhythmia as priority is given to the stability 
criterion.  
 
Dual chamber algorithms based on analysis of the atrioventricular relationship 
A hierarchical structure of single and dual chamber arrhythmia discriminators is 
applied in the algorithms PARAD, PARAD+ (ELA Medical, Le Plessis, France) and 
PR Logic (Medtronic Inc, Minneapolis, MN, USA). The PARAD algorithm first 
analyses the stability of the rhythm, then atrioventricular association, onset, and 
finally the chamber of origin.(49, 50) The chamber of origin is used to discriminate 
between ventricular tachyarrhythmias and atrial tachyarrhythmias with 1:1 AV relation 
by identification of atrial activity preceding ventricular activity or vice versa. In 
PARAD+, the additional criterion “long cycle search” can be activated to inhibit 
therapy for atrial fibrillation with fast ventricular response.  
The PR Logic algorithm is based on the timing relationship of atrial activity with 
respect to ventricular activity.(51) For atrioventricular relationship analysis, each RR 
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interval is divided into 4 zones. Arrhythmia classification is based on PP and RR 
intervals, stability of PP and RR intervals, PR:RP relation, and PR dissociation. The 
findings receive a code, which is compared with templates in a library of arrhythmias. 
PP intervals and AV relation are used for identification of atrial tachyarrhythmias, and 
stability of RR intervals and AV dissociation are used to identify ventricular 
arrhythmias when atrial fibrillation is present. In both algorithms therapy is delivered 
unless a discriminator identifies an atrial tachyarrhythmia. 
 
 
Dual chamber devices and inappropriate therapy 
Performance of dual chamber algorithms 
The reported incidence of inappropriate therapy with dual chamber devices ranges 
between 5 and 15%.(48, 49, 52-60) The majority of studies conducted with dual 
chamber devices were restricted to one manufacturer. These studies mainly 
focussed on the feasibility and safety of the dual chamber devices, and provided data 
of improved specificity of arrhythmia detection without compromising the sensitivity to 
ventricular tachyarrhythmias (Table 3). The specificity ranged between 66.7% and 
93.3% with positive predictive values for ventricular tachyarrhythmias between 87.4% 
and 98.4%. These data support an actual benefit of dual chamber devices over 
single chamber devices. However, caution is necessary when interpreting these data. 
The comparison of reports is difficult due to differences in methodology, follow-up 
time, number of patients, number of episodes, type of atrial tachyarrhythmias, and 
the applied algorithm. 
Studies comparing single chamber and dual chamber devices reported small or even 
non-existent advantages of dual chamber discrimination.(61-64) In an open-label 
nonrandomized study by Kuhlkamp et al., the number of inappropriate therapies for 
atrial fibrillation was not decreased with a dual chamber device in comparison to a 
single chamber device.(61) The authors attributed this higher incidence of 
inappropriate therapy to atrial sensing problems and the high cut-off value of the “Afib 
threshold” dual chamber detection criterion. These problems weakened the stability 
criterion in the dual chamber device. The “Afib threshold” criterion increased by 46% 
the number of inappropriate therapies as compared to the stability criterion. The 
study by Deisenhofer et al. confirmed a higher incidence of inappropriate therapy due 
to atrial sensing problems in dual chamber devices.(62) 
  
 
102
In contrast, the recently published randomized, crossover study “1+1 Trial” by 
Bänsch et al. reported a significant benefit for dual chamber detection.(65) However, 
the combined end-point included all inappropriate therapies and ventricular 
tachyarrhythmias above the tachycardia detection interval or with a significant delay 
in therapy deliverance. The absolute numbers of inappropriate therapy were not 
significantly different between both study groups (74 single chamber group versus 62 
dual chamber group). 
 
Limitations of dual chamber algorithms 
The functionality of dual chamber algorithms is influenced by the accurate 
determination of the atrial rate. This depends on the position of the atrial lead, the 
characteristics of the electrode tip, and the pulse-generator software. The presence 
of far-field R waves and atrial blanking should be recognized.(56, 61, 62, 66) Dual 
chamber ICDs use postventricular blanking periods after paced and sensed events to 
avoid oversensing of far field R waves. Atrial blanking after a ventricular sensed 
event may cause atrial undersensing, particularly during fast ventricular rates.(Figure 
5) During fast conducted atrial tachyarrhythmias, the total fraction of blanked atrial 
activity is increased, again causing atrial undersensing. This may result in 
inappropriate detection of atrial fibrillation or flutter.(61) On the other hand, without 
atrial blanking periods, atrial oversensing of far field R waves may occur, resulting in 
overestimation of the atrial rate during tachyarrhythmias with 1:1 atrioventricular 
relationship. This can cause either inappropriate classification of atrial 
tachyarrhythmia as ventricular tachyarrhythmia or inappropriate rejection of 
ventricular tachyarrhythmia.(56) Atrial sensing errors occur in up to 66% of 
episodes.(66) 
Despite the advanced detection algorithms in dual chamber devices, inappropriate 
classification of atrial tachyarrhythmias is still a problem, especially for atrial 
arrhythmias with stable atrioventricular conduction (e.g. atrial flutter and atrial 
tachycardia).(48, 64, 65)(Figure 6) Neither sinus tachycardia nor atrial fibrillation is a 
major problem for single as well as dual chamber detection algorithms.(64) 
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Figure 6. Stored bipolar electrogram showing atrial flutter with 2:1 atrioventricular 
conduction. The device classified the arrhythmia as ventricular tachycardia, resulting in 
inappropriate therapy (Medtronic, model InSync 7272). A = atrial electrogram, V = ventricular 
electrogram. Markers: AF – atrial fibrillation; AR = atrial refractory sensing; AS = atrial 
sensing; TD = tachycardia detected; TP = tachycardia pacing; TS = ventricular tachycardia 
window (< 400 ms). 
 
Conclusion 
The primary goal of the ICD is to detect and subsequently terminate life-threatening 
ventricular tachyarrhythmias. Despite the effectiveness in the treatment of ventricular 
tachyarrhythmias, inappropriate therapy due to atrial arrhythmias is still a relatively 
common problem in ICD patients. With the increasing indications for ICD 
implantation, device selection remains a matter of debate. The rules for device 
selection for patients with a primary prevention indication can be different from those 
applied for patients with a secondary prevention indication. The recently published 
DAVID trial demonstrated deleterious effects of DDD pacing with a conventional right 
ventricular lead in patients without a bradycardia pacing indication.(67) 
To reduce inappropriate therapy, detection algorithms other than timing-based 
algorithms have evolved. For further improvement of arrhythmia discrimination, the 
current generation of devices applies morphology discrimination algorithms in 
conjunction with timing-based algorithms. Nevertheless, to avoid inappropriate 
therapy, it is particularly important to program carefully the enhanced detection 
criteria of the device, irrespective of the indication.  
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Inappropriate therapy is a common clinical problem in recipients of implantable 
cardioverter-defibrillators (ICDs). The present study evaluated whether clinical 
characteristics could predict inappropriate ICD therapy due to atrial 
tachyarrhythmias in a series of 260 patients. 
 
The implantable cardioverter-defibrillator (ICD) has become the standard therapy for 
life-threatening ventricular tachyarrhythmias.1-3 Despite the accuracy and 
effectiveness in the diagnosis and treatment of ventricular tachyarrhythmias, a 
substantial proportion of patients with ICDs experience inappropriate interventions. 
The reported incidence ranges from 8% to 40%.4-7 Several studies have investigated 
clinical risk predictors for ventricular arrhythmia recurrence.8-10 In contrast, clinical 
risk predictors for inappropriate ICD use have not been investigated. This study 
examined the variables that may predict which patients are more likely to receive 
inappropriate therapy. 
• • • 
The study population consisted of 326 consecutive patients who underwent first 
transvenous implantation at the Erasmus Medical Center (Rotterdam, The 
Netherlands). Of these, 57 patients were excluded because of participation in a 
prospective, randomized study of single- and dual-chamber detection algorithms. 
Another 9 were excluded because of the presence of hyperthrophic cardiomyopathy. 
Thus, 260 patients were eligible for analysis. The patients were assigned to ICD 
therapy because of a history of cardiac arrest, spontaneous sustained ventricular 
tachycardia (VT), or nonsustained VT with subsequent inducible sustained VT. Data 
in the ICD registry are updated prospectively after each clinic visit. 
 
The prospectively collected clinical and functional variables for each patient include 
age, gender, the presence of coronary artery disease (including myocardial infarction 
and cardiomyopathy), the left ventricular ejection fraction (LVEF) as determined by 
nuclear isotopes, index arrhythmia, history of atrial tachyarrhythmias documented in 
the clinical file, and pharmacologic treatment. 
 
The implanted devices were manufactured by Biotronik (Phylax AV, Tachos DR, and 
Belos VR-T; Biotronik GmbH & Company, Berlin, Germany), ELA Medical (Defender 
IV, and Alto DR; ELA Medical, Paris, France), Guidant (Mini IV, Contak CD, Renewal 
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I, and Renewal II; Guidant Corporation, St Paul, Minnesota), and Medtronic (7227, 
7250, 7271, and 7272; Medtronic, Inc, Minneapolis, Minnesota). The tachycardia 
detection rate was programmed according to the clinical presentation of each patient. 
For all patients the detection enhancements were activated immediately after ICD 
implantation. In single- and dual-chamber devices, the stability criterion was 
programmed at 40 to 50 ms, and the onset criterion was programmed at 15% to 
20%. In all dual-chamber devices, the respective dual-chamber detection algorithms 
were activated. 
 
Follow-up began at ICD implantation. At every follow-up visit (at 3-month intervals) or 
every visit prompted by ICD therapy, all stored data of tachyarrhythmia episodes 
were collected. Two independent researchers reviewed the stored 
electrocardiograms. In case of disagreement between the 2 reviewers about the 
stored electrocardiograms, a third reviewer was consulted and made a decision. For 
each episode, the date, type, morphology (monomorphic or polymorphic), and mean 
cycle length (CL) of the tachyarrhythmia and the type and outcome of delivered ICD 
therapy were recorded. A ventricular tachyarrhythmia was defined as an event with a 
sudden increase in rate combined with a change in electrocardiographic morphology 
from the baseline rhythm. If an atrial electrogram was present, the presence of 
atrioventricular dissociation was used to classify a ventricular tachyarrhythmia. 
Therapy delivered for atrial arrhythmias (including atrial fibrillation, atrial flutter, atrial 
tachycardia, and sinus tachycardia) was defined as inappropriate. 
 
Continuous variables were evaluated using Student’s t test or analysis of variance. 
The chi-square test was used for the analysis of categorical variables. The actuarial 
event-free rates from ventricular and atrial tachyarrhythmias triggering ICD therapy 
were calculated according to the Kaplan-Meier method. Differences between pairs of 
actuarial curves were tested by the log-rank test. Relative risks expressed as hazard 
ratios with 95% confidence intervals (CIs) were based on a Cox proportional-hazards 
model. Covariates previously identified to be independently associated with the 
occurrence of inappropriate ICD therapy were used in the multivariate model. A 2-
tailed p value < 0.05 was considered significant. 
The clinical characteristics are listed in Table 1. Coronary artery disease was present 
in 70% of the patients, nonischemic cardiomyopathy (excluding hyperthrophic 
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cardiomyopathy) in 30%, with dilation in 21%. Twenty-four percent received single-
chamber devices, 53% dual-chamber devices, and 23% dual-chamber devices with 
cardiac resynchronization capability. The programmed mean detection CL of the VT 
zone was 377 ± 52 ms. 
 
Table 1. Patients’ clinical characteristics (n=260) 
Characteristics Value 
Men  216 (83%) 
Age (yrs) 60 ± 13 
LVEF (%) 31 ± 14 
Underlying cardiac disease  
Coronary artery disease 184 (71%) 
Dilated cardiomyopathy 61 (24%) 
History of atrial tachyarrhythmias 79 (29%) 
Index arrhythmia  
Ventricular fibrillation 78 (30%) 
VT 125 (48%) 
Nonsustained VT 57 (22%) 
Pharmacologic treatment at discharge  
Amiodarone 97(37%) 
Betablockers 120 (46%) 
Digoxin 57 (23%) 
ACE inhibitor 189 (73%) 
Diuretic 158 (61%) 
Lipid-lowering drug 129 (50%) 
ACE = angiotensin-converting enzyme 
 
During a mean follow-up of 22 ± 16 months (range 1 to 60 months), 107 patients 
(41%) experienced ≥ 1 episode of sustained ventricular tachyarrhythmia, triggering 
ICD therapy. The actuarial event-free rates for ventricular tachyarrhythmias were 
66.0%, 55.8%, and 45.0% at 1, 2, and 4 years, respectively. The mean CL of 
monomorphic VT was 333 ± 62 ms, for polymorphic VT or ventricular fibrillation, it 
was 223 ± 26 ms. 
 
A total of 37 patients (14%) experienced inappropriate ICD therapy due to atrial 
tachyarrhythmias. The actuarial event-free rates for inappropriate therapy were 
87.0%, 83.6, and 80.8%, at 1, 2 and 4 years, respectively (Figure 1). Nineteen 
patients experienced inappropriate therapy for atrial fibrillation at least once, and 18 
patients received inappropriate therapy for sinus or atrial tachycardia. There was no 
significant difference between actuarial event-free rates for inappropriate therapy 
triggered by atrial fibrillation (94.4% and 88.8%) or atrial or sinus tachycardia (92.7% 
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and 91.3%), at 1 and 4 years, respectively. The mean ventricular CL during atrial 
fibrillation was 319 ± 44 ms (range 260 to  400 ms), for atrial or sinus tachycardia, the 
mean ventricular CL was 374 ± 48 ms (range 300 to  480 ms). 
 
 
Figure 1. Actuarial event rates for inappropriate device therapy 
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Table 2. Comparison of patients with and without inappropriate device therapy 
Characteristic Inappropriate ICD therapy (n = 37) 
No inappropriate ICD 
therapy (n = 223) 
p  
Value 
Men  30 (81%) 186 (83%) NS 
Age (yrs) 61 ± 12 60 ± 13 NS 
LVEF (%) 31 ± 14 31 ± 14 NS 
Underlying cardiac disease    
Coronary artery disease 25 (68%) 159 (71%) NS 
Dilated cardiomyopathy 9 (24%) 52 (23%) NS 
History of atrial tachyarrhythmias 19 (51%) 57 (26%) 0.003 
Index arrhythmia    
Ventricular fibrillation 12 (32%) 66 (30%) NS 
VT 19 (52%) 106 (47%) NS 
Nonsustained VT 6 (16%) 51 (23%) NS 
Pharmacologic treatment    
Amiodarone 12 (32%) 85 (38%) NS 
Betablockade 19 (51%) 101 (45%) NS 
Digoxin 11 (30%) 46 (21%) NS 
ACE inhibitor 30 (82%) 159 (74%) NS 
Diuretic 23 (62%) 135 (63%) NS 
Lipid-lowering drug 17 (46%) 112 (52%) NS 
Abbreviation as in Table 1 
 
Figure 2. Actuarial event rates for inappropriate device therapy for patients with and without 
a history of atrial tachyarrhythmias 
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Clinical variables for patients with and without inappropriate device therapy are 
presnted in Table 2. Age, gender, LVEF, underlying cardiac disease, and 
pharmacologic treatment did not differ between those with and without inappropriate 
device therapy. The incidence of inappropriate device therapy was higher after a 
history of atrial tachyarrhythmias (p = 0.003). Additionally, inappropriate ICD therapy 
was noted more frequently in patients who received appropriate device therapy (p = 
0.001). 
 
To evaluate clinical predictors of inappropriate device therapy, variables were 
entered in a Cox proportional-hazards model (age, pharmacologic treatment, type of 
ICD, LVEF, CAD, cardiomyopathy, history of atrial tachyarrhythmias, and recurrent 
VT). This analysis revealed a history of atrial tachyarrhythmias and recurrent VT with 
CL ≥ 350 ms triggering device therapy as independent clinical predictors of 
inappropriate ICD therapy. The relative risk was 2.4 (95% CI 1.2 to 4.8, p = 0.01) for 
history of atrial tachyarrhythmias. This was supported by lower actuarial event-free 
rates for inappropriate device therapy for patients with a history of atrial 
tachyarrhythmias compared with patients without such a history (62.5% vs 88.2% at 
4 years, p = 0.002; Figure 2). 
 
The relative risk increased to 3.1 if patients had recurrent VT with CL ≥ 350 ms 
triggering device therapy (95% CI 1.5 to 6.3, p = 0.002). To address the question 
whether long interval programming explained this greater risk, we analyzed a 
detection interval of ≥ 350 ms as a tachycardia criterion. In multivariate analysis, this 
detection interval was not identified as an independent predictor for inappropriate 
therapy, with a relative risk of 2.2 (95% CI 0.6 to 7.5, p = 0.21). Although not 
significant, the programmed detection cycle length of the VT zone tended to be 
shorter in patients with inappropriate therapy compared with those without 
inappropriate therapy (386 ± 46 ms vs 371 ± 44 ms, p = 0.06). Proportionally, 
patients with dual-chamber devices experienced more inappropriate therapy 
compared with those with single-chamber devices (6% vs 17%, p < 0.05).   
• • • 
The present study evaluated whether clinical characteristics could predict 
inappropriate ICD therapy due to atrial tachyarrhythmias. The observations noted in 
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this study are: (1) a history of atrial tachyarrhythmias is an independent predictor of 
inappropriate therapy and (2) recurrent VT with CL ≥ 350 ms triggering device 
therapy is associated with an increased risk for first inappropriate therapy.  
 
In this study, the incidence of inappropriate ICD therapy was 14%. Most patients 
experienced an inappropriate ICD intervention in the first year after device 
implantation, regardless of primary and secondary prevention. These findings agree 
with studies reporting on inappropriate ICD therapy.11,12 In the Antiarrhythmics 
Versus Implantable Defibrillators Trial, atrial tachyarrhythmias were responsible for 
inappropriate therapy in 22% of patients and 16% of all treated episodes.12  
 
It is no surprise that patients with a history of atrial tachyarrhythmias are at risk for 
inappropriate intervention for atrial tachyarrhythmias. Given the epidemiology of atrial 
fibrillation, atrial tachyarrhythmias are common in ICD recipients, of whom most have 
structural heart disease.13 More recently, it has been reported that a history of 
paroxysmal atrial fibrillation predicted a higher recurrence rate of atrial 
tachyarrhythmias.14 
 
More notable is the association of recurrent VT with CL ≥ 350 ms with an increased 
risk for inappropriate therapy. The association between ventricular tachyarrhythmias 
and paroxysmal atrial tachyarrhythmias in ICD recipients has been established in 
previous studies.15-17 Slow ventricular tachyarrhythmias were associated with left 
ventricular dysfunction (LVEF < 40%) and Class III antiarrhythmic drug therapy.18 
Another aspect to be addressed is the programmed detection interval. In case of 
slow ventricular tachyarrhythmias, an overlap with the ventricular rate of atrial 
tachyarrhythmias is present. The programmed detection interval was not identified in 
multivariate analysis as an independent predictor. 
 
Whether device selection should depend on the knowledge of a history of atrial 
tachyarrhythmias is an open question, as inappropriate therapy occurs equally in 
patients with single- and dual-chamber devices. The addition of an atrial lead might 
improve the specificity of arrhythmia discrimination but introduces potential surgical 
and technical problems. This should be balanced against the potential minor 
advantages, such as the presence of slow ventricular tachyarrhythmias.  
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Abstract 
Objectives: The purpose of this randomized study was to investigate the 
performance of single- and dual-chamber tachyarrhythmia detection algorithms. 
Background: A proposed benefit of dual-chamber implantable cardioverter-
defibrillators (ICDs) is improved specificity of tachyarrhythmia detection. 
Methods: All ICD candidates received a dual-chamber ICD and were randomized to 
programmed single- or dual-chamber detection. Of 60 patients (47 male, 58 ± 14 
years, LVEF 30%), 29 had single-chamber and 31 dual-chamber settings. The 
detection results were corrected for multiple episodes within a patient with the 
generalized estimating equations (GEE) method. 
Results : A total of 653 spontaneous arrhythmia episodes (39 patients) were 
classified by the investigators; 391 episodes were ventricular tachyarrhythmia (32 
patients). All episodes of ventricular tachyarrhythmias were appropriately detected in 
both settings. In 25 patients, 262 episodes of atrial tachyarrhythmias were recorded. 
Detection was inappropriate for 109 atrial tachyarrhythmia episodes (42%, 18 
patients). Rejection of atrial tachyarrhythmias was not significantly different between 
both groups (P=0.55). Episodes of atrial flutter/tachycardia were significantly more 
misclassified (P = 0.001). Overall, no significant difference in tachyarrhythmia 
detection (atrial and ventricular) between both settings was demonstrated (P=0.77).  
Conclusion: The applied detection criteria in dual-chamber devices do not offer 
benefits in the rejection of atrial tachyarrhythmias. Discrimination of atrial 
tachyarrhythmias with stable atrioventricular relationship remains a challenge. 
Abbreviations and Acronyms 
AF   = atrial fibrillation 
AFL   = atrial flutter 
AT   = atrial tachycardia 
DC group  = dual-chamber supraventricular detection 
algorithm group 
GEE   = generalized estimating equation 
ICD   = Implantable Cardioverter-Defibrillator 
SC group  = single-chamber supraventricular detection 
algorithm group 
ST  = sinus tachycardia 
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Introduction 
Despite the proven benefit from advancing implantable cardioverter-defibrillator (ICD) 
technology, a substantial proportion of ICD recipients experience inappropriate ICD 
therapy due to atrial tachyarrhythmias (1-5). In patients with a single-chamber device, 
inappropriate classification of atrial tachyarrhythmias occurs in approximately 20% to 
30% of the patients (1,6,7). The development of dual-chamber devices provides the 
opportunity to improve the accuracy of tachyarrhythmia detection by the addition of 
atrial information (8,9). The superiority of detection algorithms in dual-chamber ICDs 
has not been proven so far. Prospective, randomized studies evaluating the efficacy 
of dual-chamber detection algorithms are lacking. The advantages of dual-chamber 
ICDs for accurate discrimination are small or even nonexistent (10,11). Even more, 
dual-chamber pacing offers no clinical advantage over ventricular backup pacing in 
ICD patients with no indication for cardiac pacing (12).  
We designed a prospective, randomized study to compare the performance of 
tachyarrhythmia detection algorithms in single-chamber and dual-chamber ICDs. 
 
 
Methods 
Study design 
The Prevention of Inappropriate (PINAPP) Therapy Study was a single-center, 
prospective, randomized study of patients comparing single- and dual-chamber 
discrimination criteria. All patients had a standard indication for ICD implantation for 
the treatment of ventricular tachyarrhythmias but without an indication for 
antibradycardia pacing. Patients with permanent atrial fibrillation (AF) or an indication 
for resynchronization therapy were excluded from the trial. The clinical characteristics 
of the patients are summarized in Table 1. 
The local ethical committee approved the study. Written informed consent was 
obtained from all patients prior to enrollment in the study. All patients received a dual-
chamber device. The patients were randomly assigned to have the device 
programmed to single-chamber supraventricular detection algorithms (SC group) or 
to the enhanced dual-chamber supraventricular detection algorithms (DC group). 
Random assignment was obtained by telephone to an independent service 
(Cardialysis, Rotterdam, the Netherlands).  
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Table 1.  Patient’s clinical characteristics 
Patient Characteristics (n=60) 
 SC group (n=29) 
DC group 
(n=31) p Value 
Gender (M/F) 24/5 23/8 NS 
Age (years) 57 ± 17  61± 10 NS 
LVEF (%) 29 ± 11 31 ± 10 NS 
History of atrial arrhythmias (n) 8 7 NS 
Underlying cardiac disease (n)    
CAD 21 26 NS 
CMP (dilated) 6 3 NS 
CMP (hyperthropic) 2 2 NS 
Presenting arrhythmia (n)    
VF 7 9 NS 
SMVT 17 15 NS 
NSVT + inducible VT/VF 5 7 NS 
Pharmacological treatment (n)    
Amiodarone 11 8 NS 
β-blockers 17 17 NS 
Digoxin 6 4 NS 
No antiarrhythmic drug 7 7 NS 
ACE inhibitor 21 26 NS 
Diuretic 15 17 NS 
Lipid-lowering drug 17 23 NS 
ACE = angiotensin-converting enzyme; CAD = coronary artery disease; CMP = 
cardiomyopathy; DC group = dual-chamber supraventricular detection algorithm group; 
LVEF = left ventricular ejection fraction; NS = nonsignificant; NSVT = non-sustained 
ventricular tachycardia; SC group = single-chamber supraventricular detection algorithm 
group; SMVT = sustained monomorphic ventricular tachycardia; VF = ventricular 
fibrillation; VT = ventricular tachycardia 
 
Device description 
The devices implanted in this study were, in equal numbers and randomized order, 
the Prizm DR (Guidant, St. Paul, Minnesota) and the Tachos DR (Biotronik, Berlin, 
Germany). The pulse generator and endocardial leads were inserted through a single 
left pectoral incision. The endocardial lead used for the high right atrium was a 
bipolar active-fixation lead with an interelectrode spacing of 8.9 mm (model 5076, 
Medtronic Inc, Minneapolis, Minnesota). Far-field R-wave sensing in the atrial 
electrogram was to be excluded. If present, the atrial lead was relocated until 
appropriate sensing could be achieved.  
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Discrimination of tachyarrhythmias 
In both the SC group and DC group, the onset and stability criterion are provided to 
inhibit therapy in case of an atrial arrhythmia. In addition, dual chamber devices have 
“enhanced discrimination” criteria to differentiate atrial from ventricular arrhythmias. 
In the Prizm DR, enhanced criteria are: 1) the “ventricular rate > atrial rate” criterion, 
and 2) the “AF rate threshold” criterion. When the ventricular rate > atrial rate (V > A) 
is programmed, onset and stability are ignored, and therapy will be delivered. The AF 
rate threshold (Afib threshold) criterion is programmed in conjunction with stability. 
The aim of this feature is to suppress inappropriate therapy for fast ventricular rates 
secondary to AF or atrial flutter (AFL). If the ventricular rhythm is classified unstable 
and the atrial rate is higher than the programmed Afib threshold, therapy is withheld 
(13).  
The Tachos DR employs the SMART algorithm (Biotronik) as enhanced 
discrimination. This algorithm is based on continuous analysis of the average atrial 
and ventricular rate and their atrioventricular relationship which results in 3 rate-
branches (VV < AA, VV > AA, and VV = AA). The features of this algorithm have 
been described in detail (14).  
 
Table 2. Programming of detection algorithms in the SC group and DC group 
 SC group DC group 
 Biotronik Guidant Biotronik Guidant 
Onset (%) 15 16 15 16 
Stability (ms) 40  40  40  40  
SMART OFF NA ON NA 
V>A NA OFF NA ON 
Afib threshold NA OFF NA 200/min 
AF = atrial fibrillation; NA  not applicable; V > A = ventricular rate > atrial rate; 
Other abbreviations as in Table 1. 
 
Programmation of the devices 
Throughout the study, the devices were programmed similarly as far as possible to 
facilitate comparison between both groups (Table 2). For all patients, the 
tachyarrhythmia detection algorithms were activated immediately after implantation. 
The SC group was programmed to supraventricular tachycardia discrimination on the 
basis of ventricular rate combined with onset (15 to 16%) and stability (40 ms). For 
the DC group, tachyarrhythmia discrimination was programmed to onset (15 to 16%) 
and stability (40 ms), and all applicable enhanced algorithms were activated. Safety 
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timers were not activated in both groups. The tachycardia detection zones were 
programmed to recognize fibrillation and either one or two tachycardia zones. The 
bradycardia support was programmed to VVI with a lower rate of 40/min for the SC 
group. The DC group was set to the DDI mode with a lower rate of 40/min. The 
storage of intracardiac electrograms was programmed to collect both atrial and 
ventricular bipolar electrograms and markers for all patients. 
 
End points 
The primary end point in the study was the deliverance of inappropriate therapy for 
atrial arrhythmias. Secondary end points were appropriate and inappropriate 
arrhythmia classification. All spontaneous episodes detected either as ventricular 
tachyarrhythmia or as atrial tachyarrhythmia with stored electrograms were retrieved 
from the device’s memory. Two independent experienced physicians analyzed the 
stored episodes to assess the type of the clinical arrhythmia and the appropriateness 
of device classification. In case of doubt, a third physician was consulted to provide 
the decision. The stored arrhythmias were classified as: 1) ventricular arrhythmia, or 
2) atrial arrhythmia without a co-existent ventricular arrhythmia. The atrial 
arrhythmias were further classified as AF, AFl, atrial tachycardia (AT), and sinus 
tachycardia (ST). Atrial fibrillation was assumed to occur if the atrial electrogram 
showed a changing morphology. The diagnosis of AFL was based on regular AA 
intervals and no changes in morphology of the atrial electrogram. The prerequisite of 
ST and AT was an atrial electrogram preceding the ventricular electrogram. Sinus 
tachycardia was diagnosed if the ventricular rhythm showed a gradual increase in 
heart rate with an unchanged morphology of the atrial and ventricular electrogram. In 
contrast, the diagnosis of AT was based on a sudden increase of the ventricular rate 
and a change in morphology of the atrial electrogram. 
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Statistical analysis 
Based on the assumption of a 30% reduction in the incidence of inappropriate 
therapy with dual-chamber devices, 27 patients were required in each arm, for a 
power of 80% and a probability value of 0.05. 
Continuous variables were expressed as mean values ± SD. Chi-square testing was 
used for analysis of categorical variables, and Student t test was used for analysis of 
continuous variables. A p value < 0.05 was considered statistically significant. 
The set of tachyarrhythmia episodes cannot be considered as independent because 
patients contribute one or more tachyarrhythmia episodes to the dataset. To correct 
for these factors, statistical analysis was performed by using the generalized 
estimating equations (GEE) statistical method with an exchangeable correlation 
structure to correct the varying number of episodes that were obtained from each 
patient (15,16). Only episodes with a stored electrogram and the physician’s 
classification were included in the analysis. Statistical analysis was performed with 
SPSS for Windows (release 10.1, SPSS Inc., Chicago, Illinois) and SAS for Windows 
(release 8.2, SAS Institute, Cary, North Carolina). 
Calculations were based on the possibility to accurately detect ventricular 
arrhythmias (true positive [TP]), accurately detect atrial arrhythmias (true negative 
[TN]), falsely detect atrial arrhythmias as ventricular (false positive [FP]), and falsely 
detect ventricular arrhythmias as atrial (false negative [FN]). The sensitivity of 
detection algorithms is the probability that a ventricular arrhythmia is detected when 
present:  [TP/(FN + TP)]. The specificity of detection algorithms is the ability to reject 
atrial tachyarrhythmias. An absolute specificity cannot be calculated. The specificity 
is dependent on the prevalence of atrial tachyarrhythmias and the programmed 
detection interval of the device. Therefore, we calculated the positive predictive value 
of the detection algorithm, as follows: [TP /(TP + FP)]. 
 
 
Results 
Patient population 
Sixty patients were included in the study. Twenty-nine patients were randomly 
assigned to the SC group and 31 to the DC group. Fifteen patients in the SC group 
were randomized to Biotronik and 14 patients to Guidant. In the DC group, 14 
patients were randomized to Biotronik and 17 patients to Guidant. Baseline clinical 
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characteristics did not differ between the two groups (Table 1). At the time of 
implantation, all patients had sinus rhythm. A history of atrial tachyarrhythmias was 
documented in 15 patients (25%), paroxysmal AF in 11 patients (18%), paroxysmal 
AFL in 2 patients (3%). Pharmacological treatment at discharge was not significantly 
different between both groups. Antiarrhythmic drug therapy was amiodarone in 19 
patients (32%), beta-blockade in 34 patients (57%), and 10 patients (17%) received 
digoxin.  
Five patients (8%) had 2 tachycardia zones activated. In four of these patients, the 
programmed detection criteria were applicable to both tachycardia zones. The 
programmed fibrillation and tachycardia zones were 290 ± 14 ms and 387 ± 34 ms, 
respectively. The programmed tachycardia detection interval was not significantly 
different between the two groups (SC group, 379 ± 31 ms versus DC group, 389 ± 35 
ms). 
 
Spontaneous tachyarrhythmias 
The mean follow-up was 12 months, with a cumulative follow-up of 717 months. 
During this follow-up, 653 tachyarrhythmia episodes with stored electrogram occurred 
in 39 patients (range 1 to 89 episodes per patient). Figure 1 presents a tree diagram 
that outlines the results of arrhythmia detection for each of the 653 stored 
tachyarrhythmia episodes. Based on the physician classification, there were a total of 
391 episodes of true ventricular tachyarrhythmias in 32 patients (mean ventricular 
rate 358 ± 77 ms). In 25 patients, 262 episodes of true atrial tachyarrhythmias (mean 
ventricular rate 368 ± 32 ms) occurred. In Figure 2, the number of episodes for the 
two study groups is presented. In the SC group, 166 episodes of ventricular 
tachyarrhythmias were recorded in 16 patients (range 1 to 57 episodes per patient); 
in the DC group, 225 episodes in 16 patients (range 1 to 89 episodes per patient). All 
ventricular tachyarrhythmias were appropriately detected in both groups. The 
sensitivity for ventricular tachyarrhythmias in both groups was 100%.  
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Figure 1. Tree diagram showing the results for 653 stored spontaneous tachyarrhythmia 
episodes. DC group = dual-chamber supraventricular detection algorithm group; EGM = 
electrogram; pts = patients; SC group = single-chamber supraventricular detection algorithm 
group; SVT = supraventricular tachyarrhythmias; VT = ventricular tachycardia. 
 
Figure 2. Number of spontaneous episodes per patient for the two study groups. The error 
bars extend down to the minimum value and up to the maximum value. The box extends 
from the 25th percentile to the 75th percentile, with a black box at the median (50th 
percentile).Abbreviations as in Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 0
10
20
30
40
50
60
70
80
90
100
N
um
be
r o
f e
pi
so
de
s 
(N
) 
SC-group DC-group 
VT (16 pts) SVT (14 pts) VT (16 pts) SVT (11 pts)
  
 
132
Of the 262 atrial tachyarrhythmia episodes in the ventricular tachyarrhythmia 
detection window, 153 (58%) were detected as atrial tachyarrhythmia and not as 
ventricular tachyarrhythmia (20 patients). Inappropriate detection was observed in 
109 atrial tachyarrhythmia episodes (18 patients). The mean ventricular rate of 
misclassified atrial tachyarrhythmias was significantly shorter as compared to 
rejected atrial tachyarrhythmias (354 ± 30 ms vs. 378 ± 30 ms; p < 0.001). The 
number of misclassified episodes was not significantly different between both groups 
(51 in the SC group versus 58 in the DC group). Analysis performed with the GEE 
method demonstrated no significant difference in the rejection of spontaneous atrial 
tachyarrhythmias between single- and dual-chamber devices (p = 0.56). The 
detection of ventricular tachyarrhythmias and the rejection of atrial tachyarrhythmias 
was not significantly different between both groups (p = 0.77). The specificity and 
positive predictive value of arrhythmia discrimination were 56% and 76% in SC 
group, versus 60% and 79% in DC group, respectively. 
During 60 atrial tachyarrhythmia episodes (13 patients), inappropriate device therapy 
was delivered. The number of inappropriately treated episodes was not significantly 
different between the two groups (28 in the SC group vs. 32 in the DC group).   
 
Subanalysis of atrial tachyarrhytmias  
The misclassified atrial tachyarrhythmias are presented in Table 3. Subanalysis of 
the type of atrial arrhythmia and the appropriateness of classification was perfomed 
with the GEE method. Analysis demonstrated a significantly higher misclassification 
in case of AFL/AT compared with ST and AF (p = 0.001). The misclassified episodes 
of AT/AFL had a sudden onset > 16% and a regular ventricular response (stability < 
40 ms). Episodes of ST were misclassified due to the presence of ventricular 
premature beats, which resulted in false sudden onset calculations or false V > A 
detection in dual-chamber devices.  
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Table 3. Inappropriate classification of spontaneous atrial tachyarrhythmias for both groups 
 Misclassified episodes  
Arrhythmia                  (n) SC group (%) DC group (%) p Value 
Atrial fibrillation             89 38 (2 patients) 26 (4 patients) NS 
Atrial flutter                   30 47 (1 patient) 50 (1 patient) NS 
Atrial tachycardia         63 97 (6 patients) 96 (5 patients) NS 
Sinus tachycardia         80 5  (1 patient) 18 (2 patients) NS 
DC-group = dual chamber group; NS = non siginificant; SC-group = single chamber group 
 
 
Discussion 
The present prospective, randomized study evaluated the performance of 
tachyarrhythmia detection algorithms in single-chamber and dual-chamber ICDs. 
Although identical programmed stability and onset values, the number of 
inappropriate classifications with dual-chamber detection was not significantly 
reduced as compared to single-chamber detection.  
Inappropriate ICD therapy for atrial tachyarrhythmias is the most common adverse 
event in ICD recipients with single chamber devices (17). With the development of 
dual-chamber cardioverter-defibrillators, it was anticipated that these devices could 
improve arrhythmia detection by providing additional information about the underlying 
atrial rhythm. In previous studies, enhanced detection algorithms in dual-chamber 
devices based on the atrioventricular relationship could accurately discriminate atrial 
from ventricular tachyarrhythmias (8,9). However, most of the studies were restricted 
to one manufacturer and mainly focused on the technical performance of the 
implanted device (8,14,18-20). Prospective, randomized studies to evaluate the 
efficacy of enhanced detection algorithms to decrease the incidence of inappropriate 
therapies are lacking in a well-defined population.  
 
Accuracy of tachyarrhythmia detection 
The primary goal of the ICD is to detect and subsequently terminate life-threatening 
ventricular tachyarrhythmias. When evaluating tachyarrhythmia detection criteria in 
our study, the sensitivity for detection of ventricular tachyarrhythmias was 100% for 
both study groups. Single-chamber and dual-chamber ICDs were equally safe and 
effective in treating ventricular tachyarrhythmias. This is in agreement with other 
device trials (8,10,11,14,18,19).  
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The secondary goal of the ICD is to deliver therapy only when required. Thus, 
accurate discrimination between atrial and ventricular tachyarrhythmias is an 
important clinical issue. The overall incidence of inaccurately detected 
tachyarrhythmias by the device was 16.7%. This finding is in agreement with studies 
reporting on inappropriate ICD therapy (21,22). We found no significant difference in 
the number of misclassified episodes between both groups (51 episodes, SC group 
vs. 58 episodes, DC group). The results in our study demonstrated that enhanced 
detection criteria in single-chamber and dual-chamber ICDs are equally effective in 
the rejection of atrial tachyarrhythmias. This finding is confirmed by previous 
comparisons of enhanced detection criteria between single- and dual-chamber ICDs 
(10,11). They reported no reduction or even an excess of inappropriate ICD therapies 
in dual-chamber devices. The failure of detection enhancements in dual-chamber 
devices to withhold therapy for atrial tachyarrhythmias was attributed by the authors 
to atrial sensing problems. Inappropriate classification of atrial tachyarrhythmias due 
to atrial sensing problems was also reported in other studies (19,23).  
 
Limitations of the applied enhanced detection criteria 
The strength and weakness of enhanced detection criteria are dependent on the 
frequency and distribution of atrial tachyarrhythmias. The complete picture of the 
performance of detection criteria is provided not only by statistical measures. The 
picture is complemented with observations during misclassified atrial 
tachyarrhythmias. The observed weaknesses of the applied detection criteria to 
discriminate between atrial and ventricular tachyarrhythmias were the presence of: 1) 
atrial tachyarrhythmias with stable N:1 atrioventricular conduction, and 2) ST with the 
presence of ventricular premature beats.  
 
Atrial tachyarrhythmias with stable atrioventricular conduction 
In both settings, detection was inappropriate in the majority of atrial tachyarrhythmias 
with a fixed N:1 atrioventricular conduction (AT and AFL). In single-chamber setting, 
the sudden onset (onset > 16%) and the stable ventricular response (stability < 40 
ms) fulfilled ventricular tachyarrhythmia detection. Given the priority of single-
chamber detection criteria, the additional dual-chamber detection enhancement “Afib 
threshold” cannot decrease the incidence of inappropriate detections for atrial 
tachyarrhythmias with stable N:1 atrioventricular conduction. A recent study 
  
 
135
confirmed the high incidence of inappropriate classification of ATs with stable 1:1 
atrioventricular conduction (24).  
Dual-chamber algorithms analyzing the atrioventricular conduction have the 
possibility to detect stable atrial tachyarrhythmias with N:1 atrioventricular 
conduction. Despite the use of the dual-chamber algorithm SMART, a variation in the 
calculated mean atrial rates led to inappropriate therapy in 2:1 conducted atrial 
flutter. A progressively prolonging atrioventricular conduction interval can be 
misclassified as ventricular tachycardia with retrograde conduction. This problem has 
been reported as the most common failure of the PR Logic algorithm (Medtronic Inc.) 
(19,25).  
 
ST 
In case of ventricular premature beats during ST, the dual-chamber detection 
enhancement “V > A” can act as an accelerator of inappropriate detection.  During a 
ventricular premature beat, the normal atrial activation might be not sensed due to 
the atrial blanking period after a sensed ventricular event, which fulfills the detection 
enhancement “V > A”. Another problem associated with premature ventricular beats 
is the inappropriate calculation of a sudden onset. This problem has also been 
reported in previous studies (26,27).  
 
Comparison with other studies 
A comparison of the performance of the applied detection criteria with other studies is 
difficult because the applied detection criteria, the number of episodes, the number of 
patients, and the methodology differ between the published studies. In an open-label 
non-randomized study comparing single- and dual-chamber devices, the incidence of 
inappropriate therapies during AF was significantly higher in dual-chamber devices 
compared to single-chamber devices (41% vs. 24%) (10). In a recent prospective, 
randomized study between single- and dual-chamber devices, no differences in 
performance of detection criteria were observed (11). However, the results must be 
interpreted with caution, because all inappropriate therapies, including those in the 
ventricular fibrillation zone and those not related to atrial tachyarrhythmias, were 
considered in the study by Deisenhofer et al. (11).  
Studies with dual-chamber ICDs have reported high sensitivity and specificity values 
for the applied dual-chamber algorithm. In a recent study with the PARAD algorithm 
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(ELA Medical, Le Plessis Robinson, France), a specificity of 89.2% on a per episode 
basis and 91.6% on a per patient basis were reported (20). Despite the high overall 
specificity, the performance during atrial fibrillation was poor (47.2% of 53 episodes 
were inappropriately detected). Studies evaluating the PR Logic algorithm reported 
lower specificity values of 66.6% or 72% on a per episode basis (19,25). For Guidant 
devices, the performance of “Afib threshold” and “V > A“ in conjunction with a more 
aggressively programmed onset (9%) and stability (24 ms) was recently reported with 
a specificity of 89% (24). 
 
 
Limitations of the study 
We used devices from only 2 manufacturers to assess the accuracy of atrial 
tachyarrhythmia detection in single- and dual-chamber ICDs. The results of our study 
must therefore be interpreted with caution. The findings of the study do not reflect the 
status of current detection algorithms in general. Current devices can apply 
morphology discrimination in conjunction with timing-based detection algorithms. The 
present study evaluated only timing-based detection algorithms. The predefined 
programming of the onset (16%) and stability criterion (40 ms) in the Guidant dual 
chamber devices reduced the potential advantage of the enhancement criteria (“V > 
A” and “Afib threshold”) (24). A more aggressive onset and stability will first cause a 
loss in sensitivity but an increase in specificity.  
“V > A”  will compensate the loss in sensitivity. As our study demonstrated that not 
ST nor AF but AT and AFL with a fixed N:1 conduction were the problem, it is very 
unlikely that lower stability values would have changed the results. Another possible 
limitation is the number of patients. However, 653 episodes of tachyarrhythmias were 
analyzed. The programmed detection rate affects both the distribution of the type of 
atrial tachyarrhythmias as well as the relative number of atrial tachyarrhythmias 
presenting to the detection algorithms. In our study, the programmed detection rate 
was similar for both groups. 
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Conclusion 
In this study, using stored atrial electrograms from dual-chamber devices, the applied 
detection criteria in single- and dual-chamber setting were equally effective for 
detection of ventricular tachyarrhythmias and the rejection of atrial tachyarrhythmias. 
This was true for this study group without a bradycardia indication. Both subgroups 
were comparable in terms of underlying heart disease, indication for implantation, 
antiarrhythmic drug therapy, and follow-up period. This has important repercussion 
on health care in general as in recent ICD trials hospital readmissions due to new or 
worsened heart failure increased (5,12). This higher incidence was related to dual 
chamber bradycardia pacing in patients without a bradycardia pacing indication. With 
the increasing indications for ICD implantation, a matter of debate is the device 
selection. The rules for device selection for patients with a primary prevention 
indication can be different from those applied for patients with a secondary 
prevention indication. Nevertheless, to avoid inappropriate therapy, it is particularly 
important to program carefully the enhanced detection criteria of the device, 
irrespective of the indication. Further work should be done to improve arrhythmia 
discrimination, in particular for atrial tachyarrhythmias with stable atrioventricular 
conduction, which was most often misclassified.  
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Abstract 
Stored electrograms in implantable cardioverter-defibrillators (ICDs) have not only 
improved our patient management, but also increased our understanding of 
tachyarrhythmias. Stored electrograms are usually visual analysed by physicians. 
The analysis can be performed in a methodological way by application of blocks with 
physiologic information. Each block contains specific timing or morphology based 
characteristics of arrhythmias. A systematic approach is proposed, which can help 
physicians and technicians to avoid bias in the analysis. 
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Introduction 
From the time of introduction of the ICD, the device has evolved from a simple shock-
box to a complete arrhythmia management device. The improvements in arrhythmia 
treatment have paralleled the advances in diagnostic information. The current 
generation of ICDs offers an array of diagnostic information, including stored 
electrograms. Analysis of this diagnostic information has not only improved the 
management of patients but also contributed to an increased understanding of 
triggers precipitating delivered or aborted device therapy. 
This article will provide an overview of diagnostic capabilities of stored electrograms. 
We will present the evolution of diagnostic information in ICD, and we propose the 
application of blocks with physiologic information for analysis of stored electrograms.  
 
 
Historical perspective of diagnostic information in ICDs 
In the first-generation devices, the definition of “appropriate” therapy relied on the 
clinical history of the patient, the presence or absence of hemodynamically significant 
symptoms, or concomitant ECG monitoring. The second-generation ICDs had 
recording of RR intervals with device activity markers or simply numerical. This 
storage allowed analysis of the rate of the arrhythmia preceding and following ICD 
therapy. Differentiation of arrhythmias was based on the regularity of RR intervals. 
Irregular RR intervals suggested atrial fibrillation (AF), while regular RR intervals 
could indicate sinus tachycardia, arial flutter, or atrial tachycardia as well as 
ventricular tachycardia. Interpretation of the appropriateness of therapy was the 
major limitation in first- and second-generation devices.(1) Appropriate ICD therapy for 
ventricular arrhythmias without hemodynamically symptoms was demonstrated in 
patients.(2,3) As a consequence, clinical decision-making in patients treated with the 
first- and second-generation devices was associated with uncertainty. With third-
generation devices, the most significant advance in diagnostic information was the 
storage of intracardiac electrogram recordings. This diagnostic information included 
recording of RR intervals preceding and following the arrhythmia, and stored 
electrograms with real-time marker channels of arrhythmias triggering ICD therapy. 
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Electrogram sources 
The current generation of devices can be programmed to record events from different 
electrogram sources. The electrograms can be recorded from the pair of electrodes 
used for rate sensing (near-field), the defibrillation coils (far-field or wide-band) or 
both. Both electrogram sources have advantages and disadvantages. Near-field 
ventricular electrograms show no atrial activity, which could result in the inability to 
discriminate between atrial and ventricular tachyarrhythmias. However, they can 
provide information on detection problems, such as the presence of over- or 
undersensing of signals. In contrast, far-field electrograms have the advantage of 
reflecting atrial activity and electrogram morphology changes, which can be both 
helpful in arrhythmia diagnosis by the physician. This resembles a surface ECG, 
which is leaving uncertainty as well. 
 
 
Visual analysis of stored electrograms 
Tachyarrhythmia detection algorithms in devices use combinations of information 
derived from intracardiac atrial and ventricular events. Tachyarrhythmia detection is 
generally performed in a stepwise process using “blocks” of physiologically relevant 
information. Each block has a specific timing or morphological aspect, which contains 
characteristics of tachyarrhythmias. These blocks with physiological information can 
be applied in the visual analysis of stored electrograms. 
 
Single chamber devices 
In single chamber devices, “blocks” are derived from the sensed ventricular activity. 
Device activity markers are usually interpreted during visual analysis. Each block has 
clinical information, but limitations to discriminate between atrial and ventricular 
tachyarrhythmias are inherent to single chamber devices. The widely used block 
‘ventricular electrogram morphology’ is mainly based on the premise that the 
electrogram morphology will change during ventricular tachyarrhythmias as 
compared to a supraventricular baseline rhythm (Figure 1). A distinct change in the 
electrogram morphology was identified in 93% of induced ventricular tachycardias.(4) 
The analysis of far-field electrograms permits a more accurate arrhythmia 
classification. However, the development of rate-dependent aberrancy during 
supraventricular tachycardia alters the electrogram morphology as compared to 
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baseline sinus rhythm.(5) Specifically, a change in electrogram morphology was 
predominantly observed at recording sites ipsilateral to the bundle branch block.(6) It 
was demonstrated that the combined use of electrogram morphology, rate 
characteristics, and VV interval stability allowed a correct diagnosis in 97% of the 
events.(7) 
 
Figure 1. Stored bipolar shock electrogram demonstrating a change in electrogram 
morphology during ventricular tachycardia as compared to the supraventricular baseline 
rhythm. (Guidant, model Mini IV) 
 
 
The block ‘VV interval stability’ is used to discriminate between monomorphic 
ventricular tachycardia, characterized by regular ventricular intervals, and atrial 
fibrillation characterized by irregular ventricular intervals. The limitation of this block is 
the regular ventricular response during atrial tachyarrhythmias with fixed N:1 
atrioventricular conduction, as 2:1 atrial flutter. Another limitation is the increased 
stability of VV intervals during atrial fibrillation with fast ventricular response.(8) 
The block ‘sudden onset’ can be used to discriminate sudden onset ventricular 
tachyarrhythmias from sinus tachycardia, which is characterized by a gradual onset. 
However, sudden onset may not be specific for atrial or ventricular tachyarrhythmias. 
Appropriate interpretation of stored electrograms in single chamber devices is not 
only based on one changes in an information block. In fact, we rather combine the 
information of the electrogram morphology with information on the rate of the 
arrhythmia, the onset and the stability of the arrhythmia. The recording of device 
activity markers (marker channel) provides additional information, which requires 
fewer computer spare. 
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Figure 2. Stored bipolar electrogram showing ventricular tachycardia (VT) with regular 
ventricular intervals detected in the programmed tachycardia detection zone. The 
programmed tachycardia detection (TD) is fulfilled and subsequently antitachycardia pacing 
(ATP) is delivered. The ventricular electrogram morphology is significantly different during 
tachycardia as compared to the restored baseline rhythm.  
Markers: FS = fibrillation sensing; TD = tachycardia detected; TP = tachycardia pacing; TS = 
tachycardia sensing; VS = ventricular sensing sensing. (Medtronic Jewel, model 7219) 
 
 
 
Figure 3. Application of blocks with physiologic information for presenting arrhythmias in 
relation to rate branch 
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Dual chamber devices 
The visual analysis of stored electrograms from dual chamber devices includes 
blocks based on atrial and ventricular physiological information. Blocks derived from 
the ventricular activity are similar to those used in single chamber devices. For 
clinical information of atrial activity, blocks are ‘AA stability’, ‘atrial cycle length’, and 
‘atrial electrogram morphology’. These blocks can be used to identify the presence of 
atrial tachyarrhythmias. As atrial information is present, analysis of the 
atrioventricular (AV) relationship can be performed. The first block ‘AV conduction 
pattern’ can be used to discriminate between atrial and ventricular tachyarrhythmias 
with stable AV conduction. The majority of atrial tachyarrhythmias have a consistent 
AV conduction pattern, but ventricular tachyarrhythmias with stable retrograde 1:1 
ventriculoatrial (VA) conduction also have a consistent AV conduction pattern. In the 
majority of ventricular tachyarrhythmias, the block ‘AV dissociation’ can be used to 
identify ventricular tachyarrhythmias. Another helpful block is the ‘chamber of origin’, 
which can be used to discriminate between atrial and ventricular tachyarrhythmias 
with 1:1 AV or VA conduction by identification of atrial activity preceding ventricular 
activity or vice versa. All blocks with physiologic information can serve as tool for 
analysis of stored electrograms. The use of specific physiologic blocks and the order 
or combination of them is dependent on the comparison of atrial and ventricular rate 
(Figure 3). 
 
 
Application of physiologic blocks in relation to rate branches 
Based on the comparison of atrial and ventricular rate, tachyarrhythmias can be 
roughly divided into three rate branches: ventricular rate > atrial rate, ventricular rate 
< atrial rate, and ventricular rate = atrial rate.  
 
Ventricular rate > atrial rate 
In the majority of ventricular tachyarrhythmias, the ventricular rate is faster than the 
atrial rate (Figure 4). In this rate branch, the timing-based physiologic blocks ‘atrial 
rate’, ‘ventricular rate’, ‘AV dissociation’, and ‘VV interval stability’ are applicable. The 
block ‘ventricular electrogram morphology’ can be used to discriminate between 
monomorphic and polymorphic ventricular tachycardias. Monomorphic ventricular 
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tachycardia has a constant cycle length, beat-to-beat variation < 10%, and a uniform 
electrogram morphology during the tachycardia.(9) 
 
Figure 4. Stored bipolar electrograms showing ventricular tachycardia (VT). Rhythm strip 
from top to bottom atrial, ventricular, and shock electrogram. Ventricular premature beat (1) 
initiates VT (2) with regular ventricular intervals detected in the programmed tachycardia 
detection zone. During VT, the ventricular rate is faster as compared to the atrial rate. 
Markers: AS = atrial sensing; PVC = premature ventricular complex; VP = ventricular pacing; 
VT = ventricular tachycardia window.  (Guidant Prizm DR, model 1861) 
 
 
 
Ventricular rate < atrial rate 
Compared to ‘ventricular rate > atrial rate’, the rate branch ‘ventricular rate < atrial 
rate’ is more complex. Atrial tachyarrhythmias within this rate branch can be atrial 
fibrillation, atrial flutter or atrial tachycardia with stable N:1 AV conduction. The 
occurrence of ventricular tachyarrhythmias in this rate branch is also known as 
double tachycardia, i.e. atrial fibrillation and ventricular tachycardia. On the atrial 
level ‘atrial rate’, ‘AA interval stability’, and ‘AV conduction pattern’ blocks are used to 
identify the type of atrial tachyarrhythmia. A regular atrial response is usually found 
during atrial flutter or tachycardia.  
For the identification of ventricular tachycardia, combinations of blocks ‘AV 
dissociation’, ‘VV interval stability’, and ‘ventricular electrogram morphology’ are used 
(Figure 5). The ventricular electrogram morphology and stability of ventricular 
intervals are applicable for identification of ventricular tachycardia during atrial 
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fibrillation. The blocks ‘AV dissociation’ and ‘ventricular electrogram morphology’ are 
suitable for identification of ventricular tachycardia during atrial flutter or tachycardia. 
Atrial flutter or tachycardia with stable N:1 AV conduction have a consistent AV 
conduction pattern. This AV conduction pattern will change when ventricular 
tachycardia is present (Figure 6). The physiologic block ‘VV interval stability’ is not 
applicable during atrial tachyarrhythmias with stable N:1 AV conduction as the 
ventricular response is regular. 
 
Figure 5. Stored bipolar electrograms demonstrating double tachycardia, which is ventricular 
tachycardia (VT) during atrial fibrillation (AF). Rhythm strip from top to bottom atrial, 
ventricular, and shock electrogram. The atrial electrogram shows atrial fibrillation. Ventricular 
premature beat (2) initiates VT (3). During VT, the morphology of the ventricular and shock 
electrogram changed as compared to baseline rhythm (3). Markers: AF = atrial fibrillation 
window; AS = atrial sensing; VP-FB = ventricular pacing, fallback; VS = ventricular sensing; 
VT = ventricular tachycardia window. (Guidant, Renewal II, model H155) 
 
Figure 6. Detection of double tachycardia, which is ventricular tachycardia (VT) during atrial 
flutter (AFl). The marker channel demonstrates appropriately detected AFl (1) with a 
consistent atrioventricular (AV) conduction pattern. A ventricular premature beat (2) initiates 
VT (3). At the onset of VT, the marker channel demonstrates a change in the AV conduction 
pattern. During VT, there is AV dissociation. Markers: TD = tachycardia detected; TS = 
tachycardia sensing; VS = ventricular sensing. (Medtronic Jewel AF, model 7250) 
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Ventricular rate = atrial rate 
The rate branch ‘ventricular rate = atrial rate’ consists of tachyarrhythmias with 1:1 
AV conduction. In this rate branch, the AV conduction relationship plays an important 
role. The atrial tachyarrhythmias (i.e. sinus and atrial tachycardia) have a consistent 
AV conduction pattern. On the other hand ventricular tachyarrhythmias with stable 
retrograde 1:1 VA conduction also have a consistent AV conduction pattern. To 
discriminate between atrial and ventricular tachyarrhythmias, the first step is to 
analyze the onset of the tachyarrhythmia. Sinus tachycardia is characterized by a 
gradual onset, whereas ventricular tachycardia has a sudden onset. The application 
of blocks ‘chamber of origin’ and ‘ventricular electrogram morphology’ offers 
additional information for further differentiation between sinus and ventricular 
tachycardia. The ‘chamber of origin’ is used to identify the initiating event at the onset 
of tachycardia. At the onset of ventricular tachycardia, an intrinsic atrial event usually 
does not occur between the last conducted sinus beat and the first ventricular ectopic 
event. On the other hand, an atrial event is present before every ventricular event at 
the onset of atrial tachycardia (Figure 7).  
 
Figure 7. Stored electrogram showing atrial tachycardia with consistent 1:1 atrioventricular 
(AV) conduction. Rhythm strip from top to bottom atrial, ventricular, and shock electrogram. 
After 6 normal conducted ventricular events (2), a ventricular premature beat (1) occurs, 
which is followed by 2 normal conducted ventricular events. A premature atrial event (3) 
initiates an atrial tachycardia with stable 1:1 AV conduction (4). ‘Chamber of origin’ is atrial 
and no change in ‘ventricular electrogram morphology’. Markers: AS = atrial sensing; VF = 
ventricular fibrillation window; VS = ventricular sensing; VT = ventricular tachycardia window; 
Epsd: initial tachycardia detection met; Suddn: sudden onset; --: no annotiation of stored 
events before detection of tachycardia. (Guidant Prizm DR, model 1861) 
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The combination of blocks ‘AV conduction pattern’, ‘chamber of origin’, ‘sudden 
onset’, and ‘ventricular electrogram morphology’ is necessary in challenging 
tachyarrhythmias with 1:1 AV conduction. Examples are atrial tachycardias with a 
sudden onset, and sinus or atrial tachycardia with progressive prolonging AV 
conduction. 
 
Figure 8. Schematic approach of the analysis of ventricular tachyarrhythmias. From top-to-
bottom are displayed the surface electrocardiogram (ECG), the atrial electrogram (A-EGM), 
and the ventricular electrogram (V-EGM). The premature ventricular depolarization initiating 
the tachyarrhythmia is labeled ‘A’. The preceding interval, the last normal conducted beat, is 
labeled ‘0’. The corresponding intervals for analysis are S-1 to S-8, V1, and T1 to T12. 
 
 
Standardized approach for electrogram analysis 
For clinical trials, correct electrogram interpretation is important. In a recent study, the 
overall performance of physicians in electrogram interpretation was similar to the 
ICD.(10) However, the composition of the misinterpretation was different, which can 
have a severe impact on the outcome of clinical trials. To improve the accuracy and 
reproducibility of electrogram analysis, a standardized approach was developed for a 
core ICD laboratory (Figure 8). The electrogram corresponding to the first beat of the 
tachycardia is labeled “A”. The preceding beat, the last “normal” conducted sinus 
beat is labeled “0”. The coupling interval of the premature depolarization initiating the 
tachycardia (from beat “0” to beat “A”) was labeled “V1”. The consecutive intervals of 
the tachyarrhythmia were numerically sequentially labeled T1 through T12. The 
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preceding intervals were labeled S–1 through S–8. This approach is now under 
validation and used in large clinical trial.(11) 
 
  
Sudden cardiac death 
In the eighties, Holter recordings during sudden death were used to analyse the 
electrical triggering mechanisms leading to this event.(12-15) Despite the fact that these 
studies were conducted in small populations, important observations were made. It 
was found that the most frequent cause of sudden death was monomorphic 
ventricular tachycardia degenerating into ventricular fibrillation.(12-14) In patients with 
advanced heart failure, bradyarrhythmias were found as the major cause of sudden 
cardiac death.(15) The majority of ventricular tachyarrhythmias was ventricular 
fibrillation, usually secondary to ventricular tachycardia. 
Stored electrograms of the ICD allows verification of the suspected mode of death. In 
a large database with follow-up of 834 ICD patients, sudden death due to 
tachyarrhythmic events with ICD therapy was observed in only 7 patients.(16) Another 
study confirmed these results with the majority of deaths (69%) being not the result of  
a tachyarrhythmia.(17) In contrast, another study on the same topic reported  that 
sudden death was associated with ventricular tachyarrhythmias despite device 
therapy in 66% of the patients.(18) However, the worsening clinical status of their 
patients suggested ventricular tachyarrhythmias secondary to acute cardiac 
mechanical dysfunction. The clinical classification of sudden cardiac death is still a 
challenge in large clinical trials. 
 
 
Onset mechanisms of ventricular tachyarrhythmias 
Stored electrograms provide the unique opportunity to analyse the triggers initiating 
ventricular arrhythmias, and to unerstand more of the physiology in larger 
populations. Reentry, triggered activity, or abnormal automaticity are distinct 
mechanisms for the generation of ventricular tachyarrhythmias.(19) These 
mechanisms are dependent on the presence of an underlying cardiac substrate and 
are modified by dynamic factors such as electrolyte imbalance, coronary ischemia, or 
neurohumoral influences. In the setting of a prior myocardial infarction, reentry 
around a fixed anatomic scar often results in monomorphic ventricular tachycardia 
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(MVT).(19,20) Ventricular arrhythmias of different mechanisms may be triggered by 
different initiation sequences. The majority of MVTs in patients with previous 
myocardial infarction is preceded by late-coupled ventricular premature beats.(9,21-23). 
The mode of onset of MVT in patients with dilated cardiomyopathy was not different 
as compared to onset of MVT in the setting of coronary artery disease.(24,25)  
Torsades de pointes is typically preceded by a “short-long-short” sequence. Some 
studies reported a “short-long” sequence as initiating mechanism for polymorphic 
ventricular arrhythmias. Diagnostic information on initiating mechanisms of 
tachyarrhythmias in new syndromes as the Brugada syndrome and short QT-
syndrome can be expected from stored electrograms.(26,27) 
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Abstract 
Background: Conventional (single lead ventricular) defibrillators (ICDs) often deliver 
“inappropriate” therapy. It is supposed that algorithms incorporating information about 
the atrial rhythm, and derived from an additional electrode in the atrium will be helpful 
in correct recognition of ventricular tachycardia or fibrillation.  
 Methods: We studied factors influencing appropriate therapy and survival (odds 
ratio and 95% confidence intervals) of 126 patients receiving an ICD. Single-chamber 
ICD’s were implanted in 99 patients, (group 1) while 27 received a dual-chamber ICD 
(group 2). The groups were comparable for most demographic and clinical variables 
except for the incidence of complete heart block, which was more frequently 
observed in group 2, p<0.01.   
Results: Dual-chamber therapy was associated with less inappropriate interventions 
(a reduction of 12%). The odds for appropriate intervention were higher when a 
history of atrial fibrillation existed.  
The Kaplan-Meier survival curve showed no significant difference between both 
groups for mortality, and for event free survival (appropriate and inappropriate 
therapy).  
Conclusion: While survival was similar for dual- and single-chamber devices, the 
use of dual-chamber devices will improve the quality of life, as less interventions 
were necessary, certainly in the long term. Even when interventions were judged as 
appropriate, previously documented atrial fibrillation was established as being a risk 
for such interventions. 
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Introduction 
Conventional (single-lead ventricular) defibrillators (ICDs) often deliver ‘inappropriate’ 
therapy for supraventricular arrhythmias, including sinus tachycardia and atrial 
fibrillation (AF).1 Some algorithms have been developed to avoid these ‘spurious’ 
interventions, but a large number of inappropriate shocks was still mentioned in 
recent reports.2 When an atrial lead is implanted, sensing the atrium becomes 
possible.3 This information can be integrated in the device. It is assumed that 
algorithms incorporating information about the atrial rhythm will be helpful in correct 
recognition of ventricular tachycardia (VT) or fibrillation (VF). As dual-chamber ICDs 
can pace the atrium, they can be used in patients with bradycardia and a poor left 
ventricular function, because they will not compromise the function by ventricular 
pacing alone. This can also help prevent atrial fibrillation, and therefore become 
important in avoiding inappropriate therapy.4  
Dual-chamber pacing is also associated with less congestive heart failure and an 
improved survival in some patient groups.  It is, therefore, anticipated that dual-
chamber defibrillators share this advantage with dual-chamber pacemakers over 
single-chamber systems.5 
 
Aim 
In this study, we wanted to test the hypothesis that dual-chamber ICDs diminish the 
number of events (appropriate and inappropriate) compared with conventional single-
chamber ICDs. Further, the short-term impact on survival of dual-chamber devices 
will be assessed. 
 
 
Methods 
Centres 
This study was a two-centre study (Departments of Electrophysiology, University 
Hospital Ghent, Belgium, and the Heart Centre, Universtity Hospital, Rotterdam, The 
Netherlands), with prospective collection of clinical follow-up data. 
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Patient population 
A total number of 100 consecutive patients with a single-chamber device and 27 
patients with a dual-chamber defibrillator were selected for this comparative, 
retrospective analysis. All patients with a dual-chamber device from both centres 
were included. Single-chamber patients were selected consecutively,with selection 
commencing as soon as the first dual-chamber ICD was implanted, so that 
contemporary patients were studied.  The general approach of implantation and 
follow-up did not change during the study period and was similar in both hospitals. 
The implantation methodology has been extensively described, and was slightly 
different for a dual-chamber device, as an atrial lead was implanted as well, in the 
high right atrium.6,7 The atrial lead was always from a type with active fixation 
(Medtronic). All patients underwent defibrillation threshold testing and a pre-hospital 
discharge test with reinduction of ventricular fibrillation. Programming was tailored to 
individual patient needs. `Rate regularity` (the most widely studied preventive 
algorithm, based upon the RR intervals, enhancing discrimination between regular 
tachycardia and irregular atrial fibrillation) was always programmed if a history of 
atrial fibrillation was available.2  
 
Follow-up 
Follow-up was defined as the time from ICD implantation until the last visit, heart 
transplantation or death.  Patients were followed at regular intervals. An interrogation 
of the device memory was performed every three months. If the first spontaneous 
arrhythmia or intervention occurred before this visit, the memory of the device was 
interrogated as soon as possible. Events were defined as antitachycardia pacing or 
shocks. Classification of interventions as appropriate and inappropriate was 
performed with the device electrograms and all other available means. For five 
patients (one in the dual-chamber and four in the VVI single-chamber group), data 
concerning inappropriate intervention were too unreliable to include in the analysis. 
Vital statistics were complete, except for one patient from the single-chamber group, 
reducing this group to 99 patients.  
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Statistical methods 
Patients were compared for clinical baseline variables. Endpoints were appropriate, 
inappropriate therapy and mortality. Univariate analysis was performed with 
confidence interval analysis comparing both groups. Multivariate analysis and 
Kaplan-Meier survival curves were performed with SPSS 8, using all available data to 
analyse whether dual-chamber devices were associated with less endpoints. A result 
was considered as significant for p values <0.05.  
 
 
Results 
Comparison between both groups 
The comparison for the base-line variables is given in table 1. The two groups were 
comparable for most demographic and clinical variables, except for the incidence of 
complete heart block (more frequently observed in the dual-chamber group,  p<0.01). 
Follow-up duration was not completely equal: the mean duration was longer in the 
single-chamber group, as initially only few patients could receive a dual-chamber 
device because of limited availability and socio-economic considerations (table 2). 
 
Table 1. Patient data 
 
 All 
(n=126) 
Dual 
(n=27) 
Single 
(n=99) 
Difference (%) and 
95% CI 
p 
value 
      
Age > 75 years 43 12 31 13 (-7 to 34) NS 
Male gender 108 20 88 -15 (-33 to 3) < 0.06 
Coronary artery disease 90 18 72 -6 (-26 to 14) NS 
Ejection fraction <25% 30 7 23 4 (-15 to 23) NS 
Ventricular tachycardia 77 18 59 7 (-13 to 27) NS 
Ventricular fibrillation 47 9 38 -5 (-25 to 15) NS 
Complete heart block 9 7 2 24 (7 to 41) < 0.01 
Previous atrial fibrillation 47 12 35 10 (-11 to 32) NS 
 
CI = confidence interval 
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Table 2. Follow-up 
 
 All 
(n=126) 
Dual 
(n=27) 
Single 
(n=99) 
Difference (%) and 
95% CI 
p 
value 
      
Mean duration (days) 502 ± 368 169 ± 593 593 ± 354  < 0.001 
Appropriate interventions 49/125 7/27 42/98 -17 (-36 to 2) NS 
Inappropriate therapy 17/121 1/26 16/95 -12 (-2 to –23) < 0.05 
Mortality 12/126 3/27 9/99 2 (-11 to 15) NS 
      
Days to appr. intervention 121 ± 155 38 ± 29 135 ±164  NS 
Days to inappr. therapy 473 ± 397 63 57 ± 91  NS 
 
Appr. = appropriate; CI = confidence interval; inappr. = inappropriate 
 
Interventions 
The relative risk for appropriate intervention was similar for dual- and single-chamber 
devices. The chances for inappropriate therapy were reduced for dual-chamber 
ICDs. The Kaplan-Meier survival curve (figures 1 and 2) showed no significant 
differences for intervention-free survival (both for appropriate and appropriate 
therapy). 
 
Figure 1. Kaplan-Meier survival for intervention-free survival for single- and dual- chamber 
defibrillators (appropriate therapy, antitachycardiapacing and shocks). 
 
  
 
165
Figure 2. Kaplan-Meier survival for intervention-free survival for single- and dual-chamber 
defibrillators (inappropriate therapy, antitachycardiapacing and shocks). 
 
 
In multivariate analysis, using logistic regression analysis, the odds for appropriate 
intervention tended to be higher when VT was the presenting arrhythmia (p<0.08). 
The only significant factor was previous AF: the chance of receiving appropriate 
therapy was higher (p<0.02). No factors were related to inappropriate therapy. Dual-
chamber or single-chamber device was not related to both intervention types (table 
3). 
 
Table 3. Results from multivariate analysis. 
 
Variable Factors p R 
    
Appropriate therapy Previous AF < 0.02 15% 
 VT < 0.08 8% 
    
Inappropriate therapy -   
    
Mortality CAD < 0.099 10% 
    
AF = atrial fibrillation; CAD = coronary artery disease; VT = ventricular tachycardia 
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When a Kaplan Meier analysis was performed for the total group, with previous AF 
as discriminating factor, a history of AF was indeed a significant predictor of 
appropriate, and not for inappropriate therapy (figure 3).  This was observed for 
single-chamber (log rank = 0.0226), but in a much less significant way for dual-
chamber devices (log rank = 0.096). 
 
Figure 3. Kaplan-Meier survival for intervention-free survival (from appropriate therapy, in 
relation to preexisting AF).  
 
 
 
 
 
Mortality 
In univariate and multivariate analysis, no influence of the device group was 
observed.  The Kaplan-Meier survival curve showed no significant difference 
between both groups (figure 4). 
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Figure 4. Kaplan-Meier survival for mortality (all causes) for single and dual chamber 
defibrillators. 
 
Discussion 
Dual-chamber ICDs and inappropriate interventions 
Inappropriate interventions (both ATP and shocks) have been a problem from the 
early ICD era,8,9 which is not surprising, as atrial fibrillation is the most frequently 
encountered arrhythmia.10 Atrial fibrillation is indeed the most frequent reason for 
‘spurious’ shocks. Attempts to avoid intervention have been undertaken, and in the 
early days they included the selection of non-programmable devices with a high cut-
off rate. When these devices became programmable, high cut-off rates could be 
programmed to avoid triggering by high ventricular rates. Alternatives for avoiding 
unnecessary shocks were prescription of drugs, depressing AV-nodal conduction, or 
even ablation of the AV-node.11 Further preventive measures became available when 
algorithms as rate regularity and the electrogram width were developed.2,12  The first 
option has the disadvantage that polymorphic ventricular tachycardia is not well 
recognised, and the second option that aberrant  conduction over the bundle 
branches is recognised as ventricular tachycardia. However, most experts believe 
that the number of spurious interventions is reduced when electrical information from 
the atrium (i.e. electrograms, or the P-wave) is used for decision making in 
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arrhythmia recognition.3,7 The first algorithm for dual-chamber devices uses the 
relation of the atrial and ventricular electrogram (association and relative number of 
each) and decides whether atrial fibrillation is present or not using other information. 
Other algorithms have been developed and are under clinical investigation. Most 
available data suggest that ventricular arrhythmias are recognised with a high 
sensitivity, but that specificity (avoiding therapy for supraventricular arrhythmias) 
remains somewhat problematic.13 
Therefore, our study (using four different brands of devices and not testing a specific 
algorithm) is important as it is the first showing that dual-chamber devices reduce the 
number of inappropriate interventions. Apart from the intelligent dual-chamber 
algorithms, other factors could play a role. One might assume that atrial pacing as 
such could already be enough to prevent supraventricular arrhythmias.14 Further, it is 
speculative that the presence of more patients with heart block could have been a 
reason for less interventions; however, heart block had no relation with AF, and it did 
not have a significant outcome in uni- and multivariate analysis in relation to ICD 
interventions. 
Other sources of inappropriate therapy are T-wave sensing and hardware-related 
problems.15 The most important one is lead fracture. While this can be theoretically 
more frequent (with two leads per patient), it was not observed in our study. 
 
Dual-chamber ICD’s appropriate interventions, and mortality. 
It can be expected that dual-chamber pacing reduces the number of events, by 
electrophysiological mechanisms (preventing reentry), and by improving the 
haemodynamic situation of the patient.16,17 If congestive heart failure is prevented, 
mortality should be reduced. No reduction in the number of correctly treated events 
was observed. The same was observed for mortality. One can assume that patients 
are selected for dual-chamber devices when their general condition is poorer. This 
might counterbalance the possible benefit in this study. On the other hand, no 
differences in ejection fraction were observed. 
It is no surprise that AF is related with appropriate interventions. That atrial 
arrhythmias can lead to ventricular arrhythmias is also well known.18 Furthermore, in 
particular conditions AF can have the same consequences as ventricular 
arrhythmias, so a shock that is technically considered inappropriate might be 
appropriate from a clinical point of view. 
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Limitation and complications of dual-chamber defibrillators 
It is often thought that dual-chamber devices are associated with more morbidity 
during implantation. While this was not specifically addressed in this study, it was not 
our experience. However, the complex hardware and software used for such ICDs is 
borne to yield more problems. For example, at least 20 out of 69 AV defibrillators in a 
clinical trial were replaced because shock delivery resulted in a marked increase in 
atrial lead impedance.19 Until now, we have encountered no such problems. 
However, as these devices have only recently been released, we feel that some 
caution in their use remains necessary.  
 
Conclusions 
Dual-chamber ICDs did not influence the amount of appropriate interventions for 
arrhythmias, but did reduce the number of inappropriate therapies. This is important 
for the quality of life; it could extend the longevity of pulse generators and is an 
additional argument for using dual-chamber devices in all patients prone for atrial 
fibrillation. Mortality was not influenced in this study, which comprised a small number 
of patients and was not randomised. Furthermore, the data analysis was 
retrospective and has a rather short follow-up. Surprisingly, a history of atrial 
fibrillation predisposed to a higher risk of appropriate shocks, emphasising again the 
importance of this common arrhythmia. Prospective, multicentre studies addressing 
the importance of dual-chamber defibrillators are certainly needed, as we are already 
facing an era of more complex devices as biventricular defibrillators, which will only 
make our approach even more difficult. 
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Summary 
Biventricular pacing is a novel therapy for patients with heart failure and severely 
diminished left ventricular function associated with intracardiac conduction delay. The 
primary aim of biventricular pacing is to re-synchronize the ventricular activation 
pattern and to improve hemodynamics. Results of early and recent studies including 
large-scale, multicenter, randomized trials demonstrated the efficacy of this treatment 
modality showing improved hemodynamics, exercise tolerance and quality of life in 
patients with severe heart failure. Preliminary data suggest that patients with atrial 
fibrillation may also benefit. There is a growing evidence showing that the frequency 
of life-threatening arrhythmias is decreased using biventricular pacing in this patient 
population. However, the effect of biventricular pacing on mortality is still unknown. 
Important ongoing trials will clarify the important issues regarding the influence on 
mortality and the problem of appropriate patient selection 
.
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Introduction 
Heart failure is a highly prevalent disease and despite recent advances in medical 
therapy it remains a growing health problem [1]. Intraventricular conduction delay is 
an independent predictor of mortality in patients with severe congestive heart failure 
(CHF) [2]. Multisite or biventricular pacing was recently developed as a possible 
novel pacing modality for patients with CHF and intraventricular conduction delay [3]. 
In patients with drug refractory heart failure and a severely diminished left ventricular 
function associated with significant intracardiac conduction delay biventricular pacing 
can be used to improve mechanical synchrony [4]. Results of available controlled and 
uncontrolled studies show improvement in hemodynamics, exercise tolerance, and 
quality of life in patients with heart failure [3-7]. The aim of this review is to 
summarize the current knowledge regarding biventricular pacing as well as the 
potential mechanism of the effectiveness of this pacing modality, including the 
evaluation of the optimal pacing sites. Furthermore, on the basis of our experience, 
we provide a description of the implantation technique. The possible role of a 
combined biventricular pacing and ICD therapy is also discussed, particularly the 
influence of biventricular pacing on the recurrence of ventricular tachyarrhythmias. 
 
 
Rationale for biventricular pacing 
A considerable proportion of the patients with severe CHF often has significant 
intraventricular conduction delay and left bundle branch block [2]. This 
intraventricular conduction delay -indicated by prolonged QRS duration- may cause 
an abnormal contraction pattern recognized as ventricular dyssynchrony [4]. 
Segments of the left and right ventricle contract in different times. Ventricular 
dyssynchrony results in abnormal interventricular septal wall motion, decreased 
contractility (dP/dt), reduced diastolic filling times, and prolonged duration of mitral 
regurgitation causing significant mechanical disadvantage for the failing heart [8,9]. 
Theoretically, multisite or biventricular pacing may resynchronize the contraction 
pattern of the ventricles [3-5]. This idea serves as a rationale for biventricular pacing 
in this severely ill patient population. Re-coordination of the activation pattern can 
normalize the so called functional mitral regurgitation and may optimize left 
ventricular filling [4]. However, the trend towards a superior hemodynamic benefit has 
to be interpreted with caution, because the atrioventricular delay was optimized in 
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most of the studies, which has had a major impact by itself [10]. Recent data suggest 
that patients in atrial fibrillation may also benefit, but to achieve sufficient pacing time, 
radiofrequency catheter ablation of the atrioventricular node is often required [11].  
 
A number of randomized trials have provided information on the efficacy and safety 
of biventricular pacing. Patients with severe heart failure (NYHA III or IV) and wide 
QRS complex were included in the PATH-CHF trial (Pacing THerapy in Congestive 
Heart Failure). During implantation invasive testing was performed and patients were 
then randomized to a one-month period of either univentricular pacing, no pacing, or 
biventricular pacing. The study utilized a three-month crossover period between 
pacing modes. The chronic pacing mode was optimized according to the results of 
crossover period. Results showed a 40% increase in the six-minute walking distance 
and a 50% improvement in quality of life with biventricular and preferred 
univentricular (usually left ventricular) pacing. The Multisite Stimulation in 
Cardiomyopathies (MUSTIC) trial randomized 67 patients with severe heart failure 
associated with a QRS duration > 150ms. This single-blind, randomized, controlled 
crossover study compared the responses of patients during two different pacing 
situations: three months of inactive pacing and three months of atriobiventricular 
pacing. The study concluded that although the procedure is technically complex, 
atriobiventricular pacing significantly improves exercise tolerance and quality of life in 
patients with chronic heart failure and significant intraventricular conduction delay [6]. 
These results were confirmed by the Multicenter InSync Randomized Clinical 
Evaluation Trial (MIRACLE) [12], which was presented at the 2001 Scientific Session 
of the American College of Cardiology. The MIRACLE trial statistically proved the 
therapeutic benefit of cardiac resynchronization therapy. The functional status of the 
patients significantly improved; this was quantified by objective measures such as a 
reduction in systolic and diastolic volumes, increase in left ventricular ejection fraction 
and reduction of mitral regurgitation.   
 
 
Selection of the optimal right and left ventricular pacing sites 
Despite the strong theoretical basis, a considerable proportion of patients does not 
respond to biventricular pacing therapy even if a decreased QRS complex is 
achieved. Different approaches are used to select patients who will benefit most from 
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biventricular pacing. In our center, a conventional electrophysiological induction study 
is combined with an acute hemodynamic evaluation of biventricular pacing. Standard 
diagnostic catheters are used to stimulate the high right atrium and the right ventricle 
at different sites. The coronary sinus is cannulated with a specially designed vascular 
sheath (Vue Port, Cardima, USA) that contains an inflatable balloon that is capable of 
performing a venogram without the need of a separate balloon catheter (Figure 1). 
After the anatomical situation is assessed and recorded for future use, a very thin 1.5 
F multipolar electrode catheter (Pathfinder, Cardima) is inserted into the CS to 
perform the pacing study (Figure 2). At least two different side branches - that seem 
feasible according to the venogram - are cannulated by this multipolar electrode 
catheter. Intracardiac electrograms are recorded and the pacing threshold is 
evaluated at each site at different atriobiventricular pacing rates and atriventricular 
delays. A non-invasive, continuous photoplethysmograph with an option of model 
flow analysis (Portapres, TNO Biomedical Instrumentation, Amsterdam) that 
measures complex hemodynamics throughout the whole study including cardiac 
output, stroke volume and total peripheral resistance is connected to the patient. A 
transthoracic echocardiography that assesses transmitral flow completes the setup. 
The optimal pacing site is selected according to the results of acute hemodynamic 
measurements. There is growing evidence showing the disadvantageous effect of 
right ventricular apical pacing on left ventricular function [13]. Therefore, in the case 
of a non-responding patient, the right ventricular lead is repositioned from the right 
ventricular apex to alternative pacing sites (i.e., right ventricular outflow tract), and 
the measurements are repeated. However, improved acute hemodynamics does not 
necessarily mean an improved clinical outcome including a reduction in mortality. 
The evaluation of this issue necessitates large-scale randomized trials.  
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Figure 1. Occlusion venogram of the distal coronary sinus shows appropriate side branches 
(arrow) for biventricular pacing. 
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Figure 2. Temporary multipolar electrode catheter (arrow) is used for acute hemodynamic 
study. 
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The technique of left ventricular lead positioning 
Transvenous implantation of the left ventricular lead via the coronary sinus (CS) is 
well- developed, however there is still a need to describe the optimal implantation 
technique. The methodology developed at the Thorax Center in Rotterdam, the 
Netherlands, is based on our own, as well as adopted international experience. After 
puncture of the subclavian vein, the CS is cannulated with a non-steerable diagnostic 
catheter using a combined electrophysiologic and anatomical approach.  After 
successful cannulation of the CS, a 9 F delivery sheath is placed over the catheter 
distal to the CS, providing a stable and multipurpose access to the targeted vein 
which is selected according to the acute hemodynamic study (see above). The “peel 
away” sheath is then used to deliver a permanent, unipolar pacing lead, preferably at 
the lateral wall, midway between the apex and the base. Other lateral and posterior 
sites are also acceptable, but the great cardiac vein and the middle cardiac vein are 
used only when the other veins are not available. 
 
 
Biventricular ICD therapy and recurrences of ventricular tachyarrhythmias 
Although most of the recent studies demonstrated the beneficial effects of 
biventricular pacing on this patient population, the mortality rate still remains fairly 
high [14]. Nevertheless, none of the studies mentioned above aimed to assess the 
mortality in a randomized fashion. The high mortality rate suggests the natural course 
of this severe, advanced stage of heart failure disease because this pacing modality 
is used mainly for very sick patients with CHF, which is usually refractory to drug 
therapy. Since the incidence of sudden cardiac death accounts for 30 - 50% in this 
patient population [14], combined biventricular pacemaker and defibrillator therapy 
should be considered. Improved hemodynamics with biventricular pacing may reduce 
the need for interventions by the device. This possible and logical synergistic effect 
was proposed and studied by Higgins and his colleagues [15]. They reported that 
biventricular pacing diminished the need for ICD therapy for patients with 
tachyarrhythmias [15]. The decreased number of interventions by the ICD was 
possibly related to the improved hemodynamics. A decrease in ventricular 
conduction delay with biventricular pacing reduces macro-reentry and pause-
dependent tachyarrhythmias because the dispersion of refractoriness is decreased, 
comparing with right ventricular pacing [15,16]. The decrease in plasma nor-
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epinephrine levels and decreased sympathetic activity may also play role [17,18]. 
Zagrodzky et al. showed that acute biventricular pacing decreases the inducibility of 
sustained monomorphic tachycardias in patients with ischemic cardiomyopathy [16]. 
In contrast, in a retrospective study conducted by Theuns et al., the time between the 
implantation and the first recurrence of ventricular tachyarrhythmias was not modified 
by biventricular pacing in a virtually identical patient population [19]. Furthermore, 
subgroup analysis revealed a slightly earlier recurrence of ventricular 
tachyarrhythmias with a cycle length slower than 350 ms in the group treated with 
biventricular pacing, compared with groups having a dual-chamber ICD either with a 
narrow or broad QRS complex [19]. According to these results, the proarrhythmic 
effect of left ventricular lead can not be excluded. However, this potential and 
probably temporary disadvantage of this therapy’s effect exists in the peri-procedural 
period. There is no available data  comparing the late recurrence of the same 
arrhythmias with the recurrence of index arrhythmias.  
 
 
Future considerations 
So far, biventricular pacing is based on a modified conventional pacing setup. The 
placement of a permanent endocardial left ventricular lead using a transseptal 
technique seems technically feasible; however, the potential for life-threatening, 
thrombo-embolic complications has not yet been investigated. The enhanced 
hemodynamic response of multisite, left ventricular pacing in various clinical 
circumstances, such as the adjusted right ventricular-left ventricular stimulation delay, 
also necessitates further controlled studies. 
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Abstract 
Background: The incidence of ventricular tachyarrhythmias in ICD patients with 
cardiac resynchronisation therapy (CRT-D) is not well studied. 
Aim: To analyse event free survival in CRT-D patients with a primary or a secondary 
prophylactic ICD indication  
Methods: Prospective, single centre. Eighty-six patients, 44% with a primary 
prophylactic indication. Actuarial event-free rates for mortality and arrhythmias were 
calculated.  
Results: Baseline clinical characteristics were not significantly different between 
primary and secondary prophylaxis. Primary prophylaxis patients tended to have 
more often NYHA class III. Over 21 months, 724 ventricular events with therapy 
occurred in 36 patients (42%). The actuarial event-free rates, at 1 and 3 years, from 
appropriate ICD therapy were higher (P < 0.001) for primary (79.0% and 67.8%) than 
for secondary prophylaxis (45.6% and 27.0%). Appropriate ICD therapy occurred 
more in NYHA class II compared to class III (P = 0.016). Underlying disease 
(ischemic versus non-ischemic) and functional class did not play a role in multivariate 
analysis.  
Conclusion: Important arrhythmic events in patients with congestive heart failure, 
and CRT-D occur at a very high rate when the indication is secondary prophylaxis. 
Patients with primary prophylaxis have an annual event rate of 10%, even when they 
tend to have a worse heart failure class. 
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Introduction 
Congestive heart failure (CHF) is reported to occur in 1% to 5% of the European 
population.[1] The long-term prognosis still remains poor.[2] Mortality is high, due to 
deterioration of left ventricular function and sudden death.[3] Arrhythmic sudden 
death is diverse and includes ventricular tachycardia (VT), ventricular fibrillation (VF), 
and bradycardic events, including some unrecognized hemodynamic situations 
leading to electromechanic dissociation or asystole. The prevention of life-threatening 
ventricular arrhythmias as such is a major goal in the management of patients with 
CHF. In multiple randomised studies, the implantable cardioverter-defibrillator (ICD) 
has demonstrated to be effective for life-threatening ventricular arrhythmias and to 
prevent sudden cardiac death in patients with reduced left ventricular function.[4-10] 
Although ICD treatment prolongs life in patients at risk, it does not improve quality of 
life or symptoms of CHF. Recent data demonstrated that cardiac resynchronisation 
therapy (CRT) has the potential to improve hemodynamic parameters and symptoms 
in heart failure patients, thereby potentially preventing disease progression and 
prolonging life.[11-13] The latter however, has never been proven in randomised 
trials. Recent trials demonstrated that CHF patients have a mortality benefit with ICD 
therapy.[10,14] This benefit can be achieved with conventional, single chamber ICDs, 
whereas patients with a profile suitable for resynchronisation show lower morbidity 
after receiving a combined device with CRT as well.  
The aim of this study was to analyse the outcome and incidence of ventricular 
tachyarrhythmias in patients with congestive heart failure, treated with a cardiac 
resynchronisation ICD (CRT-D). 
 
Methods 
Patient population 
The study population consisted of patients who received a CRT-D in combination 
with a transvenous approach. Indications for ICD therapy were a history of 
symptomatic sustained ventricular tachyarrhythmia or aborted sudden death without 
reversible cause (secondary prophylaxis). The primary prophylaxis group included 
patients with ischemic and nonischemic heart diseases, which were considered for 
cardiac transplantation, and patients who fulfilled criteria as described in the first 
Multicenter Automatic Defibrillator Implantation Trial or MADIT I [LVEF < 30%, 
nonsustained ventricular tachycardia (NSVT), inducible, but without rechallenge after 
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drugs].[4] All patients met CRT criteria: symptomatic CHF, inter- or intraventricular 
conduction delay (QRS duration ≥ 120 ms), LVEF ≤ 35%, and left ventricular end-
diastolic diameter of more than 55 mm. Nonischemic dilated cardiomyopathy was 
diagnosed after exclusion of coronary artery disease by the absence of a Q wave 
myocardial infarction, and/or exclusion of significant luminal stenosis in one or more 
coronary arteries. The clinical characteristics of the patients are summarised in Table 
1. 
 
Implantation procedure and programming 
Implantations were performed preferably with a single left pectoral incision, a left 
cephalic vein cutdown and a left subclavian puncture. Defibrillation leads were 
positioned in the right ventricular apex. The LV pacing lead was placed in a tributary 
of the coronary sinus. A postero-lateral branch was used in 39 patients (45%), an 
anterior branch in 20%, and a lateral branch in 10% of patients. The lowest effective 
defibrillation energy was less than 15 J in 49/56 tested patients. The selected devices 
were InSync 7272 and 7279 (Medtronic Inc., Minneapolis, MN, USA), Contak CD, 
Renewal I, and Renewal II (Guidant Inc., St. Paul, MN, USA), and Epic HF (St Jude 
Medical, Sylmar, CA, USA). ICD programming was intended to avoid inappropriate 
therapy and tailored according to the clinical presentation. The mean ventricular 
tachycardia detection rate was 383 ± 40 ms, the mean fibrillation detection interval 
was 290 ± 22 ms. Biventricular pacing was monitored by 12-lead surface ECG during 
threshold testing. At the 3-month visit, the mean programmed AV delay was 106 ms 
and the ventricular output to ensure biventricular capture was programmed at 3.6 V. 
The maximum ventricular output was programmed in only 9 patients (10%) at this 
interval. 
 
Data collection and tachyarrhythmia classification 
Follow-up started at the time of ICD implantation. All patients were followed at 3-
monthly intervals and were advised to contact our out-patient clinic as soon as 
possible after a symptomatic event. At each visit, arrhythmic events were retrieved 
from the device’s memory. The stored electrograms (EGMs) were visually analysed 
by 2 investigators to assess the type of the recurrent arrhythmia. In case of 
disagreement between the 2 reviewers about the stored EGMs, a third one was 
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consulted to reach a final agreement. The stored arrhythmias were classified as (1) 
ventricular tachyarrhythmia or (2) atrial tachyarrhythmia without a coexistent 
ventricular arrhythmia. As the atrial electrogram was present, the presence of 
atrioventricular dissociation was used to diagnose ventricular tachycardia. Otherwise, 
a ventricular tachyarrhythmia was defined as an event with a sudden increase in rate 
combined with a change in electrogram morphology from the baseline rhythm. 
Ventricular arrhythmias were classified as “sustained” or “nonsustained”. A 
“sustained ventricular tachyarrhythmia” was defined as a ventricular event lasting 
long enough to allow delivery of device therapy. “Nonsustained” events were defined 
as events, not long enough for triggering device therapy, and were excluded from 
analysis. 
 
Statistical analysis 
Continuous variables are expressed as mean ± SD if normally distributed, or 
otherwise by median. Continuous variables were analysed with Student’s t-test. 
Categorical data are summarised as frequency (percentage). Chi-square test was 
used for analysis of categorical variables. Estimated survival and the actuarial event-
free rates were calculated according to the Kaplan-Meier method and were 
compared by use of the log-rank test. Survival time was defined as the date from ICD 
implantation to the date of death or last follow-up. Patients undergoing cardiac 
transplantation were censored from the moment of transplantation. The actuarial 
event-free rates from ventricular tachyarrhythmias triggering ICD therapy were 
measured from the date of ICD implantation to the date of the first ventricular 
tachyarrhythmia triggering ICD therapy or last follow-up; deaths and cardiac 
transplantation were treated as censored observations. Covariates previously 
identified to be independently associated with the occurrence of appropriate ICD 
therapy were used in a Cox proportional-hazards model. A P value < 0.05 was 
considered statistically significant. 
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Results 
Patient population 
A total number of 86 patients received a CRT-D. Clinical characteristics and 
demographic data are listed in Table 1. The underlying cardiac disease was coronary 
artery disease (CAD) in 50 patients (58%). Mean QRS duration was 174 ± 31 ms. 
The ICD was indicated as secondary prophylaxis for 48 patients (56%), and as 
primary prophylaxis in 38 patients (44%). Twenty-one patients were formally listed for 
cardiac transplantation, 8 belonging to the secondary prophylaxis, 13 to the primary 
prophylaxis group.  
The mean follow-up duration was 21 months, with a cumulative follow-up of 1772 
months. During this follow-up, a total of 11 deaths were reported. Of these deaths, 5 
(45%) were attributed to progressive heart failure, 2 (18%) were arrhythmic, and 2 
(18%) were non-cardiac. Operative mortality, defined as death from any cause within 
30 days of the implant procedure, was documented in 1 (9%) patient. The cause of 
death was unknown in 1 patient. Eight patients underwent successful heart 
transplantation. The actuarial mortality was 6.7% and 21.9%, at 1 and 4 years, 
respectively (Figure 1). 
 
Figure 1. Actuarial event-free curves from all-cause mortality (dashed line) and from 
ventricular tachyarrhythmias triggering ICD therapy (solid line). 
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Spontaneous ventricular tachyarrhythmias 
During the follow-up period, 869 episodes with ventricular tachyarrhythmias were 
recorded in 40 patients (46.5%). Of the 869 episodes, 145 episodes of nonsustained 
ventricular tachyarrhythmias were excluded from analysis. Thus 724 episodes were 
eligible for analysis in 36 patients (range 1 to 92 episodes per patient). The first 
appropriate therapy occurred at a median interval of 63 days after ICD implantation. 
The actuarial event-free rates from appropriate ICD intervention were 59.4% and 
38.8% at 1 and 4 years, respectively (Figure 1). Seventy episodes (10%) were 
treated with shock therapy (18 patients, range 1 to 12 episodes per patient). 
Antitachycardia pacing therapy was delivered in 654 episodes (90%) occurring in 23 
patients (range 1 to 91 episodes per patient).  
Clinical characteristics of patients with and without ventricular tachyarrhythmias 
during follow-up are summarised in Table 2. Ventricular tachyarrhythmias occurred in 
only 7 out-of-38 patients with a primary prophylactic indication against in 29 out-of-48 
patients with a secondary prophylactic indication (P < 0.001). In a univariate model, 
male gender, lower NYHA class, and a secondary prophylactic indication correlated 
with a higher recurrence rate for ventricular tachyarrhythmias. To evaluate clinical 
predictors of appropriate device therapy, univariate covariates with P value ≤ 0.10 
were entered in a Cox proportional hazards model adjusted for difference in follow-up 
time. This multivariate model with “appropriate device therapy” as the dependent 
variable revealed the prophylactic indication as the only independent predictor (P = 
0.009). 
 
Primary and secondary prophylaxis 
Of the 86 patients, a total of 38 patients had a primary prophylactic indication and 48 
patients a secondary prophylactic indication for ICD implantation. Demographic and 
clinical variables for both groups are listed in Table 1. Underlying cardiac disease 
was not different between the 2 groups. Proportionally, patients with NYHA Class III 
were significantly higher in the primary prophylactic group. Amiodarone as 
antiarrhythmic drug treatment was significantly higher for patients with secondary 
prophylaxis. The Kaplan-Meier curves illustrating time to first appropriate ICD 
intervention for patients in both groups are shown in Figure 2. The actuarial event-
free rates from appropriate ICD intervention were lower in the secondary prophylaxis 
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group (79.0% and 67.8% for primary versus 45.6% and 27.0% for secondary 
prophylaxis, at 1 and 3 years, respectively; P = 0.001). 
Twelve patients (14%) experienced ventricular tachyarrhythmias with cycle length 
(CL) ≤ 250 ms, and 19 patients (22%) had ventricular tachyarrhythmias with CL > 
350 ms. For the primary prophylactic group, 75% of ventricular tachyarrhythmias had 
CL ≤ 350 ms, for the other group it was 52%. 
 
Inappropriate therapy 
Inappropriate tachyarrhythmia detection was observed in 17 patients (20%). The first 
inappropriate therapy occurred at a median interval of 194 days after ICD 
implantation. Six patients experienced inappropriate device therapy for atrial 
fibrillation or atrial flutter, and 12 patients received inappropriate therapy for sinus or 
atrial tachycardia. Inappropriate detection was not significantly different between the 
primary and secondary prophylaxis group. 
 
Figure 2. Actuarial event-free rates from first appropriate ICD intervention for patients with 
primary prevention indication and patients with secondary prevention indication 
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Discussion 
The present study addresses the incidence of appropriate ICD interventions in CHF 
patients with either a primary or secondary prophylactic indication for ICD therapy 
using a CRT-D. The major finding of this study is that recurrent ventricular 
tachyarrhythmias triggering device therapy are more common in patients with 
secondary prophylactic indications as compared to patients with a primary 
prophylactic indication for ICD implantation. However, the annual event rate in the 
primary prophylactic group remains 10% which is a generally accepted criterion for 
defining very high risk. The interpretation is difficult as it was suggested that patients 
with a MADIT I profile would have the same recurrence rate as secondary 
prophylaxis patients. On the other hand, the more advanced CHF patients in the 
primary prophylactic group (as suggested by their NYHA classification) are expected 
to die rather from heart failure than from arrhythmias. 
 
Heart failure and secondary prophylaxis for arrhythmias 
ICD therapy has demonstrated an improvement in survival after sudden cardiac 
death in high-risk patients.[6-8] Meta-analysis of secondary prophylactic trials 
demonstrated a significant benefit from ICD therapy for patients with LVEF ≤ 35% as 
compared to those with LVEF > 35%.[15] The ICD can be regarded as the treatment 
of choice in heart failure patients with life-threatening ventricular tachyarrhythmias. In 
the present study, we observed a very high incidence of ventricular tachyarrhythmias 
triggering device therapy in CHF patients with a secondary prophylactic indication. 
Almost all patients had a recurrence after 2 years. The benefit of ICD therapy was 
observed in patients with ischemic heart disease as well in patients with nonischemic 
heart disease. These findings reconfirm the guideline to implant an ICD in patients 
who already experienced a life-threatening ventricular arrhythmia, and demonstrate 
the frightening high recurrence rate of ventricular tachyarrhythmias. 
 
Heart failure and primary prophylaxis for arrhythmias 
The first primary prophylactic trials showed that patients with ischemic heart disease, 
a poor left ventricular function, NSVT, and inducible sustained ventricular 
tachyarrhythmias benefit from prophylactic ICD implantation.[4, 5] In contrast, the 
benefit from prophylactic ICD implantation was not proven in patients with 
nonischemic heart disease.[16, 17] The presence of NSVT is common in patients 
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with CHF and does not always predict sudden cardiac death.[18] The presence of 
NSVT in functional class III patients is rather a marker of worse prognosis related to 
poor left ventricular function than an indication for sudden cardiac death. The MADIT 
II trial reported a 31% reduction in all-cause mortality for post-myocardial infarction 
patients with LVEF ≤ 30%, even without NSVT an effect that was enhanced as a 
function of QRS duration.[9] This was confirmed with data from the Sudden Cardiac 
Death in Heart Failure Trial (SCD-HeFT), showing that a simple back-up ICD reduces 
overall mortality with 23%.[10] Adding CRT will provide more quality of life, and the 
Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure 
(COMPANION) trial confirmed again the superiority of CRT-D over pacing alone in 
patients with a primary indication.[14] Wilkoff et al. reviewed recently the difference in 
tachyarrhythmia detection between primary and secondary prophylaxis in patients 
with resynchronization therapy.[19] Patients with a primary prophylaxis were much 
less likely to develop ventricular tachyarrhythmias; when they did, it was at 
significantly faster cycle lengths compared to patients with secondary prophylaxis. 
We confirmed their findings of ventricular tachyarrhythmias in our series. We 
observed an annual recurrence rate of 10%, which is very high, given the 
prophylactic indication. The majority of ventricular tachyarrhythmias in the primary 
prophylactic group had a cycle length ≤ 350 ms. 
It has always been thought that sudden cardiac death comes early in the course of 
cardiac disease, while non-sudden cardiac death comes later, i.e. in stages of more 
advanced heart failure.[20] This finding is supported by the Metoprolol CR/XL 
Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF), in which 
sudden death was more common in patients with NYHA class II.[21] This is also in 
harmony with our data, as appropriate device therapy occurred more frequently in 
patients with NYHA class II. These patients had more often a secondary prophylactic 
indication. It should be noted that the rate of interventions in the other group remains 
high in spite of resynchronisation therapy. 
 
Limitations of the study 
The present study was a retrospective analysis in a highly selected group of patients 
with CHF. However, both groups were followed prospectively on a regular basis at 
the out-patient clinic. We selected primary prophylactic patients with ischemic heart 
disease who fulfilled MADIT I criteria or when considered for cardiac transplantation, 
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as was also the case for nonischemic patients. In spite of the small numbers in the 
subgroups, a support for the policy to add the ICD component to CRT was observed 
for the primary prophylaxis group. 
  
Conclusion 
Ventricular tachyarrhythmias triggering device therapy appear extremely frequent in 
patients with CHF receiving the ICD after a first symptomatic arrhythmia or sudden 
death, in spite of CRT which was well delivered in our study. Further, patients 
selected for primary prophylactic indication, using MADIT I criteria, or when waiting 
for cardiac transplantation face a high recurrence rate.  
The decision-making process to implant an ICD in CHF patients for primary 
prophylactic of sudden cardiac death now becomes a clinical decision based on low 
LVEF plus heart failure. This will probably result in a lower recurrence rate (SCD-
HeFT). The uncertainty remains the option of cardiac resynchronisation: SCD-HeFT 
improved survival without CRT. COMPANION had no arm without CRT and yet a 
simple ICD. Till these questions are answered, our policy to combine both ICD and 
CRT in the field for primary prophylaxis remains an option, which is open for 
discussion. 
  
 
198
References 
1. Cowie M, Mosterd A, Wood D, et al. The epidemiology of heart failure. Eur Heart J 
1997;18:208-223. 
2. Erikson H. Heart failure: a growing public health problem. J Intern Med 1995;237:135-
141. 
3. Cleland J, Massie BM, Packer M. Sudden death in heart failure: Vascular or electrical? 
Eur J Heart Fail 1999;1:41-45. 
4. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator 
in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter 
Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996;335:1933-
1940. 
5. Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with 
coronary artery disease who are at risk for sudden death. Multicenter Unsustained 
Tachycardia Trial Investigators. N Engl J Med 2000;342:1937-1945. 
6. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. A 
comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients 
resuscitated from near-fatal ventricular arrhythmias.  N Engl J Med 1997;337:1576-
1583. 
7. Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study 
(CIDS): a randomized trial of the implantable cardioverter defibrillator against 
amiodarone. Circulation 2000;101:1297-1302. 
8. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic 
drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : 
the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748-754. 
9. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in 
patients with myocardial infarction and reduced ejection fraction. N Engl J Med 
2002;346:877-883. 
10. Bardy G, Lee KL, Mark DB, et al. for the Investigators of the Sudden Cardiac Death in 
Heart Failure Trial (SCD-HeFT). Amiodarone or an implantable cardioverter-defibrillator 
for congestive heart failure. N Engl J Med 2005;352:225-337. 
11. Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in 
patients with heart failure and intraventricular conduction delay. N Engl J Med 
2001;344:873-880. 
12. Abraham W, Fisher A, Smith A, et al. Multicenter InSync Randomized Clinical 
Evaluation. Cardiac resynchronization in chronic heart failure. N Engl J Med 
2002;346:1845-1853. 
  
 
199
13. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in 
congestive heart failure: results from the MUltisite STimulation in cardiomyopathy 
(MUSTIC) study. J Am Coll Cardiol 2002;40:111-118. 
14. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or 
without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 
2004;350:2140-2150. 
15. Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable 
cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. 
Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . 
Canadian Implantable Defibrillator Study. Eur Heart J 2000;21:2071-2078. 
16. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable 
cardioverter-defibrillator:randomized trial in patients with nonischemic dilated 
cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT. J 
Am Coll Cardiol 2003;41:1707-1712. 
17. Bansch D, Antz M, Boczor S, et al. Primary prevention of sudden cardiac death in 
idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation 
2002;105:1453-1458. 
18. Teerlink JR, Jalaluddin M, Anderson S, et al. Ambulatory ventricular arrhythmias in 
patients with heart failure do not specifically predict an increased risk of sudden death. 
PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators. 
Circulation 2000;101:40-46. 
19. Wilkoff BL, Hess M, Young J, Abraham WT. Differences in tachyarrhythmia detection 
and implantable cardioverter defibrillator therapy by primary or secondary prevention 
indication in cardiac resynchronization therapy patients. J Cardiovasc Electrophysiol 
2004;15:1002-1009. 
20. Myerburg RJ, Interian A, Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of 
sudden cardiac death and profiles of risk. Am J Cardiol 1997;80:10F-19F. 
21. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised 
Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-
2007. 
 
 
 
 
 
 
  
 
 
 
 
  
 
201
Summary 
  
 
202
During the past 25 years, the implantable cardioverter-defibrillator (ICD) has evolved 
from the treatment of last resort to the gold standard for patients at high risk for life-
threatening ventricular tachyarrhythmias. Patients at high risk include those who 
survived life-threatening ventricular tachyarrhythmias, and patients with cardiac 
diseases who carry an increased risk for these tachyarrhythmias. We performed a 
clinical assessment during implantation and follow-up of our patients in Rotterdam.  
 
Part I  Prognosis and follow-up of patients with an ICD 
In Chapter 1, the clinical benefit of ICD therapy, survival, and adverse events of 
patients who received an ICD at the Erasmus MC Rotterdam are described. Our data 
confirm the benefit from ICD implantation, especially for those patients with a poor 
left ventricular function.  
In Chapter 2, defibrillation efficacy testing is investigated. The role of a second 
defibrillation threshold test after implantation appears questionable. With the 
advances in ICD technology, defibrillation thresholds are low and stable, which 
changed the mode of death in ICD patients from instantaneous arrhythmic death to 
heart failure. Our data demonstrate that despite the advanced ICD technology, a 
subset of patients may require a second defibrillation efficacy test to confirm a poor 
prognosis. 
The feasibility of remote monitoring of ICD therapy is discussed in Chapter 3. The 
expanding indications for ICD therapy and the complexity of current devices have a 
high impact on follow-up policy. Currently, the quality of medical supervision only 
depends on scheduled regular follow-up visits, which is time consuming and 
expensive. Too long follow-up intervals may have the disadvantage of a delay in the 
awareness of changes of the clinical course of the underlying disease or in the 
technical status of the device. Transmission of stored ICD data can overcome this 
problem and thus offers the potential to improve patient care. 
Finally, a case of Twiddler’s syndrome, which was detected by home monitoring is 
presented in Chapter 4. 
 
Part II  Rhythm discrimination by the ICD 
The primary goal of the ICD is to detect and subsequently terminate ventricular 
tachyarrhythmias. The secondary goal is to deliver therapy only when necessary. 
Inappropriate therapy due to atrial tachyarrhythmias is the most common adverse 
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event in ICD patients. In this second part of the thesis, rhythm discrimination by the 
ICD is investigated. 
Chapter 5 describes a confusing stored ICD electrogram. This electrogram 
demonstrates an apparent induction of ventricular tachycardia after appropriate 
pacing by the ICD. However, accurate analysis demonstrated an artefact 
representing a ventricular premature beat initiating the ventricular tachycardia. 
The initial clinical experience with a new dual-chamber algorithm, SMART, is 
discussed in Chapter 6. This new algorithm is based on comparison of atrial and 
ventricular rates, which divide tachyarrhythmias into 3 rate branches. Next, 
applicable single- and dual-chamber arrhythmia discriminators are applied in order to 
classify the tachyarrhythmia. In our series, the SMART algorithm achieved a 
sensitivity of 100%, with a positive predictive value of 95.6% for all ventricular 
arrhythmias. The majority of misclassified episodes appeared to be atrial 
tachyarrhythmias with stable atrioventricular conduction. 
In Chapter 7, the evolution of timing-based detection algorithms in ICDs is studied. 
Over the last 25 years, ICDs base arrhythmia discrimination on timing-based 
detection criteria in order to avoid inappropriate therapy for atrial tachyarrhythmias. 
Original single-chamber detection criteria have been implemented as such in dual-
chamber devices. Atrial signals can be reliably recognized with atrial leads and 
improved arrhythmia discrimination algorithms based on atrial signals were 
developed. However, this did not reduce the incidence of inappropriate therapy over 
time with the development of algorithms as was proven with comparative studies. 
Chapter 8 evaluated whether clinical characteristics can predict inappropriate 
therapy due to atrial tachyarrhythmias. We identified a history of atrial 
tachyarrhythmias and recurrent slow ventricular tachycardias, rate < 170 bpm, as 
independent predictors of inappropriate therapy. Whether device selection should 
depend on the knowledge of a history of atrial tachyarrhythmias still is open for 
debate, as inappropriate therapy equally occurs in patients with single- and dual-
chamber devices. 
The results of our prospective, randomized study comparing the performance of 
tachyarrhythmia detection algorithms in single- and dual-chamber devices are 
presented in Chapter 9. During a mean follow-up of 12 months, the investigators 
classified 653 tachyarrhythmia episodes with stored electrograms: 391 episodes 
were ventricular tachyarrhythmias and 262 epsiodes were atrial tachyarrhythmias. 
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Overall, no significant difference in tachyarrhythmia detection, atrial or ventricular,  
between single- and dual-chamber devices was observed.  Not sinus tachycardia or 
atrial fibrillation were a problem, but atrial tachyarrhythmias with stable N:1 
atrioventricular conduction remain a problem for both devices. 
In Chapter 10, a systematic approach for the analysis of stored electrograms is 
proposed. Stored electrograms in ICDs have not only improved our patient 
management, but also contributed to our understanding of tachyarrhythmias. Stored 
electrograms are usually visually analyzed, but the analysis can also be performed in 
a methodological way by application of blocks containing physiologic information.  
 
Part III Single-chamber, dual-chamber or biventricular devices 
In Chapter 11, we studied factors influencing appropriate therapy and survival in ICD 
patients with single- and dual-chamber devices, in an era that dual chamber devices 
were only implanted for patients with bradycardia indication. Survival analysis 
demonstrated no significant difference between patients with single- and dual-
chamber devices for mortality and for event-free rate of appropriate therapy. A 
tendency to less inappropriate interventions was observed in a small series of dual 
chamber devices. In addition, it was observed that a history of atrial fibrillation 
contributed to appropriate therapy. 
Resynchronization therapy by means of biventricular pacing is a novel therapy for 
patients with heart failure and severely diminished left ventricular function associated 
with intracardiac conduction delay. In Chapter 12, we present a brief review of early 
trials evaluating the therapeutic effect of biventricular pacing. Furthermore, we 
propose a method to select the optimal right and left ventricular pacing sites together 
with a technique of left ventricular lead positioning. 
The incidence of ventricular tachyarrhythmias in ICD patients with resynchronization 
therapy is presented in Chapter 13. Event-free survival was analyzed for patients 
with either a primary or a secondary prevention indication for ICD therapy. Ventricular 
tachyarrhythmias are very common for congestive heart failure patients with a 
secondary prevention indication. Patients with primary prophylaxis have an annual 
event rate of 10%, even when they tend to have a worse heart failure class. The 
decision-making process to implant an ICD in heart failure patients for primary 
prophylaxis of sudden cardiac death has presently become a clinical decision, based 
on low left ventricular ejection fraction plus heart failure. 
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Samenvatting 
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Het concept van de implantable cardioverter-defibrillator (ICD) heeft de afgelopen 25 
jaar een grote ontwikkeling doorgemaakt. De eerste generatie defibrillatoren was 
uitsluitend in staat om ventrikelfibrilleren te herkennen en te onderbreken door middel 
van een elektrische shock. De volgende generaties defibrillatoren werden uitgerust 
met functies om verschillende ritmestoornissen te herkennen en te behandelen. 
Vanuit klinisch oogpunt is er een verschuiving opgetreden van secundaire preventie 
naar primaire preventie van plotse dood ten gevolge van ventriculaire 
ritmestoornissen. Dit proefschrift beschrijft zowel de klinische als technische 
aspecten van defibrillator therapie. 
 
Deel 1 Prognose en follow-up van ICD patiënten 
Hoofdstuk 1 beschrijft zowel het klinische voordeel als de potentiële complicaties 
van defibrillator therapie bij patiënten, bij wie een ICD in het Erasmus MC werd 
geïmplanteerd.  
De rol van het testen van de defibrillatie effectiviteit wordt in Hoofdstuk 2 behandeld. 
Door de technische vooruitgang kunnen ventriculaire ritmestoornissen effectief met 
lage energie gedefibrilleerd worden. Vanuit dit technisch oogpunt is een tweede 
defibrillatie test niet nodig, echter vanuit klinisch oogpunt kan deze test een slechte 
prognose bij een kleine groep patiënten bevestigen. 
Veranderingen in de klinische status van de ICD patiënt worden vaak pas 
vastgesteld bij het volgende poliklinisch bezoek. In Hoofdstuk 3 wordt de 
mogelijkheid van het op afstand waarnemen van zowel klinische als technische 
aspecten van defibrillator therapie beschreven. Het verzenden van opgeslagen data 
in de ICD heeft een potentiële meerwaarde voor de klinische follow-up van de 
patiënt. 
Ter illustratie wordt in Hoofdstuk 4 een voorbeeld van het op afstand waarnemen 
van ICD data  gepresenteerd.  Bij interpretatie van de ontvangen data werd een 
malfunctie van de ventriculaire elektrode vastgesteld. 
 
Deel 2 Onderscheiden van ritmestoornissen door de ICD 
Hoofdstuk 5 behandelt een voorbeeld van een opgeslagen registratie van een 
ventriculaire ritmestoornis, die na nauwkeurige analyse een ander 
ontstaansmechanisme heeft dan het op eerste oog doet lijken.  
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In Hoofdstuk 6 wordt een nieuw tweekamer detectie algoritme, SMART, 
geëvalueerd. Na de vergelijking van de atriale en ventriculaire frequentie worden 
enkelkamer detectie criteria toegepast om een ritmestoornis te classificeren. 
Ventriculaire ritmestoornissen worden met behulp van dit algoritme betrouwbaar 
waargenomen. Ondanks een goede discriminatie tussen atriale en ventriculaire 
ritmestoornissen, worden atriale ritmestoornissen met een stabiele atrioventriculaire 
geleiding vooral verkeerd geclassificeerd. 
De ontwikkeling van detectie algoritmen om onterechte therapie ten gevolge van 
atriale ritmestoornissen te vermijden, wordt in Hoofdstuk 7 gepresenteerd. De 
classificatie van de ritmestoornis door de ICD is primair gebaseerd op de timing van 
ventriculaire signalen. De originele eenkamer detectie algoritmen zijn in de 
tweekamer ICD geïmplementeerd. De toevoeging van atriale informatie heeft tot 
betere en geavanceerde detectie algoritmen geleidt. Echter, onderzoeken die 
eenkamer met tweekamer detectie algoritmen vergeleken, lieten geen afname van 
onterechte therapie zien. 
Hoofdstuk 8 gaat over klinische variabelen die een verhoogd risico op onterechte 
therapie kunnen voorspellen. Uit onderzoek blijkt dat de aanwezigheid van atriale 
ritmestoornissen in het verleden en het voorkomen van trage ventriculaire 
ritmestoornissen, beide een verhoogd risico op onterechte therapie voorspellen. De 
beslissing om een tweekamer defibrillator bij patiënten met atriale ritmestoornissen te 
implanteren is een open vraag. Onterechte therapie werd namelijk in gelijke mate bij 
zowel eenkamer als tweekamer defibrillatoren waargenomen. 
Een gerandomiseerd onderzoek tussen eenkamer en tweekamer detectie algoritmen 
wordt in Hoofdstuk 9 gepresenteerd. De resultaten van dit onderzoek laten geen 
verschil zien in de discriminatie van ritmestoornissen tussen beide detectie 
algoritmen. Ventriculaire ritmestoornissen worden betrouwbaar door beide detectie 
algoritmen waargenomen. Van de atriale ritmestoornissen zijn zowel 
sinustachycardie als atriumfibrilleren geen probleem voor eenkamer en tweekamer 
detectie algoritmen. Atriale ritmestoornissen met een stabiele atrioventriculaire 
geleiding blijven een probleem voor beide defibrillator detectie algoritmen. 
Een systematische methode voor de beoordeling van opgeslagen elektrogrammen 
wordt in Hoofdstuk 10 gepresenteerd. Opgeslagen elektrogrammen geven inzicht in 
ritmestoornissen en bepalen het klinisch beleid van de patiënt. De toepassing van 
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blokken met fysiologische informatie, die kenmerken beschrijven van 
ritmestoornissen, is een methodiek voor het analyseren van ritmestoornissen. 
 
Deel 3 Enkel kamer, dubbel kamer of biventriculaire ICDs 
In Hoofdstuk 11 worden factoren die invloed hebben op terechte ICD therapie en 
overleving onderzocht in een groep patiënten met eenkamer en tweekamer 
defibrillatoren. Er wordt geen verschil in terechte therapie en overleving gevonden 
tussen patiënten met een eenkamer of een tweekamer defibrillator. Een trend tot 
minder onterechte therapie werd waargenomen bij de kleine groep patiënten met een 
tweekamer systeem. Patiënten met atriale ritmestoornissen hebben een groter risico 
op terechte therapie voor ventriculaire ritmestoornissen. 
In Hoofdstuk 12 wordt een nieuwe toepassing beschreven: resynchronisatie 
therapie bij patiënten met hartfalen en een intra- of interventriculaire 
geleidingsstoornis. Een  kort overzicht van onderzoeken over resynchronisatie 
therapie wordt gepresenteerd. Verder wordt in dit hoofdstuk een methode 
voorgesteld om de beste positie van de rechter en linker ventrikel elektrode te 
bepalen. 
Hoofdstuk 13 gaat in op een klinisch vraagstuk van patiënten die in aanmerking 
komen voor resynchronisatie therapie. Een hoge incidentie van ventriculaire 
ritmestoornissen wordt waargenomen bij patiënten met hartfalen en een indicatie 
voor resynchronisatie therapie. Bij patiënten die eveneens een ICD indicatie hebben 
op basis van secundaire preventie is de incidentie van ventriculaire ritmestoornissen 
hoger ten opzichte van patiënten met een primaire preventie indicatie voor ICD 
therapie. Echter, de jaarlijkse incidentie van ventriculaire ritmestoornissen in de 
primaire preventie groep bedraagt 10%, ongeacht het stadium van hartfalen. 
Profylactische ICD therapie bij patiënten met hartfalen is een klinische beslissing op 
basis van de lage linker ventrikel ejectiefractie en hartfalen. 
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